CINXE.COM

<!DOCTYPE html> <html lang="en" xmlns:fb="http://www.facebook.com/2008/fbml" class="wf-loading"> <head prefix="og: https://ogp.me/ns# fb: https://ogp.me/ns/fb# academia: https://ogp.me/ns/fb/academia#"> <meta charset="utf-8"> <meta name=viewport content="width=device-width, initial-scale=1"> <meta rel="search" type="application/opensearchdescription+xml" href="/open_search.xml" title="Academia.edu"> <title>Luis Souhami - Academia.edu</title>  <link href="//a.academia-assets.com/images/favicons/favicon-production.ico" rel="shortcut icon" type="image/vnd.microsoft.icon"> <link rel="apple-touch-icon" sizes="57x57" href="//a.academia-assets.com/images/favicons/apple-touch-icon-57x57.png"> <link rel="apple-touch-icon" sizes="60x60" href="//a.academia-assets.com/images/favicons/apple-touch-icon-60x60.png"> <link rel="apple-touch-icon" sizes="72x72" href="//a.academia-assets.com/images/favicons/apple-touch-icon-72x72.png"> <link rel="apple-touch-icon" sizes="76x76" href="//a.academia-assets.com/images/favicons/apple-touch-icon-76x76.png"> <link rel="apple-touch-icon" sizes="114x114" href="//a.academia-assets.com/images/favicons/apple-touch-icon-114x114.png"> <link rel="apple-touch-icon" sizes="120x120" href="//a.academia-assets.com/images/favicons/apple-touch-icon-120x120.png"> <link rel="apple-touch-icon" sizes="144x144" href="//a.academia-assets.com/images/favicons/apple-touch-icon-144x144.png"> <link rel="apple-touch-icon" sizes="152x152" href="//a.academia-assets.com/images/favicons/apple-touch-icon-152x152.png"> <link rel="apple-touch-icon" sizes="180x180" href="//a.academia-assets.com/images/favicons/apple-touch-icon-180x180.png"> <link rel="icon" type="image/png" href="//a.academia-assets.com/images/favicons/favicon-32x32.png" sizes="32x32"> <link rel="icon" type="image/png" href="//a.academia-assets.com/images/favicons/favicon-194x194.png" sizes="194x194"> <link rel="icon" type="image/png" href="//a.academia-assets.com/images/favicons/favicon-96x96.png" sizes="96x96"> <link rel="icon" type="image/png" href="//a.academia-assets.com/images/favicons/android-chrome-192x192.png" sizes="192x192"> <link rel="icon" type="image/png" href="//a.academia-assets.com/images/favicons/favicon-16x16.png" sizes="16x16"> <link rel="manifest" href="//a.academia-assets.com/images/favicons/manifest.json"> <meta name="msapplication-TileColor" content="#2b5797"> <meta name="msapplication-TileImage" content="//a.academia-assets.com/images/favicons/mstile-144x144.png"> <meta name="theme-color" content="#ffffff"> <script> window.performance && window.performance.measure && window.performance.measure("Time To First Byte", "requestStart", "responseStart"); </script> <script> (function() { if (!window.URLSearchParams || !window.history || !window.history.replaceState) { return; } var searchParams = new URLSearchParams(window.location.search); var paramsToDelete = [ 'fs', 'sm', 'swp', 'iid', 'nbs', 'rcc', // related content category 'rcpos', // related content carousel position 'rcpg', // related carousel page 'rchid', // related content hit id 'f_ri', // research interest id, for SEO tracking 'f_fri', // featured research interest, for SEO tracking (param key without value) 'f_rid', // from research interest directory for SEO tracking 'f_loswp', // from research interest pills on LOSWP sidebar for SEO tracking 'rhid', // referrring hit id ]; if (paramsToDelete.every((key) => searchParams.get(key) === null)) { return; } paramsToDelete.forEach((key) => { searchParams.delete(key); }); var cleanUrl = new URL(window.location.href); cleanUrl.search = searchParams.toString(); history.replaceState({}, document.title, cleanUrl); })(); </script> <script async src="https://www.googletagmanager.com/gtag/js?id=G-5VKX33P2DS"></script> <script> window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-5VKX33P2DS', { cookie_domain: 'academia.edu', send_page_view: false, }); gtag('event', 'page_view', { 'controller': "profiles/works", 'action': "summary", 'controller_action': 'profiles/works#summary', 'logged_in': 'false', 'edge': 'unknown', // Send nil if there is no A/B test bucket, in case some records get logged // with missing data - that way we can distinguish between the two cases. // ab_test_bucket should be of the form <ab_test_name>:<bucket> 'ab_test_bucket': null, }) </script> <script type="text/javascript"> window.sendUserTiming = function(timingName) { if (!(window.performance && window.performance.measure)) return; var entries = window.performance.getEntriesByName(timingName, "measure"); if (entries.length !== 1) return; var timingValue = Math.round(entries[0].duration); gtag('event', 'timing_complete', { name: timingName, value: timingValue, event_category: 'User-centric', }); }; window.sendUserTiming("Time To First Byte"); </script> <meta name="csrf-param" content="authenticity_token" /> <meta name="csrf-token" content="9Q86yCLtDcoS0YrmUvvHkTaRKCSanoNyRcnvtS4Un5oGwPpoe4Vb8bNRg5YDhZaq83jz1u_0LmpdJJT22qI8eg" /> <link rel="stylesheet" media="all" href="//a.academia-assets.com/assets/wow-3d36c19b4875b226bfed0fcba1dcea3f2fe61148383d97c0465c016b8c969290.css" /><link rel="stylesheet" media="all" href="//a.academia-assets.com/assets/social/home-79e78ce59bef0a338eb6540ec3d93b4a7952115b56c57f1760943128f4544d42.css" /><link rel="stylesheet" media="all" href="//a.academia-assets.com/assets/design_system/heading-95367dc03b794f6737f30123738a886cf53b7a65cdef98a922a98591d60063e3.css" /><link rel="stylesheet" media="all" href="//a.academia-assets.com/assets/design_system/button-bfbac2a470372e2f3a6661a65fa7ff0a0fbf7aa32534d9a831d683d2a6f9e01b.css" /><link rel="stylesheet" media="all" href="//a.academia-assets.com/assets/design_system/body-170d1319f0e354621e81ca17054bb147da2856ec0702fe440a99af314a6338c5.css" /><link crossorigin="" href="https://fonts.gstatic.com/" rel="preconnect" /><link href="https://fonts.googleapis.com/css2?family=DM+Sans:ital,opsz,wght@0,9..40,100..1000;1,9..40,100..1000&family=Gupter:wght@400;500;700&family=IBM+Plex+Mono:wght@300;400&family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20,400,0,0&display=swap" rel="stylesheet" /><link rel="stylesheet" media="all" href="//a.academia-assets.com/assets/design_system/common-2b6f90dbd75f5941bc38f4ad716615f3ac449e7398313bb3bc225fba451cd9fa.css" /> <meta name="author" content="luis souhami" /> <meta name="description" content="Luis Souhami: 100 Followers, 15 Following, 377 Research papers. Research interests: Radiation Shielding, Radiation, and Radiation Physics." /> <meta name="google-site-verification" content="bKJMBZA7E43xhDOopFZkssMMkBRjvYERV-NaN4R6mrs" /> <script> var $controller_name = 'works'; var $action_name = "summary"; var $rails_env = 'production'; var $app_rev = '29cbb9485f79f49ca3eb38b6f0905739256f19a4'; var $domain = 'academia.edu'; var $app_host = "academia.edu"; var $asset_host = "academia-assets.com"; var $start_time = new Date().getTime(); var $recaptcha_key = "6LdxlRMTAAAAADnu_zyLhLg0YF9uACwz78shpjJB"; var $recaptcha_invisible_key = "6Lf3KHUUAAAAACggoMpmGJdQDtiyrjVlvGJ6BbAj"; var $disableClientRecordHit = false; </script> <script> window.Aedu = { hit_data: null }; window.Aedu.SiteStats = {"premium_universities_count":14022,"monthly_visitors":"104 million","monthly_visitor_count":104255865,"monthly_visitor_count_in_millions":104,"user_count":283539070,"paper_count":55203019,"paper_count_in_millions":55,"page_count":432000000,"page_count_in_millions":432,"pdf_count":16500000,"pdf_count_in_millions":16}; window.Aedu.serverRenderTime = new Date(1740366098000); window.Aedu.timeDifference = new Date().getTime() - 1740366098000; window.Aedu.isUsingCssV1 = false; window.Aedu.enableLocalization = true; window.Aedu.activateFullstory = false; window.Aedu.serviceAvailability = { status: {"attention_db":"on","bibliography_db":"on","contacts_db":"on","email_db":"on","indexability_db":"on","mentions_db":"on","news_db":"on","notifications_db":"on","offsite_mentions_db":"on","redshift":"on","redshift_exports_db":"on","related_works_db":"on","ring_db":"on","user_tests_db":"on"}, serviceEnabled: function(service) { return this.status[service] === "on"; }, readEnabled: function(service) { return this.serviceEnabled(service) || this.status[service] === "read_only"; }, }; window.Aedu.viewApmTrace = function() { // Check if x-apm-trace-id meta tag is set, and open the trace in APM // in a new window if it is. var apmTraceId = document.head.querySelector('meta[name="x-apm-trace-id"]'); if (apmTraceId) { var traceId = apmTraceId.content; // Use trace ID to construct URL, an example URL looks like: // https://app.datadoghq.com/apm/traces?query=trace_id%31298410148923562634 var apmUrl = 'https://app.datadoghq.com/apm/traces?query=trace_id%3A' + traceId; window.open(apmUrl, '_blank'); } }; </script>  <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet"> <link rel="preload" href="//maxcdn.bootstrapcdn.com/font-awesome/4.3.0/css/font-awesome.min.css" as="style" onload="this.rel='stylesheet'"> <link rel="stylesheet" media="all" href="//a.academia-assets.com/assets/libraries-a9675dcb01ec4ef6aa807ba772c7a5a00c1820d3ff661c1038a20f80d06bb4e4.css" /> <link rel="stylesheet" media="all" href="//a.academia-assets.com/assets/academia-1eb081e01ca8bc0c1b1d866df79d9eb4dd2c484e4beecf76e79a7806c72fee08.css" /> <link rel="stylesheet" media="all" href="//a.academia-assets.com/assets/design_system_legacy-056a9113b9a0f5343d013b29ee1929d5a18be35fdcdceb616600b4db8bd20054.css" /> <script src="//a.academia-assets.com/assets/webpack_bundles/runtime-bundle-005434038af4252ca37c527588411a3d6a0eabb5f727fac83f8bbe7fd88d93bb.js"></script> <script src="//a.academia-assets.com/assets/webpack_bundles/webpack_libraries_and_infrequently_changed.wjs-bundle-b42d48e01e9cb3bf5ae55ea154ab7133fe47240c1d7c59b0249065c67d6f65ab.js"></script> <script src="//a.academia-assets.com/assets/webpack_bundles/core_webpack.wjs-bundle-f3fdf92d2e211a3fd7a717a75adb7bf4af30f5d7651964d9f223129f218112cd.js"></script> <script src="//a.academia-assets.com/assets/webpack_bundles/sentry.wjs-bundle-5fe03fddca915c8ba0f7edbe64c194308e8ce5abaed7bffe1255ff37549c4808.js"></script> <script> jade = window.jade || {}; jade.helpers = window.$h; jade._ = window._; </script>  <script id="tag-manager-head-root">(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer_old','GTM-5G9JF7Z');</script>  <script> window.gptadslots = []; window.googletag = window.googletag || {}; window.googletag.cmd = window.googletag.cmd || []; </script> <script type="text/javascript"> // TODO(jacob): This should be defined, may be rare load order problem. // Checking if null is just a quick fix, will default to en if unset. // Better fix is to run this immedietely after I18n is set. if (window.I18n != null) { I18n.defaultLocale = "en"; I18n.locale = "en"; I18n.fallbacks = true; } </script> <link rel="canonical" href="https://independent.academia.edu/LSouhami" /> </head>   <body class='c-profiles/works a-summary logged_out'>  <div id="fb-root"></div><script>window.fbAsyncInit = function() { FB.init({ appId: "2369844204", version: "v8.0", status: true, cookie: true, xfbml: true }); // Additional initialization code. if (window.InitFacebook) { // facebook.ts already loaded, set it up. window.InitFacebook(); } else { // Set a flag for facebook.ts to find when it loads. window.academiaAuthReadyFacebook = true; } };</script><script>window.fbAsyncLoad = function() { // Protection against double calling of this function if (window.FB) { return; } (function(d, s, id){ var js, fjs = d.getElementsByTagName(s)[0]; if (d.getElementById(id)) {return;} js = d.createElement(s); js.id = id; js.src = "//connect.facebook.net/en_US/sdk.js"; fjs.parentNode.insertBefore(js, fjs); }(document, 'script', 'facebook-jssdk')); } if (!window.defer_facebook) { // Autoload if not deferred window.fbAsyncLoad(); } else { // Defer loading by 5 seconds setTimeout(function() { window.fbAsyncLoad(); }, 5000); }</script> <div id="google-root"></div><script>window.loadGoogle = function() { if (window.InitGoogle) { // google.ts already loaded, set it up. window.InitGoogle("331998490334-rsn3chp12mbkiqhl6e7lu2q0mlbu0f1b"); } else { // Set a flag for google.ts to use when it loads. window.GoogleClientID = "331998490334-rsn3chp12mbkiqhl6e7lu2q0mlbu0f1b"; } };</script><script>window.googleAsyncLoad = function() { // Protection against double calling of this function (function(d) { var js; var id = 'google-jssdk'; var ref = d.getElementsByTagName('script')[0]; if (d.getElementById(id)) { return; } js = d.createElement('script'); js.id = id; js.async = true; js.onload = loadGoogle; js.src = "https://accounts.google.com/gsi/client" ref.parentNode.insertBefore(js, ref); }(document)); } if (!window.defer_google) { // Autoload if not deferred window.googleAsyncLoad(); } else { // Defer loading by 5 seconds setTimeout(function() { window.googleAsyncLoad(); }, 5000); }</script> <div id="tag-manager-body-root">  <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-5G9JF7Z" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>   <script> window.addEventListener('load', function() { if (document.querySelector('input[name="commit"]')) { document.querySelector('input[name="commit"]').addEventListener('click', function() { gtag('event', 'click', { event_category: 'button', event_label: 'Log In' }) }) } }); </script> </div> <script>var _comscore = _comscore || []; _comscore.push({ c1: "2", c2: "26766707" }); (function() { var s = document.createElement("script"), el = document.getElementsByTagName("script")[0]; s.async = true; s.src = (document.location.protocol == "https:" ? "https://sb" : "http://b") + ".scorecardresearch.com/beacon.js"; el.parentNode.insertBefore(s, el); })();</script><img src="https://sb.scorecardresearch.com/p?c1=2&c2=26766707&cv=2.0&cj=1" style="position: absolute; visibility: hidden" /> <div id='react-modal'></div> <div class='DesignSystem'> <a class='u-showOnFocus' href='#site'> Skip to main content </a> </div> <div id="upgrade_ie_banner" style="display: none;"><p>Academia.edu no longer supports Internet Explorer.</p><p>To browse Academia.edu and the wider internet faster and more securely, please take a few seconds to <a href="https://www.academia.edu/upgrade-browser">upgrade your browser</a>.</p></div><script>// Show this banner for all versions of IE if (!!window.MSInputMethodContext || /(MSIE)/.test(navigator.userAgent)) { document.getElementById('upgrade_ie_banner').style.display = 'block'; }</script> <div class="DesignSystem bootstrap ShrinkableNav"><div class="navbar navbar-default main-header"><div class="container-wrapper" id="main-header-container"><div class="container"><div class="navbar-header"><div class="nav-left-wrapper u-mt0x"><div class="nav-logo"><a data-main-header-link-target="logo_home" href="https://www.academia.edu/"><img class="visible-xs-inline-block" style="height: 24px;" alt="Academia.edu" src="//a.academia-assets.com/images/academia-logo-redesign-2015-A.svg" width="24" height="24" /><img width="145.2" height="18" class="hidden-xs" style="height: 24px;" alt="Academia.edu" src="//a.academia-assets.com/images/academia-logo-redesign-2015.svg" /></a></div><div class="nav-search"><div class="SiteSearch-wrapper select2-no-default-pills"><form class="js-SiteSearch-form DesignSystem" action="https://www.academia.edu/search" accept-charset="UTF-8" method="get"><i class="SiteSearch-icon fa fa-search u-fw700 u-positionAbsolute u-tcGrayDark"></i><input class="js-SiteSearch-form-input SiteSearch-form-input form-control" data-main-header-click-target="search_input" name="q" placeholder="Search" type="text" value="" /></form></div></div></div><div class="nav-right-wrapper pull-right"><ul class="NavLinks js-main-nav list-unstyled"><li class="NavLinks-link"><a class="js-header-login-url Button Button--inverseGray Button--sm u-mb4x" id="nav_log_in" rel="nofollow" href="https://www.academia.edu/login">Log In</a></li><li class="NavLinks-link u-p0x"><a class="Button Button--inverseGray Button--sm u-mb4x" rel="nofollow" href="https://www.academia.edu/signup">Sign Up</a></li></ul><button class="hidden-lg hidden-md hidden-sm u-ml4x navbar-toggle collapsed" data-target=".js-mobile-header-links" data-toggle="collapse" type="button"><span class="icon-bar"></span><span class="icon-bar"></span><span class="icon-bar"></span></button></div></div><div class="collapse navbar-collapse js-mobile-header-links"><ul class="nav navbar-nav"><li class="u-borderColorGrayLight u-borderBottom1"><a rel="nofollow" href="https://www.academia.edu/login">Log In</a></li><li class="u-borderColorGrayLight u-borderBottom1"><a rel="nofollow" href="https://www.academia.edu/signup">Sign Up</a></li><li class="u-borderColorGrayLight u-borderBottom1 js-mobile-nav-expand-trigger"><a href="#">more&nbsp<span class="caret"></span></a></li><li><ul class="js-mobile-nav-expand-section nav navbar-nav u-m0x collapse"><li class="u-borderColorGrayLight u-borderBottom1"><a rel="false" href="https://www.academia.edu/about">About</a></li><li class="u-borderColorGrayLight u-borderBottom1"><a rel="nofollow" href="https://www.academia.edu/press">Press</a></li><li class="u-borderColorGrayLight u-borderBottom1"><a rel="false" href="https://www.academia.edu/documents">Papers</a></li><li class="u-borderColorGrayLight u-borderBottom1"><a rel="nofollow" href="https://www.academia.edu/terms">Terms</a></li><li class="u-borderColorGrayLight u-borderBottom1"><a rel="nofollow" href="https://www.academia.edu/privacy">Privacy</a></li><li class="u-borderColorGrayLight u-borderBottom1"><a rel="nofollow" href="https://www.academia.edu/copyright">Copyright</a></li><li class="u-borderColorGrayLight u-borderBottom1"><a rel="nofollow" href="https://www.academia.edu/hiring"><i class="fa fa-briefcase"></i> We're Hiring!</a></li><li class="u-borderColorGrayLight u-borderBottom1"><a rel="nofollow" href="https://support.academia.edu/hc/en-us"><i class="fa fa-question-circle"></i> Help Center</a></li><li class="js-mobile-nav-collapse-trigger u-borderColorGrayLight u-borderBottom1 dropup" style="display:none"><a href="#">less&nbsp<span class="caret"></span></a></li></ul></li></ul></div></div></div><script>(function(){ var $moreLink = $(".js-mobile-nav-expand-trigger"); var $lessLink = $(".js-mobile-nav-collapse-trigger"); var $section = $('.js-mobile-nav-expand-section'); $moreLink.click(function(ev){ ev.preventDefault(); $moreLink.hide(); $lessLink.show(); $section.collapse('show'); }); $lessLink.click(function(ev){ ev.preventDefault(); $moreLink.show(); $lessLink.hide(); $section.collapse('hide'); }); })() if ($a.is_logged_in() || false) { new Aedu.NavigationController({ el: '.js-main-nav', showHighlightedNotification: false }); } else { $(".js-header-login-url").attr("href", $a.loginUrlWithRedirect()); } Aedu.autocompleteSearch = new AutocompleteSearch({el: '.js-SiteSearch-form'});</script></div></div> <div id='site' class='fixed'> <div id="content" class="clearfix"> <script>document.addEventListener('DOMContentLoaded', function(){ var $dismissible = $(".dismissible_banner"); $dismissible.click(function(ev) { $dismissible.hide(); }); });</script> <script src="//a.academia-assets.com/assets/webpack_bundles/profile.wjs-bundle-6e7abecbfd0bf8149b30c67f14f697778b51c925ffaf0902383f452f4270c74f.js" defer="defer"></script><script>$viewedUser = Aedu.User.set_viewed( {"id":42486127,"first_name":"Luis","middle_initials":null,"last_name":"Souhami","page_name":"LSouhami","domain_name":"independent","created_at":"2016-02-01T10:54:47.452-08:00","display_name":"Luis Souhami","url":"https://independent.academia.edu/LSouhami","photo":"/images/s65_no_pic.png","has_photo":false,"is_analytics_public":false,"interests":[{"id":4720,"name":"Radiation Shielding","url":"https://www.academia.edu/Documents/in/Radiation_Shielding"},{"id":1328,"name":"Radiation","url":"https://www.academia.edu/Documents/in/Radiation"},{"id":8030,"name":"Radiation Physics","url":"https://www.academia.edu/Documents/in/Radiation_Physics"},{"id":10032,"name":"Radiation Protection","url":"https://www.academia.edu/Documents/in/Radiation_Protection"},{"id":2443,"name":"Radiation Oncology","url":"https://www.academia.edu/Documents/in/Radiation_Oncology"}]} ); if ($a.is_logged_in() && $viewedUser.is_current_user()) { $('body').addClass('profile-viewed-by-owner'); } $socialProfiles = []</script><div id="js-react-on-rails-context" style="display:none" data-rails-context="{"inMailer":false,"i18nLocale":"en","i18nDefaultLocale":"en","href":"https://independent.academia.edu/LSouhami","location":"/LSouhami","scheme":"https","host":"independent.academia.edu","port":null,"pathname":"/LSouhami","search":null,"httpAcceptLanguage":null,"serverSide":false}"></div> <div class="js-react-on-rails-component" style="display:none" data-component-name="ProfileCheckPaperUpdate" data-props="{}" data-trace="false" data-dom-id="ProfileCheckPaperUpdate-react-component-fdb245a6-6255-4640-b2d2-203b4356d12e"></div> <div id="ProfileCheckPaperUpdate-react-component-fdb245a6-6255-4640-b2d2-203b4356d12e"></div> <div class="DesignSystem"><div class="onsite-ping" id="onsite-ping"></div></div><div class="profile-user-info DesignSystem"><div class="social-profile-container"><div class="left-panel-container"><div class="user-info-component-wrapper"><div class="user-summary-cta-container"><div class="user-summary-container"><div class="social-profile-avatar-container"><img class="profile-avatar u-positionAbsolute" border="0" alt="" src="//a.academia-assets.com/images/s200_no_pic.png" /></div><div class="title-container"><h1 class="ds2-5-heading-sans-serif-sm">Luis Souhami</h1><div class="affiliations-container fake-truncate js-profile-affiliations"></div></div></div><div class="sidebar-cta-container"><button class="ds2-5-button hidden profile-cta-button grow js-profile-follow-button" data-broccoli-component="user-info.follow-button" data-click-track="profile-user-info-follow-button" data-follow-user-fname="Luis" data-follow-user-id="42486127" data-follow-user-source="profile_button" data-has-google="false"><span class="material-symbols-outlined" style="font-size: 20px" translate="no">add</span>Follow</button><button class="ds2-5-button hidden profile-cta-button grow js-profile-unfollow-button" data-broccoli-component="user-info.unfollow-button" data-click-track="profile-user-info-unfollow-button" data-unfollow-user-id="42486127"><span class="material-symbols-outlined" style="font-size: 20px" translate="no">done</span>Following</button></div></div><div class="user-stats-container"><a><div class="stat-container js-profile-followers"><p class="label">Followers</p><p class="data">100</p></div></a><a><div class="stat-container js-profile-followees" data-broccoli-component="user-info.followees-count" data-click-track="profile-expand-user-info-following"><p class="label">Following</p><p class="data">15</p></div></a><a><div class="stat-container js-profile-coauthors" data-broccoli-component="user-info.coauthors-count" data-click-track="profile-expand-user-info-coauthors"><p class="label">Co-authors</p><p class="data">14</p></div></a><div class="js-mentions-count-container" style="display: none;"><a href="/LSouhami/mentions"><div class="stat-container"><p class="label">Mentions</p><p class="data"></p></div></a></div><span><div class="stat-container"><p class="label"><span class="js-profile-total-view-text">Public Views</span></p><p class="data"><span class="js-profile-view-count"></span></p></div></span></div><div class="suggested-academics-container"><div class="suggested-academics--header"><p class="ds2-5-body-md-bold">Related Authors</p></div><ul class="suggested-user-card-list"><div class="suggested-user-card"><div class="suggested-user-card__avatar social-profile-avatar-container"><a href="https://modares.academia.edu/bhashemi"><img class="profile-avatar u-positionAbsolute" alt="Bijan Hashemi" border="0" onerror="if (this.src != '//a.academia-assets.com/images/s200_no_pic.png') this.src = '//a.academia-assets.com/images/s200_no_pic.png';" width="200" height="200" src="https://0.academia-photos.com/30563/9910/54069/s200_bijan.hashemi.30563" /></a></div><div class="suggested-user-card__user-info"><a class="suggested-user-card__user-info__header ds2-5-body-sm-bold ds2-5-body-link" href="https://modares.academia.edu/bhashemi">Bijan Hashemi</a><p class="suggested-user-card__user-info__subheader ds2-5-body-xs">Tarbiat Modares University</p></div></div><div class="suggested-user-card"><div class="suggested-user-card__avatar social-profile-avatar-container"><a href="https://uow.academia.edu/AndrewMiller"><img class="profile-avatar u-positionAbsolute" alt="Andrew Miller" border="0" onerror="if (this.src != '//a.academia-assets.com/images/s200_no_pic.png') this.src = '//a.academia-assets.com/images/s200_no_pic.png';" width="200" height="200" src="https://0.academia-photos.com/49001/15115/58424/s200_andrew.miller.jpg" /></a></div><div class="suggested-user-card__user-info"><a class="suggested-user-card__user-info__header ds2-5-body-sm-bold ds2-5-body-link" href="https://uow.academia.edu/AndrewMiller">Andrew Miller</a><p class="suggested-user-card__user-info__subheader ds2-5-body-xs">University of Wollongong</p></div></div><div class="suggested-user-card"><div class="suggested-user-card__avatar social-profile-avatar-container"><a href="https://uni-sofia.academia.edu/YavorShopov"><img class="profile-avatar u-positionAbsolute" alt="Yavor Shopov" border="0" onerror="if (this.src != '//a.academia-assets.com/images/s200_no_pic.png') this.src = '//a.academia-assets.com/images/s200_no_pic.png';" width="200" height="200" src="https://0.academia-photos.com/108450/29688/10986304/s200_yavor.shopov.jpg" /></a></div><div class="suggested-user-card__user-info"><a class="suggested-user-card__user-info__header ds2-5-body-sm-bold ds2-5-body-link" href="https://uni-sofia.academia.edu/YavorShopov">Yavor Shopov</a><p class="suggested-user-card__user-info__subheader ds2-5-body-xs">Sofia University "St. Kliment Ohridski"</p></div></div><div class="suggested-user-card"><div class="suggested-user-card__avatar social-profile-avatar-container"><a href="https://qmul.academia.edu/PeterHobson"><img class="profile-avatar u-positionAbsolute" alt="Peter Hobson" border="0" onerror="if (this.src != '//a.academia-assets.com/images/s200_no_pic.png') this.src = '//a.academia-assets.com/images/s200_no_pic.png';" width="200" height="200" src="https://0.academia-photos.com/228301/50789/46760/s200_peter.hobson.jpg" /></a></div><div class="suggested-user-card__user-info"><a class="suggested-user-card__user-info__header ds2-5-body-sm-bold ds2-5-body-link" href="https://qmul.academia.edu/PeterHobson">Peter Hobson</a><p class="suggested-user-card__user-info__subheader ds2-5-body-xs">Queen Mary, University of London</p></div></div><div class="suggested-user-card"><div class="suggested-user-card__avatar social-profile-avatar-container"><a href="https://upenn.academia.edu/kaolab"><img class="profile-avatar u-positionAbsolute" alt="Dr. Gary Kao" border="0" onerror="if (this.src != '//a.academia-assets.com/images/s200_no_pic.png') this.src = '//a.academia-assets.com/images/s200_no_pic.png';" width="200" height="200" src="https://0.academia-photos.com/477925/161592/188247/s200_dr._gary_kao_and.dr._jay_dorsey.jpg" /></a></div><div class="suggested-user-card__user-info"><a class="suggested-user-card__user-info__header ds2-5-body-sm-bold ds2-5-body-link" href="https://upenn.academia.edu/kaolab">Dr. Gary Kao</a><p class="suggested-user-card__user-info__subheader ds2-5-body-xs">University of Pennsylvania</p></div></div><div class="suggested-user-card"><div class="suggested-user-card__avatar social-profile-avatar-container"><a href="https://curie.academia.edu/GiorgioSeano"><img class="profile-avatar u-positionAbsolute" alt="Giorgio Seano" border="0" onerror="if (this.src != '//a.academia-assets.com/images/s200_no_pic.png') this.src = '//a.academia-assets.com/images/s200_no_pic.png';" width="200" height="200" src="https://0.academia-photos.com/658872/2839271/19819729/s200_giorgio.seano.jpg" /></a></div><div class="suggested-user-card__user-info"><a class="suggested-user-card__user-info__header ds2-5-body-sm-bold ds2-5-body-link" href="https://curie.academia.edu/GiorgioSeano">Giorgio Seano</a><p class="suggested-user-card__user-info__subheader ds2-5-body-xs">Institut Curie</p></div></div><div class="suggested-user-card"><div class="suggested-user-card__avatar social-profile-avatar-container"><a href="https://cern.academia.edu/RoxanaRataPanait"><img class="profile-avatar u-positionAbsolute" alt="Dr. Roxana Rata (Panait)" border="0" onerror="if (this.src != '//a.academia-assets.com/images/s200_no_pic.png') this.src = '//a.academia-assets.com/images/s200_no_pic.png';" width="200" height="200" src="https://0.academia-photos.com/3473536/1178986/9176523/s200_roxana.rata_panait_.jpg" /></a></div><div class="suggested-user-card__user-info"><a class="suggested-user-card__user-info__header ds2-5-body-sm-bold ds2-5-body-link" href="https://cern.academia.edu/RoxanaRataPanait">Dr. Roxana Rata (Panait)</a><p class="suggested-user-card__user-info__subheader ds2-5-body-xs">CERN</p></div></div><div class="suggested-user-card"><div class="suggested-user-card__avatar social-profile-avatar-container"><a href="https://just.academia.edu/YahiaQawasmi"><img class="profile-avatar u-positionAbsolute" alt="Yahia Qawasmi" border="0" onerror="if (this.src != '//a.academia-assets.com/images/s200_no_pic.png') this.src = '//a.academia-assets.com/images/s200_no_pic.png';" width="200" height="200" src="https://0.academia-photos.com/7624054/3039934/3573035/s200_yahia.qawasmi.jpg" /></a></div><div class="suggested-user-card__user-info"><a class="suggested-user-card__user-info__header ds2-5-body-sm-bold ds2-5-body-link" href="https://just.academia.edu/YahiaQawasmi">Yahia Qawasmi</a><p class="suggested-user-card__user-info__subheader ds2-5-body-xs">Jordan University of Science and Technology</p></div></div><div class="suggested-user-card"><div class="suggested-user-card__avatar social-profile-avatar-container"><a href="https://pw.academia.edu/TomaszPiotrowski"><img class="profile-avatar u-positionAbsolute" alt="Tomasz Piotrowski" border="0" onerror="if (this.src != '//a.academia-assets.com/images/s200_no_pic.png') this.src = '//a.academia-assets.com/images/s200_no_pic.png';" width="200" height="200" src="https://0.academia-photos.com/8265903/2828734/70056582/s200_tomasz.piotrowski.jpg" /></a></div><div class="suggested-user-card__user-info"><a class="suggested-user-card__user-info__header ds2-5-body-sm-bold ds2-5-body-link" href="https://pw.academia.edu/TomaszPiotrowski">Tomasz Piotrowski</a><p class="suggested-user-card__user-info__subheader ds2-5-body-xs">Warsaw University of Technology</p></div></div><div class="suggested-user-card"><div class="suggested-user-card__avatar social-profile-avatar-container"><a href="https://tu-berlin.academia.edu/AdalbertDing"><img class="profile-avatar u-positionAbsolute" border="0" alt="" src="//a.academia-assets.com/images/s200_no_pic.png" /></a></div><div class="suggested-user-card__user-info"><a class="suggested-user-card__user-info__header ds2-5-body-sm-bold ds2-5-body-link" href="https://tu-berlin.academia.edu/AdalbertDing">Adalbert Ding</a><p class="suggested-user-card__user-info__subheader ds2-5-body-xs">Technische Universität Berlin</p></div></div></ul></div><div class="ri-section"><div class="ri-section-header"><span>Interests</span></div><div class="ri-tags-container"><a data-click-track="profile-user-info-expand-research-interests" data-has-card-for-ri-list="42486127" href="https://www.academia.edu/Documents/in/Radiation_Shielding"><div id="js-react-on-rails-context" style="display:none" data-rails-context="{"inMailer":false,"i18nLocale":"en","i18nDefaultLocale":"en","href":"https://independent.academia.edu/LSouhami","location":"/LSouhami","scheme":"https","host":"independent.academia.edu","port":null,"pathname":"/LSouhami","search":null,"httpAcceptLanguage":null,"serverSide":false}"></div> <div class="js-react-on-rails-component" style="display:none" data-component-name="Pill" data-props="{"color":"gray","children":["Radiation Shielding"]}" data-trace="false" data-dom-id="Pill-react-component-c81eb4b2-43ff-449c-9662-1b4a9abaf5c1"></div> <div id="Pill-react-component-c81eb4b2-43ff-449c-9662-1b4a9abaf5c1"></div> </a><a data-click-track="profile-user-info-expand-research-interests" data-has-card-for-ri-list="42486127" href="https://www.academia.edu/Documents/in/Radiation"><div class="js-react-on-rails-component" style="display:none" data-component-name="Pill" data-props="{"color":"gray","children":["Radiation"]}" data-trace="false" data-dom-id="Pill-react-component-2e3696b8-e51d-46b3-912a-7d97955342db"></div> <div id="Pill-react-component-2e3696b8-e51d-46b3-912a-7d97955342db"></div> </a><a data-click-track="profile-user-info-expand-research-interests" data-has-card-for-ri-list="42486127" href="https://www.academia.edu/Documents/in/Radiation_Physics"><div class="js-react-on-rails-component" style="display:none" data-component-name="Pill" data-props="{"color":"gray","children":["Radiation Physics"]}" data-trace="false" data-dom-id="Pill-react-component-0f8874cc-eb23-423f-8d0d-577a278bd080"></div> <div id="Pill-react-component-0f8874cc-eb23-423f-8d0d-577a278bd080"></div> </a><a data-click-track="profile-user-info-expand-research-interests" data-has-card-for-ri-list="42486127" href="https://www.academia.edu/Documents/in/Radiation_Protection"><div class="js-react-on-rails-component" style="display:none" data-component-name="Pill" data-props="{"color":"gray","children":["Radiation Protection"]}" data-trace="false" data-dom-id="Pill-react-component-44211fc0-203f-4103-bb9b-c46c5f8b4b93"></div> <div id="Pill-react-component-44211fc0-203f-4103-bb9b-c46c5f8b4b93"></div> </a><a data-click-track="profile-user-info-expand-research-interests" data-has-card-for-ri-list="42486127" href="https://www.academia.edu/Documents/in/Radiation_Oncology"><div class="js-react-on-rails-component" style="display:none" data-component-name="Pill" data-props="{"color":"gray","children":["Radiation Oncology"]}" data-trace="false" data-dom-id="Pill-react-component-886d6783-0da1-4e6a-bb2d-6de80ffa48af"></div> <div id="Pill-react-component-886d6783-0da1-4e6a-bb2d-6de80ffa48af"></div> </a></div></div></div></div><div class="right-panel-container"><div class="user-content-wrapper"><div class="uploads-container" id="social-redesign-work-container"><div class="upload-header"><h2 class="ds2-5-heading-sans-serif-xs">Uploads</h2></div><div class="documents-container backbone-social-profile-documents" style="width: 100%;"><div class="u-taCenter"></div><div class="profile--tab_content_container js-tab-pane tab-pane active" id="all"><div class="profile--tab_heading_container js-section-heading" data-section="Papers" id="Papers"><h3 class="profile--tab_heading_container">Papers by Luis Souhami</h3></div><div class="js-work-strip profile--work_container" data-work-id="115450617"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" rel="nofollow" href="https://www.academia.edu/115450617/WE_D_BRE_02_BEST_IN_PHYSICS_THERAPY_Radiogenomic_Modeling_of_Normal_Tissue_Toxicities_in_Prostate_Cancer_Patients_Receiving_Hypofractionated_Radiotherapy"><img alt="Research paper thumbnail of WE-D-BRE-02: BEST IN PHYSICS (THERAPY) - Radiogenomic Modeling of Normal Tissue Toxicities in Prostate Cancer Patients Receiving Hypofractionated Radiotherapy" class="work-thumbnail" src="https://a.academia-assets.com/images/blank-paper.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" rel="nofollow" href="https://www.academia.edu/115450617/WE_D_BRE_02_BEST_IN_PHYSICS_THERAPY_Radiogenomic_Modeling_of_Normal_Tissue_Toxicities_in_Prostate_Cancer_Patients_Receiving_Hypofractionated_Radiotherapy">WE-D-BRE-02: BEST IN PHYSICS (THERAPY) - Radiogenomic Modeling of Normal Tissue Toxicities in Prostate Cancer Patients Receiving Hypofractionated Radiotherapy</a></div><div class="wp-workCard_item"><span>Medical Physics</span><span>, May 29, 2014</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">It has been realized that inter-patient radiation sensitivity variability is a multifactorial pro...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">It has been realized that inter-patient radiation sensitivity variability is a multifactorial process involving dosimetric, clinical, and genetic factors. Therefore, we explore a new framework to integrate physical, clinical, and biological data denoted as radiogenomic modeling. In demonstrating the feasibility of this work, we investigate the association of genetic variants (copy number variations [CNVs] and single nucleotide polymorphisms [SNPs]) with radiation induced rectal bleeding (RB) and erectile dysfunction (ED) while taking into account dosimetric and clinical variables in prostate cancer patients treated with curative irradiation. A cohort of 62 prostate cancer patients who underwent hypofractionated radiotherapy (66 Gy in 22 fractions) was retrospectively genotyped for CNV and SNP rs25489 in the xrcc1 DNA repair gene. Dosevolume metrics were extracted from treatment plans of 54 patients who had complete dosimetric profiles. Treatment outcomes were considered to be a RESULT OF FUNCTIONAL MAPPING OF RADIOGENOMIC INPUT VARIABLES ACCORDING TO A LOGIT TRANSFORMATION. MODEL ORDERS WERE ESTIMATED USING RESAMPLING BY LEAVE-ONE OUT CROSS-VALIDATION (LOO-CV). RADIOGENOMIC MODEL PERFORMANCE WAS EVALUATED USING AREA UNDER THE ROC CURVE (AUC) AND LOO-CV. FOR CONTINUOUS UNIVARIATE DOSIMETRIC AND CLINICAL VARIABLES, SPEARMANS RANK COEFFICIENTS WERE CALCULATED AND P-VALUES REPORTED ACCORDINGLY. IN THE CASE OF BINARY VARIABLES, CHI-SQUARED STATISTICS AND CONTINGENCY TABLE CALCULATIONS WERE USED. Ten patients were found to have three copies of xrcc1 CNV (RB: χ2=14.6 [p&amp;lt;0.001] and ED: χ2=4.88[p=0.0272]) and twelve had heterozygous rs25489 SNP (RB: χ2=0.278[p=0.599] and ED: χ2=0.112[p=0.732]). LOO-CV identified penile bulb D60 as the only significant QUANTEC predictor (rs=0.312 [p=0.0145]) for ED. Radiogenomic modeling yielded statistically significant, cross-validated NTCP models for RB (rs=0.243[p=0.0443], AUC=0.665) and ED (rs=0.276[p=0.0217], AUC=0.754). The radiogenomic modeling approach presented herein has been shown to identify NTCP models which have increased predictive power. Furthermore, CNVs appears to be useful genetic variants when added to dosimetric NTCP models. This work was partially supported by CIHR grant MOP-114910.</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="115450617"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="115450617"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 115450617; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=115450617]").text(description); $(".js-view-count[data-work-id=115450617]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 115450617; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='115450617']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (false){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "-1" } } $('.js-work-strip[data-work-id=115450617]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":115450617,"title":"WE-D-BRE-02: BEST IN PHYSICS (THERAPY) - Radiogenomic Modeling of Normal Tissue Toxicities in Prostate Cancer Patients Receiving Hypofractionated Radiotherapy","internal_url":"https://www.academia.edu/115450617/WE_D_BRE_02_BEST_IN_PHYSICS_THERAPY_Radiogenomic_Modeling_of_Normal_Tissue_Toxicities_in_Prostate_Cancer_Patients_Receiving_Hypofractionated_Radiotherapy","owner_id":42486127,"coauthors_can_edit":true,"owner":{"id":42486127,"first_name":"Luis","middle_initials":null,"last_name":"Souhami","page_name":"LSouhami","domain_name":"independent","created_at":"2016-02-01T10:54:47.452-08:00","display_name":"Luis Souhami","url":"https://independent.academia.edu/LSouhami"},"attachments":[]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="115450615"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/115450615/Endometrial_Carcinoma_in_Elderly_Women_Disease_Outcome_and_Treatment_Morbidity"><img alt="Research paper thumbnail of Endometrial Carcinoma in Elderly Women: Disease Outcome and Treatment Morbidity" class="work-thumbnail" src="https://attachments.academia-assets.com/111854040/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/115450615/Endometrial_Carcinoma_in_Elderly_Women_Disease_Outcome_and_Treatment_Morbidity">Endometrial Carcinoma in Elderly Women: Disease Outcome and Treatment Morbidity</a></div><div class="wp-workCard_item"><span>International Journal of Radiation Oncology Biology Physics</span><span>, Nov 1, 2007</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="1071b40cd9c1877f81571cb3bec00c6a" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":111854040,"asset_id":115450615,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/111854040/download_file?s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="115450615"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="115450615"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 115450615; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=115450615]").text(description); $(".js-view-count[data-work-id=115450615]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 115450615; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='115450615']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "1071b40cd9c1877f81571cb3bec00c6a" } } $('.js-work-strip[data-work-id=115450615]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":115450615,"title":"Endometrial Carcinoma in Elderly Women: Disease Outcome and Treatment Morbidity","internal_url":"https://www.academia.edu/115450615/Endometrial_Carcinoma_in_Elderly_Women_Disease_Outcome_and_Treatment_Morbidity","owner_id":42486127,"coauthors_can_edit":true,"owner":{"id":42486127,"first_name":"Luis","middle_initials":null,"last_name":"Souhami","page_name":"LSouhami","domain_name":"independent","created_at":"2016-02-01T10:54:47.452-08:00","display_name":"Luis Souhami","url":"https://independent.academia.edu/LSouhami"},"attachments":[{"id":111854040,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/111854040/thumbnails/1.jpg","file_name":"j.ijrobp.2007.07.152120240226-1-y1fijc.pdf","download_url":"https://www.academia.edu/attachments/111854040/download_file","bulk_download_file_name":"Endometrial_Carcinoma_in_Elderly_Women_D.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/111854040/j.ijrobp.2007.07.152120240226-1-y1fijc-libre.pdf?1708960034=\u0026response-content-disposition=attachment%3B+filename%3DEndometrial_Carcinoma_in_Elderly_Women_D.pdf\u0026Expires=1740369698\u0026Signature=cJVLagwFhmduzGRGfyaiLHlDrOctvql5zJojuA78wVJWPuFCjH2vY4J7xsLDjzH2kZg55G4~fs2Q9rPjYSv2McxXpzi7yebAJQBFnxfp2hv4lqXlzdaH8r-fDy9BKyTJ9QYsmQSVwNw0d-qKS1y8Lh4Msdk3utCIx5t4oR4H1p6r5Ut4UF4M1lcQrhIUjNlYhPrZk6JW92THsH1Zq--94EVHQg8q~XIsltMfNDK6jHCktrfTS4N4Du89Fr5JmLp74mVPjNbuNsU7gNi0sDLjIOlt9Jj5HYNBVV7smKUL1W1YFmqwOUHdsELeBNLgVN2McyvKyiuJDeSlIeu77zzppA__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="115450612"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/115450612/Met%C3%A1stase_cerebral_tratamento_paliativo_com_radiocirurgia"><img alt="Research paper thumbnail of Metástase cerebral: tratamento paliativo com radiocirurgia" class="work-thumbnail" src="https://attachments.academia-assets.com/111854362/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/115450612/Met%C3%A1stase_cerebral_tratamento_paliativo_com_radiocirurgia">Metástase cerebral: tratamento paliativo com radiocirurgia</a></div><div class="wp-workCard_item"><span>Arquivos De Neuro-psiquiatria</span><span>, Sep 1, 1995</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">RESUMO-O artigo faz avaliação de 52 pacientes com metástase cerebral tratados com radiocirurgia e...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">RESUMO-O artigo faz avaliação de 52 pacientes com metástase cerebral tratados com radiocirurgia estereotática na Universidade McGill, em Montreal. A radiocirurgia foi realizada com a técnica dinâmica em que, ao mesmo tempo, giram a mesa e a cabeça do acelerador linear de 10 MV. Todos os pacientes (56 tratamentos ao todo) foram tratados com um único isocentro e uma dose única mediana de 1800 cGy na periferia da metástase. Em 88% dos casos a radiocirurgia foi usada após falha de tratamento radioterápico fracionado em todo cérebro. Todos os 52 casos tiveram avaliação com CT pós radiocirurgia. O seguimento mediano foi de 6 meses (variou entre 1 e 37 meses) e a taxa de resposta, parcial ou completa, foi de 64%. Apenas 4 pacientes (7%) tiveram algum tipo de complicação tardia relacionada ao tratamento. Estes achados vão de encontro com dados da literatura. A radiocirurgia é tratamento pouco agressivo, bem tolerado e com alta taxa de resposta para lesões locais e pode ser útil para pacientes selecionados. O seu valor definitivo, como tratamento único ou combinado com radioterapia em todo cérebro, está sendo avaliado de forma prospectiva e randomizada. PALAVRAS-CHAVE : radiocirurgia estereotática, metástase cerebral, tratamento paliativo. Brain metastasis: palliative treatment with radiosurgery SUMMARY-This is a retrospective review of 52 patients with metastatic brain disease who underwent stereotactic radiosurgery at McGill University in Montreal. The radiosurgical treatment was performed with the dynamic rotation technique in which there is continuous and simultaneous movement of treatment couch and machine gantry of a 10 MV linac. All patients were treated with a single isocenter and a median dose of 1800 cGy was delivered. In 88% of the cases radiosurgery was given after failure from whole brain conventional irradiation. All 52 cases were assessed with brain CT post radiosurgery. The median follow up time was 6 months (range 1-37 months) and the response rate (partial or complete) was 64%. Only 4 patientes (7%) developed late complications related to the treatment. These findings are similar to the literature. Stereotactic radiosurgery is a well tolerated, effective and minimally invasive treatment technique which has a high response rate in selected patients with small, well delineated metastatic brain lesion. Its definitive value as a single therapy or combined with whole brain conventional radiotherapy is being studied in prospective and randomized trials.</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="689fd1e8c5ac9d477c4f8d02729af7d9" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":111854362,"asset_id":115450612,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/111854362/download_file?s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="115450612"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="115450612"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 115450612; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=115450612]").text(description); $(".js-view-count[data-work-id=115450612]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 115450612; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='115450612']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "689fd1e8c5ac9d477c4f8d02729af7d9" } } $('.js-work-strip[data-work-id=115450612]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":115450612,"title":"Metástase cerebral: tratamento paliativo com radiocirurgia","internal_url":"https://www.academia.edu/115450612/Met%C3%A1stase_cerebral_tratamento_paliativo_com_radiocirurgia","owner_id":42486127,"coauthors_can_edit":true,"owner":{"id":42486127,"first_name":"Luis","middle_initials":null,"last_name":"Souhami","page_name":"LSouhami","domain_name":"independent","created_at":"2016-02-01T10:54:47.452-08:00","display_name":"Luis Souhami","url":"https://independent.academia.edu/LSouhami"},"attachments":[{"id":111854362,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/111854362/thumbnails/1.jpg","file_name":"hrrHQBsjZzzQ6DTGy9cd4Pm.pdf","download_url":"https://www.academia.edu/attachments/111854362/download_file","bulk_download_file_name":"Metastase_cerebral_tratamento_paliativo.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/111854362/hrrHQBsjZzzQ6DTGy9cd4Pm-libre.pdf?1708960021=\u0026response-content-disposition=attachment%3B+filename%3DMetastase_cerebral_tratamento_paliativo.pdf\u0026Expires=1740208816\u0026Signature=MeP2UHCHfAx0D6dXzQ4qqGVT0JqjmAYQkuf1a4H8n5un39BVuJMrK9Knw~3xzA~GVjRREfY0l45ktADtig7ufaEmoKQIxguZqX1I4uNwJz1ThNY2g7LepaGXdDNBCTTOgv2eFKzZPR92a27KRnInQKFDEWD6cmGJYprL1Wt38oJXQA~scD53Tp4iEJIrSylGjwTvmQzqgpUVgqXWQjAEe5CH19VXNSr0e0MjdsPWEEZ9u8Oc8WVZwVLI5Ra36fHl~VLyZiJqEXBovrpB-9efaD1i0mUdUcARHwS8~CDbmogqolwPIFx31OZyk9C613iqaffJMrmfIC9YFFM5z2g1OQ__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="115450605"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/115450605/Bladder_Sparing_Hypofractionated_Intensity_Modulated_Radiation_Therapy_plus_Weekly_Gemcitabine_in_Patients_with_Invasive_Bladder_Cancer"><img alt="Research paper thumbnail of Bladder-Sparing Hypofractionated Intensity Modulated Radiation Therapy plus Weekly Gemcitabine in Patients with Invasive Bladder Cancer" class="work-thumbnail" src="https://attachments.academia-assets.com/111854039/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/115450605/Bladder_Sparing_Hypofractionated_Intensity_Modulated_Radiation_Therapy_plus_Weekly_Gemcitabine_in_Patients_with_Invasive_Bladder_Cancer">Bladder-Sparing Hypofractionated Intensity Modulated Radiation Therapy plus Weekly Gemcitabine in Patients with Invasive Bladder Cancer</a></div><div class="wp-workCard_item"><span>International Journal of Radiation Oncology Biology Physics</span><span>, Nov 1, 2018</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">Time to local failure was defined from the start of radiotherapy to pathological confirmation of ...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">Time to local failure was defined from the start of radiotherapy to pathological confirmation of relapse, and was estimated using Kaplan Meier method. Cystoscopy and imaging (CT/MRI) were used to reconstruct the bladder relapse volume (GTV relapse) on the initial planning CT. Dose to GTV relapse (D 98%) was determined from planning scan used for treatment. Results: Twenty-seven of 38 (71%) of all patients had disease recurrence. Eighteen of 38 (47%) patients experienced first relapse within the bladder following radiotherapy. Median time to local relapse was 9.0 months (95% CI, 6.3-11.7 months). Fifteen of 18 (83.3%) of these patients received neoadjuvant chemotherapy and 10/18 (56.6%) had received concurrent chemotherapy. Ten of 18 (55.6%) patients relapsed with T2 local disease, 5/18 (27.8%) with pTa/pT1 disease, and 3/18 (16.7%) with carcinoma in situ. Fifteen of 18 (83%) of these relapses occurred within 1cm of the original bladder tumor site. Overall median GTV relapse D 98% was 57.1Gy (range 49.9-63.3Gy), 89.1% (77.9-99.0) of the prescribed dose (64Gy). Median GTV relapse D 98% where all or partial of the relapse volume was within 1cm of the original bladder tumor edge was 54.5Gy (range 51.4-63.3Gy), 85.2% (range 80.3-99.0%) of the prescribed dose (64Gy). Conclusion: Relapse patterns suggest local failure occurs within close proximity of the original bladder boost volume but outside the high dose treatment field (64Gy). Work is ongoing to expand the patient numbers and to determine actual dose delivered to GTV relapse D 98% from on-line CBCT data. This will inform whether dose escalation, and or margin modification could improve reported outcomes.</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="6c2e9ceb7fd93361bba66f5f6245529b" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":111854039,"asset_id":115450605,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/111854039/download_file?s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="115450605"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="115450605"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 115450605; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=115450605]").text(description); $(".js-view-count[data-work-id=115450605]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 115450605; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='115450605']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "6c2e9ceb7fd93361bba66f5f6245529b" } } $('.js-work-strip[data-work-id=115450605]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":115450605,"title":"Bladder-Sparing Hypofractionated Intensity Modulated Radiation Therapy plus Weekly Gemcitabine in Patients with Invasive Bladder Cancer","internal_url":"https://www.academia.edu/115450605/Bladder_Sparing_Hypofractionated_Intensity_Modulated_Radiation_Therapy_plus_Weekly_Gemcitabine_in_Patients_with_Invasive_Bladder_Cancer","owner_id":42486127,"coauthors_can_edit":true,"owner":{"id":42486127,"first_name":"Luis","middle_initials":null,"last_name":"Souhami","page_name":"LSouhami","domain_name":"independent","created_at":"2016-02-01T10:54:47.452-08:00","display_name":"Luis Souhami","url":"https://independent.academia.edu/LSouhami"},"attachments":[{"id":111854039,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/111854039/thumbnails/1.jpg","file_name":"j.ijrobp.2018.07.44420240226-1-hxr3kf.pdf","download_url":"https://www.academia.edu/attachments/111854039/download_file","bulk_download_file_name":"Bladder_Sparing_Hypofractionated_Intensi.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/111854039/j.ijrobp.2018.07.44420240226-1-hxr3kf-libre.pdf?1708960035=\u0026response-content-disposition=attachment%3B+filename%3DBladder_Sparing_Hypofractionated_Intensi.pdf\u0026Expires=1740208816\u0026Signature=AQVksJTWlqERYiZlsz6UKuaVsfPazC9n4wLn-aVfZKKP2sd1C4yHF9hRH9O8m~B~Mah8aXusc4oKFCMUaviqVr5gK5mr6SsUpS1HsjMx6vTUfQMgSb3aFHizJOQK9JeVWk~t~gS8fldMetsb5PGmraUVIcFU4uNKEEXkzZLawTo1XmJtUinrEet8RyRBziqFCXzTLZMkFKScsyZWFDVxtcYL4TfKYVWyuolLiDyt-BiaQAEzJDrhoSOTzwRuy6WJKScM109Q3Vv~qnKxL5UW4HBMHsJB73mBWSRciIkamn2HiKoYp3VfPsPJq9iJWAJ7KHkKosVhMA~fjpJlhcitYQ__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="115450603"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/115450603/ACTR_13_Final_Results_with_Chemoradiotherapy_for_Anaplastic_Oligodendroglial_Tumors_from_NRG_Oncology_Rtog_9402"><img alt="Research paper thumbnail of ACTR-13. Final Results with Chemoradiotherapy for Anaplastic Oligodendroglial Tumors from NRG Oncology/Rtog 9402" class="work-thumbnail" src="https://attachments.academia-assets.com/111854038/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/115450603/ACTR_13_Final_Results_with_Chemoradiotherapy_for_Anaplastic_Oligodendroglial_Tumors_from_NRG_Oncology_Rtog_9402">ACTR-13. Final Results with Chemoradiotherapy for Anaplastic Oligodendroglial Tumors from NRG Oncology/Rtog 9402</a></div><div class="wp-workCard_item"><span>Neuro-oncology</span><span>, Nov 1, 2019</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">NEURO-ONCOLOGY • NOVEMBER 2019 tients experience recurrent/progressive disease, with a median sur...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">NEURO-ONCOLOGY • NOVEMBER 2019 tients experience recurrent/progressive disease, with a median survival after recurrence of 3-9 months. Second-line treatment for recurrent GBM with bevacizumab (BEV) has not improved survival, and effective therapies for GBM are lacking. Unmethylated promoter for O 6-methylguanine-DNAmethyltransferase (MGMT) is a validated biomarker for TMZ-resistance and is correlated with poor patient prognosis. VAL-083 is a bi-functional DNA-targeting agent which rapidly induces interstrand DNA cross-links at N 7-guanine, induces double-strand breaks and acts independent of MGMT DNA repair. The current ongoing trial is a biomarker-driven Phase 2 study in MGMT-unmethylated BEV-naïve adult GBM. The primary objective of this study is to determine the effect of VAL-083 on median overall survival (mOS) for MGMT-unmethylated GBM patients compared to historical control. Secondary efficacy endpoints include progression-free survival (PFS), overall response rate (ORR), duration of response (DOR), and quality-of-life. Thirtyfive (35) subjects with recurrent GBM have received 40 mg/m 2 /day VAL-083 on days 1, 2, 3 of a 21-day cycle as the starting dose. Myelosuppression is the most common adverse event and a higher potential for this toxicity correlated with those patients who received a higher number of cycles of prior TMZ maintenance therapy, (>5 cycles vs. ≤5 cycles, p< 0.05). To minimize the potential for hematological toxicity in rGBM, subsequent subjects initiated treatment at 30 mg/m 2 /d VAL-083 x 3 consecutive days every 21 days. In addition, since TMZ is of limited value in the MGMT-unmethylated setting, a second arm in newly diagnosed GBM has been included to explore whether substituting TMZ with VAL-083 offers clinical benefit and extends the time to recurrence. Enrollment, safety data and study updates will be presented at the meeting. Clinicaltrials.gov identifier: NCT02717962.</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="c1eebb099f9e2d4fa0e36fd783e82ca0" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":111854038,"asset_id":115450603,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/111854038/download_file?s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="115450603"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="115450603"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 115450603; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=115450603]").text(description); $(".js-view-count[data-work-id=115450603]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 115450603; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='115450603']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "c1eebb099f9e2d4fa0e36fd783e82ca0" } } $('.js-work-strip[data-work-id=115450603]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":115450603,"title":"ACTR-13. Final Results with Chemoradiotherapy for Anaplastic Oligodendroglial Tumors from NRG Oncology/Rtog 9402","internal_url":"https://www.academia.edu/115450603/ACTR_13_Final_Results_with_Chemoradiotherapy_for_Anaplastic_Oligodendroglial_Tumors_from_NRG_Oncology_Rtog_9402","owner_id":42486127,"coauthors_can_edit":true,"owner":{"id":42486127,"first_name":"Luis","middle_initials":null,"last_name":"Souhami","page_name":"LSouhami","domain_name":"independent","created_at":"2016-02-01T10:54:47.452-08:00","display_name":"Luis Souhami","url":"https://independent.academia.edu/LSouhami"},"attachments":[{"id":111854038,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/111854038/thumbnails/1.jpg","file_name":"noz175.056.pdf","download_url":"https://www.academia.edu/attachments/111854038/download_file","bulk_download_file_name":"ACTR_13_Final_Results_with_Chemoradiothe.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/111854038/noz175.056-libre.pdf?1708960035=\u0026response-content-disposition=attachment%3B+filename%3DACTR_13_Final_Results_with_Chemoradiothe.pdf\u0026Expires=1740369698\u0026Signature=abzIMTolImd3qGQdOXVqRjOg2FMiCBbmCQ4sw~kMI00AS2Z0B34tTZHY-MR1q4E2T0E-iDxjRglwBq4PfWHROOWFzsEl~MFkVpflzSv11d13ZlN1565-z0OQUeZJR9xbZsmNwb9OePS~WUvl6JXEVeuFKqt6E8paGwntO9Mgd7xt6CEXm00zYWSREMWCRG72DsHb27BLjIGpkCZFwhrazyMTFGsNamBX0A4dEeKPq6u2h~MOf4KzmLoLzUNzACCEY3BGgOvJXa5of-0vcuKpu9c2zpN9cwVO4ZnQiSZYlm4uybqFtPsb63l2C-1kw3HwzICsJDFf6IxV8~Ej3rxgbQ__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="115450601"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" rel="nofollow" href="https://www.academia.edu/115450601/Pelvic_lymph_node_displacement_in_high_risk_prostate_cancer_patients_treated_with_image_guided_intensity_modulated_radiation_therapy_with_2_independent_target_volumes"><img alt="Research paper thumbnail of Pelvic lymph node displacement in high-risk prostate cancer patients treated with image guided intensity modulated radiation therapy with 2 independent target volumes" class="work-thumbnail" src="https://a.academia-assets.com/images/blank-paper.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" rel="nofollow" href="https://www.academia.edu/115450601/Pelvic_lymph_node_displacement_in_high_risk_prostate_cancer_patients_treated_with_image_guided_intensity_modulated_radiation_therapy_with_2_independent_target_volumes">Pelvic lymph node displacement in high-risk prostate cancer patients treated with image guided intensity modulated radiation therapy with 2 independent target volumes</a></div><div class="wp-workCard_item"><span>Practical radiation oncology</span><span>, Nov 1, 2015</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">To evaluate the displacement of the pelvic lymph node (PLN) target when using cone beam computed ...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">To evaluate the displacement of the pelvic lymph node (PLN) target when using cone beam computed tomography (CBCT) for localization of the prostate in patients treated with simultaneous integrated boost. High-risk prostate cancer patients treated with image guided intensity modulated radiation therapy with simultaneous integrated boost receiving 60 Gy in 20 fractions to the prostate and proximal seminal vesicles (PTV60) and 44 Gy in the same 20 fractions to the PLN (PTV44) were studied. Two hundred weekly CBCTs of 50 patients were retrospectively reviewed to assess the displacement of the iliac vessels compared with the simulation computed tomography. For each CBCT, possible displacements were analyzed at 3 levels of PTV44: a superior, middle, and inferior slice, making a total of 600 slices reviewed. Geographical miss (GM) was defined when any part of the iliac vessels on the CBCT was outside of the PTV44 contour. GM was found in 7 of the 600 CBCT slices, all in different patients. All GMs were of ≤5 mm. Four GMs occurred on the middle slice and 3 on the superior slice. In 3 cases, the GM was related to shifts ≥7 mm applied to the prostate. Our review suggests that for high-risk prostate cancer, the chance of not appropriately covering the PLN target after adjusting the prostate is low. GM was uncommon and in the order of only a few millimeters when it occurred.</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="115450601"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="115450601"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 115450601; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=115450601]").text(description); $(".js-view-count[data-work-id=115450601]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 115450601; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='115450601']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (false){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "-1" } } $('.js-work-strip[data-work-id=115450601]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":115450601,"title":"Pelvic lymph node displacement in high-risk prostate cancer patients treated with image guided intensity modulated radiation therapy with 2 independent target volumes","internal_url":"https://www.academia.edu/115450601/Pelvic_lymph_node_displacement_in_high_risk_prostate_cancer_patients_treated_with_image_guided_intensity_modulated_radiation_therapy_with_2_independent_target_volumes","owner_id":42486127,"coauthors_can_edit":true,"owner":{"id":42486127,"first_name":"Luis","middle_initials":null,"last_name":"Souhami","page_name":"LSouhami","domain_name":"independent","created_at":"2016-02-01T10:54:47.452-08:00","display_name":"Luis Souhami","url":"https://independent.academia.edu/LSouhami"},"attachments":[]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="115450600"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" rel="nofollow" href="https://www.academia.edu/115450600/Report_of_NRG_Oncology_RTOG_9601_A_Phase_3_Trial_in_Prostate_Cancer_Anti_androgen_Therapy_AAT_With_Bicalutamide_During_and_After_Radiation_Therapy_RT_in_Patients_Following_Radical_Prostatectomy_RP_With_pT2_3pN0_Disease_and_an_Elevated_PSA"><img alt="Research paper thumbnail of Report of NRG Oncology/RTOG 9601, A Phase 3 Trial in Prostate Cancer: Anti-androgen Therapy (AAT) With Bicalutamide During and After Radiation Therapy (RT) in Patients Following Radical Prostatectomy (RP) With pT2-3pN0 Disease and an Elevated PSA" class="work-thumbnail" src="https://a.academia-assets.com/images/blank-paper.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" rel="nofollow" href="https://www.academia.edu/115450600/Report_of_NRG_Oncology_RTOG_9601_A_Phase_3_Trial_in_Prostate_Cancer_Anti_androgen_Therapy_AAT_With_Bicalutamide_During_and_After_Radiation_Therapy_RT_in_Patients_Following_Radical_Prostatectomy_RP_With_pT2_3pN0_Disease_and_an_Elevated_PSA">Report of NRG Oncology/RTOG 9601, A Phase 3 Trial in Prostate Cancer: Anti-androgen Therapy (AAT) With Bicalutamide During and After Radiation Therapy (RT) in Patients Following Radical Prostatectomy (RP) With pT2-3pN0 Disease and an Elevated PSA</a></div><div class="wp-workCard_item"><span>International Journal of Radiation Oncology Biology Physics</span><span>, 2016</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">Hospitalization final 90 days of life 48.3% 64.0% .0004 Hospitalization final 30 days of life 31....</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">Hospitalization final 90 days of life 48.3% 64.0% .0004 Hospitalization final 30 days of life 31.5% 61.5% &lt;.0001 Died in a hospital 8.4% 38.5% &lt;.0001 Hospice care provided 69.6% 47.0% &lt;.0001 Hospice median stay (days) 22 days 13 days .0004 Mean inpatient costs final 90 days of life $12,976 $20,398 .0065 Mean total costs final 90 days of life $20,771 $28,088 .0128 Volume 94 Number 1 2016 Selected for Clinical Trials and Plenary Sessions 3</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="115450600"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="115450600"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 115450600; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=115450600]").text(description); $(".js-view-count[data-work-id=115450600]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 115450600; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='115450600']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (false){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "-1" } } $('.js-work-strip[data-work-id=115450600]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":115450600,"title":"Report of NRG Oncology/RTOG 9601, A Phase 3 Trial in Prostate Cancer: Anti-androgen Therapy (AAT) With Bicalutamide During and After Radiation Therapy (RT) in Patients Following Radical Prostatectomy (RP) With pT2-3pN0 Disease and an Elevated PSA","internal_url":"https://www.academia.edu/115450600/Report_of_NRG_Oncology_RTOG_9601_A_Phase_3_Trial_in_Prostate_Cancer_Anti_androgen_Therapy_AAT_With_Bicalutamide_During_and_After_Radiation_Therapy_RT_in_Patients_Following_Radical_Prostatectomy_RP_With_pT2_3pN0_Disease_and_an_Elevated_PSA","owner_id":42486127,"coauthors_can_edit":true,"owner":{"id":42486127,"first_name":"Luis","middle_initials":null,"last_name":"Souhami","page_name":"LSouhami","domain_name":"independent","created_at":"2016-02-01T10:54:47.452-08:00","display_name":"Luis Souhami","url":"https://independent.academia.edu/LSouhami"},"attachments":[]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="115450599"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" rel="nofollow" href="https://www.academia.edu/115450599/Body_composition_and_mortality_in_men_receiving_prostate_radiotherapy_A_pooled_analysis_of_NRG_RTOG_9406_and_NRG_RTOG_0126"><img alt="Research paper thumbnail of Body composition and mortality in men receiving prostate radiotherapy: A pooled analysis of NRG/RTOG 9406 and NRG/RTOG 0126" class="work-thumbnail" src="https://a.academia-assets.com/images/blank-paper.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" rel="nofollow" href="https://www.academia.edu/115450599/Body_composition_and_mortality_in_men_receiving_prostate_radiotherapy_A_pooled_analysis_of_NRG_RTOG_9406_and_NRG_RTOG_0126">Body composition and mortality in men receiving prostate radiotherapy: A pooled analysis of NRG/RTOG 9406 and NRG/RTOG 0126</a></div><div class="wp-workCard_item"><span>Cancer</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">PurposeTo validate the association between body composition and mortality in men treated with rad...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">PurposeTo validate the association between body composition and mortality in men treated with radiation for localized prostate cancer (PCa). Secondarily, to integrate body composition as a factor to classify patients by risk of all‐cause mortality.Materials and MethodsParticipants of NRG/Radiation Therapy Oncology Group (RTOG) 9406 and NRG/RTOG 0126 with archived computed tomography were included. Muscle mass and muscle density were estimated by measuring the area and attenuation of the psoas muscles on a single slice at L4–L5. Bone density was estimated by measuring the attenuation of the vertebral body at mid‐L5. Survival analyses, including Cox proportional hazards models, assessed the relationship between body composition and mortality. Recursive partitioning analysis (RPA) was used to create a classification tree to classify participants by risk of death.ResultsData from 2066 men were included in this study. In the final multivariable model, psoas area, comorbidity score, basel...</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="115450599"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="115450599"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 115450599; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=115450599]").text(description); $(".js-view-count[data-work-id=115450599]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 115450599; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='115450599']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (false){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "-1" } } $('.js-work-strip[data-work-id=115450599]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":115450599,"title":"Body composition and mortality in men receiving prostate radiotherapy: A pooled analysis of NRG/RTOG 9406 and NRG/RTOG 0126","internal_url":"https://www.academia.edu/115450599/Body_composition_and_mortality_in_men_receiving_prostate_radiotherapy_A_pooled_analysis_of_NRG_RTOG_9406_and_NRG_RTOG_0126","owner_id":42486127,"coauthors_can_edit":true,"owner":{"id":42486127,"first_name":"Luis","middle_initials":null,"last_name":"Souhami","page_name":"LSouhami","domain_name":"independent","created_at":"2016-02-01T10:54:47.452-08:00","display_name":"Luis Souhami","url":"https://independent.academia.edu/LSouhami"},"attachments":[]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="115450598"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" rel="nofollow" href="https://www.academia.edu/115450598/Validation_of_the_performance_of_the_Decipher_biopsy_genomic_classifier_in_intermediate_risk_prostate_cancer_on_the_phase_III_randomized_trial_NRG_Oncology_RTOG_0126"><img alt="Research paper thumbnail of Validation of the performance of the Decipher biopsy genomic classifier in intermediate-risk prostate cancer on the phase III randomized trial NRG Oncology/RTOG 0126" class="work-thumbnail" src="https://a.academia-assets.com/images/blank-paper.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" rel="nofollow" href="https://www.academia.edu/115450598/Validation_of_the_performance_of_the_Decipher_biopsy_genomic_classifier_in_intermediate_risk_prostate_cancer_on_the_phase_III_randomized_trial_NRG_Oncology_RTOG_0126">Validation of the performance of the Decipher biopsy genomic classifier in intermediate-risk prostate cancer on the phase III randomized trial NRG Oncology/RTOG 0126</a></div><div class="wp-workCard_item"><span>Journal of Clinical Oncology</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">269 Background: The 22-gene Decipher genomic classifier (GC) is a prognostic biomarker that has b...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">269 Background: The 22-gene Decipher genomic classifier (GC) is a prognostic biomarker that has been validated in phase III trials in high-risk localized, post-prostatectomy, and metastatic and non-metastatic castration-resistant prostate cancer. Herein, we report the first validation of the biopsy GC in intermediate-risk prostate cancer from the phase III randomized trial NRG/RTOG 0126. Methods: After National Cancer Institute approval, biopsy slides were collected from the NRG biobank from RTOG 0126, a phase III randomized trial of men with intermediate-risk prostate cancer randomized to 70.2 Gy versus 79.2 Gy of radiotherapy without the use of concomitant hormone therapy. RNA was extracted from the highest grade tumor foci and processed through a quality control (QC) pipeline prior to generation of the previously locked 22-gene GC model. After GC data was generated it was linked with clinical outcomes to assess prognostic performance. The primary endpoint for this ancillary proje...</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="115450598"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="115450598"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 115450598; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=115450598]").text(description); $(".js-view-count[data-work-id=115450598]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 115450598; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='115450598']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (false){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "-1" } } $('.js-work-strip[data-work-id=115450598]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":115450598,"title":"Validation of the performance of the Decipher biopsy genomic classifier in intermediate-risk prostate cancer on the phase III randomized trial NRG Oncology/RTOG 0126","internal_url":"https://www.academia.edu/115450598/Validation_of_the_performance_of_the_Decipher_biopsy_genomic_classifier_in_intermediate_risk_prostate_cancer_on_the_phase_III_randomized_trial_NRG_Oncology_RTOG_0126","owner_id":42486127,"coauthors_can_edit":true,"owner":{"id":42486127,"first_name":"Luis","middle_initials":null,"last_name":"Souhami","page_name":"LSouhami","domain_name":"independent","created_at":"2016-02-01T10:54:47.452-08:00","display_name":"Luis Souhami","url":"https://independent.academia.edu/LSouhami"},"attachments":[]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="115450597"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" rel="nofollow" href="https://www.academia.edu/115450597/Analysis_of_10_327_pre_treatment_ultrasound_localizations_for_387_prostate_cancer_patients_treated_with_conformal_3D_external_beam_radiation_therapy"><img alt="Research paper thumbnail of Analysis of 10,327 pre-treatment ultrasound localizations for 387 prostate cancer patients treated with conformal 3D external beam radiation therapy" class="work-thumbnail" src="https://a.academia-assets.com/images/blank-paper.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" rel="nofollow" href="https://www.academia.edu/115450597/Analysis_of_10_327_pre_treatment_ultrasound_localizations_for_387_prostate_cancer_patients_treated_with_conformal_3D_external_beam_radiation_therapy">Analysis of 10,327 pre-treatment ultrasound localizations for 387 prostate cancer patients treated with conformal 3D external beam radiation therapy</a></div><div class="wp-workCard_item"><span>Apresentado no: 48th Annual Meeting American Association of Physics in Medicine, July 30 - August 3, Orlando, EUA</span><span>, Aug 6, 2014</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="115450597"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="115450597"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 115450597; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=115450597]").text(description); $(".js-view-count[data-work-id=115450597]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 115450597; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='115450597']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (false){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "-1" } } $('.js-work-strip[data-work-id=115450597]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":115450597,"title":"Analysis of 10,327 pre-treatment ultrasound localizations for 387 prostate cancer patients treated with conformal 3D external beam radiation therapy","internal_url":"https://www.academia.edu/115450597/Analysis_of_10_327_pre_treatment_ultrasound_localizations_for_387_prostate_cancer_patients_treated_with_conformal_3D_external_beam_radiation_therapy","owner_id":42486127,"coauthors_can_edit":true,"owner":{"id":42486127,"first_name":"Luis","middle_initials":null,"last_name":"Souhami","page_name":"LSouhami","domain_name":"independent","created_at":"2016-02-01T10:54:47.452-08:00","display_name":"Luis Souhami","url":"https://independent.academia.edu/LSouhami"},"attachments":[]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="115450596"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" rel="nofollow" href="https://www.academia.edu/115450596/PROGRAMME_SCIENTIFIQUE_Samedi_le_15_novembre_2008_Session_scientifique_VIII"><img alt="Research paper thumbnail of PROGRAMME SCIENTIFIQUE : Samedi, le 15 novembre 2008, Session scientifique VIII" class="work-thumbnail" src="https://a.academia-assets.com/images/blank-paper.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" rel="nofollow" href="https://www.academia.edu/115450596/PROGRAMME_SCIENTIFIQUE_Samedi_le_15_novembre_2008_Session_scientifique_VIII">PROGRAMME SCIENTIFIQUE : Samedi, le 15 novembre 2008, Session scientifique VIII</a></div><div class="wp-workCard_item"><span>Canadian Urological Association Journal = Journal de L'association des Urologues du Canada</span><span>, Oct 1, 2008</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="115450596"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="115450596"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 115450596; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=115450596]").text(description); $(".js-view-count[data-work-id=115450596]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 115450596; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='115450596']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (false){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "-1" } } $('.js-work-strip[data-work-id=115450596]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":115450596,"title":"PROGRAMME SCIENTIFIQUE : Samedi, le 15 novembre 2008, Session scientifique VIII","internal_url":"https://www.academia.edu/115450596/PROGRAMME_SCIENTIFIQUE_Samedi_le_15_novembre_2008_Session_scientifique_VIII","owner_id":42486127,"coauthors_can_edit":true,"owner":{"id":42486127,"first_name":"Luis","middle_initials":null,"last_name":"Souhami","page_name":"LSouhami","domain_name":"independent","created_at":"2016-02-01T10:54:47.452-08:00","display_name":"Luis Souhami","url":"https://independent.academia.edu/LSouhami"},"attachments":[]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="115450595"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" rel="nofollow" href="https://www.academia.edu/115450595/Quality_of_Life_Implications_of_Dose_Escalated_External_Beam_Radiation_for_Localized_Prostate_Cancer_Results_of_a_Prospective_Randomized_Phase_3_Clinical_Trial_NRG_RTOG_0126"><img alt="Research paper thumbnail of Quality of Life Implications of Dose-Escalated External Beam Radiation for Localized Prostate Cancer: Results of a Prospective Randomized Phase 3 Clinical Trial, NRG/RTOG 0126" class="work-thumbnail" src="https://a.academia-assets.com/images/blank-paper.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" rel="nofollow" href="https://www.academia.edu/115450595/Quality_of_Life_Implications_of_Dose_Escalated_External_Beam_Radiation_for_Localized_Prostate_Cancer_Results_of_a_Prospective_Randomized_Phase_3_Clinical_Trial_NRG_RTOG_0126">Quality of Life Implications of Dose-Escalated External Beam Radiation for Localized Prostate Cancer: Results of a Prospective Randomized Phase 3 Clinical Trial, NRG/RTOG 0126</a></div><div class="wp-workCard_item"><span>International Journal of Radiation Oncology*Biology*Physics</span><span>, 2022</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">External beam radiation therapy (EBRT) dose escalation has been tested in multiple prospective tr...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">External beam radiation therapy (EBRT) dose escalation has been tested in multiple prospective trials. However, the impact on patient reported outcomes (PROs) associated with higher doses of EBRT remain poorly understood. We sought to assess the differences in PROs between men treated with a dose of 70.2 Gy versus 79.2 Gy of EBRT for prostate cancer. The phase 3 clinical trial RTOG 0126 randomized 1532 patients with prostate cancer between March 2002 and August 2008 to 79.2 Gy over 44 fractions versus 70.2 Gy over 39 fractions. Eligible patients participated in the PRO data collection. PROs completed included the International Index of Erectile Function Questionnaire (IIEF), Functional Alterations due to Changes in Elimination (FACE), and the Spitzer Quality of Life Index (SQLI). The timepoints for the IIEF were collected pre-entry and at 6, 12, and 24 months. The FACE and SQLI were collected pre-entry and at 3, 6, 12, 18, and 24 months. The impact of EBRT dose to normal structures (penile bulb, rectum, and bladder) on PROs was also examined. Mixed effects models were used to analyze trends across time. In total, 1144 patients completed baseline IIEF forms and of these, 56%, 64%, and 61% completed the IIEF at 6, 12, and 24 months, respectively; 1123 patients completed the FACE score at baseline and 50%, 61%, 73%, 61%, and 65% completed all 15 items for the FACE metric at timepoints of 3, 6, 12, 18, and 24 months, respectively. Erectile dysfunction at 12 months based on the single question was not significantly different between arms (38.1% for the standard dose radiation therapy arm vs 49.7% for the dose escalated radiation therapy arm; P = .051). Treatment arm (70.2 vs 79.2) had no significant impact on any PRO metrics measured across all collected domains. Comprehensive dosimetric analyses are presented and reveal multiple significant differences to regional organs at risk. Compliance with PRO data collection was lower than anticipated in this phase 3 trial. Examining the available data, dose escalated EBRT did not appear to be associated with any detriment to PROs across numerous prospectively collected domains. These data, notwithstanding limitations, add to our understanding of the implications of EBRT dose escalation in prostate cancer. Furthermore, these results illustrate challenges associated with PRO data collection.</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="115450595"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="115450595"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 115450595; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=115450595]").text(description); $(".js-view-count[data-work-id=115450595]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 115450595; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='115450595']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (false){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "-1" } } $('.js-work-strip[data-work-id=115450595]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":115450595,"title":"Quality of Life Implications of Dose-Escalated External Beam Radiation for Localized Prostate Cancer: Results of a Prospective Randomized Phase 3 Clinical Trial, NRG/RTOG 0126","internal_url":"https://www.academia.edu/115450595/Quality_of_Life_Implications_of_Dose_Escalated_External_Beam_Radiation_for_Localized_Prostate_Cancer_Results_of_a_Prospective_Randomized_Phase_3_Clinical_Trial_NRG_RTOG_0126","owner_id":42486127,"coauthors_can_edit":true,"owner":{"id":42486127,"first_name":"Luis","middle_initials":null,"last_name":"Souhami","page_name":"LSouhami","domain_name":"independent","created_at":"2016-02-01T10:54:47.452-08:00","display_name":"Luis Souhami","url":"https://independent.academia.edu/LSouhami"},"attachments":[]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="115450594"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/115450594/NCOG_12_Cognitive_Function_CF_Quality_of_Life_Qol_in_Patients_Treated_with_Procarbazine_Ccnu_Vincristine_PCV_Radiotherapy_RT_vs_RT_for_Anaplastic_Oligodendroglioma_Ao_on_NRG_Rtog_Trial_9402"><img alt="Research paper thumbnail of NCOG-12. Cognitive Function (CF) Quality of Life (Qol) in Patients Treated with Procarbazine, Ccnu, Vincristine (PCV) + Radiotherapy (RT) vs. RT for Anaplastic Oligodendroglioma (Ao) on NRG Rtog Trial 9402" class="work-thumbnail" src="https://attachments.academia-assets.com/111854037/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/115450594/NCOG_12_Cognitive_Function_CF_Quality_of_Life_Qol_in_Patients_Treated_with_Procarbazine_Ccnu_Vincristine_PCV_Radiotherapy_RT_vs_RT_for_Anaplastic_Oligodendroglioma_Ao_on_NRG_Rtog_Trial_9402">NCOG-12. Cognitive Function (CF) Quality of Life (Qol) in Patients Treated with Procarbazine, Ccnu, Vincristine (PCV) + Radiotherapy (RT) vs. RT for Anaplastic Oligodendroglioma (Ao) on NRG Rtog Trial 9402</a></div><div class="wp-workCard_item"><span>Neuro-Oncology</span><span>, 2021</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">BACKGROUND PCV+RT substantially prolongs survival in AO patients, but long-term CF and QOL implic...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">BACKGROUND PCV+RT substantially prolongs survival in AO patients, but long-term CF and QOL implications are unclear. We compared CF and QOL by treatment arm in RTOG 9402 participants and evaluated the impact that baseline characteristics had on CF, QOL, and survival. METHODS CF and QOL were evaluated using the Mini Mental State Exam (MMSE) and Brain-Quality of Life (B-QOL) scale at baseline and annually. Scores were analyzed between treatment arms at each time point for patients with ≥ 10 years of follow-up data. Shared parameter models evaluated MMSE and B-QOL scores and survival for all patients. RESULTS 42/148 (28.4%) participants in PCV+RT and 20/143 (14%) in RT alone arms survived ≥ 10 years. 35/42 and 39/42 (PCV+RT) and 18/20 and 17/20 (RT) participants completed baseline B-QOL and MMSE assessments, respectively. B-QOL scores did not differ between treatment groups at any time-point. Among 16 patients (10 PCV+RT, 6 RT) who completed year 10 MMSE evaluations, mean MMSE score at...</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="73562f4897c5107fdcee54433b9bdcad" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":111854037,"asset_id":115450594,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/111854037/download_file?s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="115450594"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="115450594"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 115450594; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=115450594]").text(description); $(".js-view-count[data-work-id=115450594]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 115450594; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='115450594']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "73562f4897c5107fdcee54433b9bdcad" } } $('.js-work-strip[data-work-id=115450594]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":115450594,"title":"NCOG-12. Cognitive Function (CF) Quality of Life (Qol) in Patients Treated with Procarbazine, Ccnu, Vincristine (PCV) + Radiotherapy (RT) vs. RT for Anaplastic Oligodendroglioma (Ao) on NRG Rtog Trial 9402","internal_url":"https://www.academia.edu/115450594/NCOG_12_Cognitive_Function_CF_Quality_of_Life_Qol_in_Patients_Treated_with_Procarbazine_Ccnu_Vincristine_PCV_Radiotherapy_RT_vs_RT_for_Anaplastic_Oligodendroglioma_Ao_on_NRG_Rtog_Trial_9402","owner_id":42486127,"coauthors_can_edit":true,"owner":{"id":42486127,"first_name":"Luis","middle_initials":null,"last_name":"Souhami","page_name":"LSouhami","domain_name":"independent","created_at":"2016-02-01T10:54:47.452-08:00","display_name":"Luis Souhami","url":"https://independent.academia.edu/LSouhami"},"attachments":[{"id":111854037,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/111854037/thumbnails/1.jpg","file_name":"noab196.603.pdf","download_url":"https://www.academia.edu/attachments/111854037/download_file","bulk_download_file_name":"NCOG_12_Cognitive_Function_CF_Quality_of.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/111854037/noab196.603-libre.pdf?1708960036=\u0026response-content-disposition=attachment%3B+filename%3DNCOG_12_Cognitive_Function_CF_Quality_of.pdf\u0026Expires=1740369698\u0026Signature=SwJVgcZJK2kxFmdKen9LbHLKhL5VNlF6QJqAupsPMGD5reAyRIlKfytF869klY1m7pr4Q6D~nqnTY-rugPyJdnIZESdJaBAQZZiwEa2hJfdeLbDyuQ15ZkRBi4nwyJPIQ9Psm63gBuL3gtdNG4TjzKpVEnhhEaxkARcR5ggtGpHP~HKqlI1VI~hR4-g-qxW7hlLEy3gHPbTq1CgHsmvgnZiYKqOtER0MPCl9ihor6bCsKD3VHbJQkpigRbpdJ~VqMqlrwsBvWWgdASDEud4ND80VjSKlqApK-ZP3cp~BHeGXLt~~o2leKG0Xa54Uj6K-ETSEITfqL0yiSgNJcK0otg__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="115450593"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" rel="nofollow" href="https://www.academia.edu/115450593/Body_Composition_and_Risk_of_All_Cause_Mortality_in_Men_Treated_With_Radiation_Therapy_for_Prostate_Cancer_A_Pooled_Analysis_of_NRG_RTOG_9406_and_NRG_RTOG_0126"><img alt="Research paper thumbnail of Body Composition and Risk of All-Cause Mortality in Men Treated With Radiation Therapy for Prostate Cancer: A Pooled Analysis of NRG/RTOG 9406 and NRG/RTOG 0126" class="work-thumbnail" src="https://a.academia-assets.com/images/blank-paper.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" rel="nofollow" href="https://www.academia.edu/115450593/Body_Composition_and_Risk_of_All_Cause_Mortality_in_Men_Treated_With_Radiation_Therapy_for_Prostate_Cancer_A_Pooled_Analysis_of_NRG_RTOG_9406_and_NRG_RTOG_0126">Body Composition and Risk of All-Cause Mortality in Men Treated With Radiation Therapy for Prostate Cancer: A Pooled Analysis of NRG/RTOG 9406 and NRG/RTOG 0126</a></div><div class="wp-workCard_item"><span>International Journal of Radiation Oncology*Biology*Physics</span><span>, 2021</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">PURPOSE/OBJECTIVE(S) To validate the association between body composition and all-cause mortality...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">PURPOSE/OBJECTIVE(S) To validate the association between body composition and all-cause mortality in men treated with radiation therapy for localized prostate cancer (PCa). Secondarily, to integrate body composition as a factor to help classify patients by risk of all-cause mortality. MATERIALS/METHODS All participants of NRG/RTOG 9406 and NRG/RTOG 0126 with archived computed tomography that extended cranially to include the L4-L5 interface were included. Muscle mass and muscle density were estimated by measuring the cross-sectional area and average attenuation of the paired psoas muscles on a single slice at the level of L4-L5. Bone density was estimated by measuring the average attenuation of the vertebral body cancellous bone on a single slice at mid-L5. Adipose tissue density was estimated by measuring the average attenuation of the subcutaneous adipose tissue on a single slice at L4-L5. Survival analyses, including Cox proportional hazards models, were performed to assess the relationship between body composition variables and all-cause mortality. Recursive partitioning (RPA) was utilized to create a classification tree to classify NRG/RTOG 0126 participants by risk of death, and the discriminant ability of the classification model was validated using the NRG/RTOG 9406 data set. RESULTS Data from 2,066 men was included in this study (864 from NRG/RTOG 9406 and 1,202 from NRG/RTOG 0126). A total of 648 men died in the follow-up period and 51 (7.9%) were due to PCa. Psoas area, psoas density, and vertebral body density were individually associated with overall survival. In the final multivariable model, psoas area, comorbidity score, and age were associated with overall survival (Table). The RPA yielded a classification tree with 4 prognostic groups determined by age, comorbidity, and psoas cross-sectional area. When the RPA classification was applied to the NRG/RTOG 9406 validation set the discriminant ability was preserved (P &lt; 0.001 groupwise log-rank). CONCLUSION The results of this study strongly support that body composition is related to all-cause mortality in men with localized PCa, with most deaths due to causes other than PCa. The inclusion of psoas cross-sectional area in the RPA classification tree suggests that body composition provides additive information to age and comorbidity status for mortality prediction. This study also confirms the feasibility of performing body composition analysis using archived CT scans using NRG Oncology clinical trial data sets. These methods can be applied to other NRG Oncology data sets to further explore how body composition is related to patient outcomes.</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="115450593"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="115450593"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 115450593; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=115450593]").text(description); $(".js-view-count[data-work-id=115450593]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 115450593; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='115450593']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (false){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "-1" } } $('.js-work-strip[data-work-id=115450593]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":115450593,"title":"Body Composition and Risk of All-Cause Mortality in Men Treated With Radiation Therapy for Prostate Cancer: A Pooled Analysis of NRG/RTOG 9406 and NRG/RTOG 0126","internal_url":"https://www.academia.edu/115450593/Body_Composition_and_Risk_of_All_Cause_Mortality_in_Men_Treated_With_Radiation_Therapy_for_Prostate_Cancer_A_Pooled_Analysis_of_NRG_RTOG_9406_and_NRG_RTOG_0126","owner_id":42486127,"coauthors_can_edit":true,"owner":{"id":42486127,"first_name":"Luis","middle_initials":null,"last_name":"Souhami","page_name":"LSouhami","domain_name":"independent","created_at":"2016-02-01T10:54:47.452-08:00","display_name":"Luis Souhami","url":"https://independent.academia.edu/LSouhami"},"attachments":[]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="115450592"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/115450592/Combined_Long_Term_Androgen_Deprivation_and_Pelvic_Radiotherapy_in_the_Post_operative_Management_of_Pathologically_Defined_High_Risk_Prostate_Cancer_Patients_Results_of_the_Prospective_Phase_II_McGill_0913_Study"><img alt="Research paper thumbnail of Combined Long-Term Androgen Deprivation and Pelvic Radiotherapy in the Post-operative Management of Pathologically Defined High-Risk Prostate Cancer Patients: Results of the Prospective Phase II McGill 0913 Study" class="work-thumbnail" src="https://attachments.academia-assets.com/111854034/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/115450592/Combined_Long_Term_Androgen_Deprivation_and_Pelvic_Radiotherapy_in_the_Post_operative_Management_of_Pathologically_Defined_High_Risk_Prostate_Cancer_Patients_Results_of_the_Prospective_Phase_II_McGill_0913_Study">Combined Long-Term Androgen Deprivation and Pelvic Radiotherapy in the Post-operative Management of Pathologically Defined High-Risk Prostate Cancer Patients: Results of the Prospective Phase II McGill 0913 Study</a></div><div class="wp-workCard_item"><span>Frontiers in Oncology</span><span>, 2020</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">Following radical prostatectomy, prostate bed radiotherapy (PBRT) has been combined with either l...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">Following radical prostatectomy, prostate bed radiotherapy (PBRT) has been combined with either long-term androgen deprivation therapy (LT-ADT) or short-term ADT with pelvic lymph node radiotherapy (PLNRT) to provide an oncological benefit in randomized trials. McGill 0913 was designed to characterize the efficacy of combining PBRT, PLNRT, and LT-ADT. It is the first study to do so prospectively. Methods: In a single arm phase II trial conduced from 2010 to 2016, 46 post-prostatectomy prostate cancer patients at a high-risk for relapse (pathological Gleason 8+ or T3) were assessed for treatment with combined LT-ADT (24 months), PBRT, and PLNRT. Patients received PLNRT and PBRT (44 Gy in 22 fractions) followed by a PBRT boost (22 Gy in 11 fractions). The primary endpoint was progression-free survival (PFS). Toxicity and quality of life (QoL) were evaluated using CTCAE V3.0 and EQ-5D-3L questionnaires, respectively. Results: Among the 43 patients were treated as per protocol, median PSA was 0.30 µg/L. On surgical pathology, 51% had positive margins, 40% had Gleason 8+ disease, 42% had seminal vesicle involvement, and 19% had lymph node involvement. At a median follow-up of 5.2 years, there were no deaths or clinical progression. At 5 years, PFS was 78.0% (95% Confidence Interval 63.7-95.5%). Not including erectile dysfunction, patients experienced: 14% grade 2 endocrine toxicity while on ADT, one incident of long-term gynecomastia, 5% grade 2 acute urinary toxicity, 5% grade 2 late Kucharczyk et al. McGill 0913: Pelvic Radiotherapy and LT-ADT Urinary toxicity, and 24% long-term hypogonadism. No comparison between the average or minimum self-reported QoL at baseline, during ADT, nor after ADT demonstrated a statistically significant difference. Conclusions: Combining PBRT, PLNRT, and LT-ADT had an acceptable PFS in patients with significant post-operative risk factors for recurrence. While therapy was well-tolerated, long-term hypogonadism was a substantial risk. Further investigations are needed to determine if this combination is beneficial. Trial registration: NCT01255891.</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="bac08c8ed0ff8f5274c5762219e8e1fa" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":111854034,"asset_id":115450592,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/111854034/download_file?s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="115450592"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="115450592"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 115450592; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=115450592]").text(description); $(".js-view-count[data-work-id=115450592]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 115450592; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='115450592']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "bac08c8ed0ff8f5274c5762219e8e1fa" } } $('.js-work-strip[data-work-id=115450592]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":115450592,"title":"Combined Long-Term Androgen Deprivation and Pelvic Radiotherapy in the Post-operative Management of Pathologically Defined High-Risk Prostate Cancer Patients: Results of the Prospective Phase II McGill 0913 Study","internal_url":"https://www.academia.edu/115450592/Combined_Long_Term_Androgen_Deprivation_and_Pelvic_Radiotherapy_in_the_Post_operative_Management_of_Pathologically_Defined_High_Risk_Prostate_Cancer_Patients_Results_of_the_Prospective_Phase_II_McGill_0913_Study","owner_id":42486127,"coauthors_can_edit":true,"owner":{"id":42486127,"first_name":"Luis","middle_initials":null,"last_name":"Souhami","page_name":"LSouhami","domain_name":"independent","created_at":"2016-02-01T10:54:47.452-08:00","display_name":"Luis Souhami","url":"https://independent.academia.edu/LSouhami"},"attachments":[{"id":111854034,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/111854034/thumbnails/1.jpg","file_name":"pdf.pdf","download_url":"https://www.academia.edu/attachments/111854034/download_file","bulk_download_file_name":"Combined_Long_Term_Androgen_Deprivation.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/111854034/pdf-libre.pdf?1708960040=\u0026response-content-disposition=attachment%3B+filename%3DCombined_Long_Term_Androgen_Deprivation.pdf\u0026Expires=1740369698\u0026Signature=bzCWWJE-3oJoE5HhA9GpHaM2i72klwggx0hmo0eHogNK00wsfTL9OJH9ZFElmBvEC1uN-iG52XlBgHmVJtv7UKlRlm20P5EMGXxsLhIlAj7lyza5P4squAPvJRYEerD8b5b2alHhVUVhvBzfN2YZldQGbElNZEQCCFM3uftTo3hJLHD3JDn9BYdwzUk2BBI~RniTBQJ84dtBCLlHumzxsR5xs3mHrOqyB~UshnQbK4-MmUvztEio~pd-9T-SkX2I6iTl3IQN588jwthluPL8ozOYuVB~Rb4QlbcaEFeJ4S25jY4fp9TnpfdNS7pc-7XEX~8vkSlApGcc92tu4NJa1g__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="115450591"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/115450591/11_Prostate_Bed_Treatment_Intensification_with_Long_Term_Androgen_Deprivation_and_Pelvic_Nodal_Radiotherapy_is_Effective_and_Well_Tolerated_Results_from_the_McGill_0913_Phase_II_Clinical_Trial"><img alt="Research paper thumbnail of 11 Prostate Bed Treatment Intensification with Long Term Androgen Deprivation and Pelvic Nodal Radiotherapy is Effective and Well Tolerated: Results from the McGill 0913 Phase II Clinical Trial" class="work-thumbnail" src="https://attachments.academia-assets.com/111854036/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/115450591/11_Prostate_Bed_Treatment_Intensification_with_Long_Term_Androgen_Deprivation_and_Pelvic_Nodal_Radiotherapy_is_Effective_and_Well_Tolerated_Results_from_the_McGill_0913_Phase_II_Clinical_Trial">11 Prostate Bed Treatment Intensification with Long Term Androgen Deprivation and Pelvic Nodal Radiotherapy is Effective and Well Tolerated: Results from the McGill 0913 Phase II Clinical Trial</a></div><div class="wp-workCard_item"><span>Radiotherapy and Oncology</span><span>, 2019</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">The dose to the bladder neck was only reported and no constraint was applied. The International P...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">The dose to the bladder neck was only reported and no constraint was applied. The International Prostate Symptom Score (IPSS) at six weeks and six months and urinary obstruction rate were used to report acute and late urinary toxicity, respectively. Clinical and dosimetric factors associated with urinary toxicity were analyzed using multivariate generalized linear model including pretreatment IPSS, bladder neck D2cc and prostate volume as covariates. Results: Mean age and median follow-up were 69.9 years and 25 months, respectively. The mean pretreatment PSA was 9.30 ng/ml. According to D'Amico definition 70% were intermediate risk and 30% high-risk. The mean prostate volume was 57.5 cc. The mean pretreatment, six weeks and six months IPSS were 8.35, 12.24 and 9.97 respectively. We observed 17 cases (5.34%) of GU obstruction in our cohort of patients. Pretreatment IPSS was significantly associated with acute and late urinary toxicity (p<0.001). Prostate volume was also associated with acute (p=0.013) and late urinary toxicity (p=0.024). The dose for the most exposed 2cc (D2cc) of bladder neck was not correlated with acute mean IPSS 12.24 (p=0.737) or late mean IPSS 9.97 (p=0.785). There was also no correlation between D2cc and urinary obstruction 8.5 Gy versus 7.5 Gy (p = 0.191). Even if the mean D2cc was higher in the US group 10.1 Gy versus 7.6 Gy CT p < 0.00001 it was also not correlated with GU acute/late toxicity and urinary obstruction.</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="d0aa02263a04ee15a000be432e465fce" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":111854036,"asset_id":115450591,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/111854036/download_file?s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="115450591"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="115450591"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 115450591; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=115450591]").text(description); $(".js-view-count[data-work-id=115450591]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 115450591; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='115450591']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "d0aa02263a04ee15a000be432e465fce" } } $('.js-work-strip[data-work-id=115450591]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":115450591,"title":"11 Prostate Bed Treatment Intensification with Long Term Androgen Deprivation and Pelvic Nodal Radiotherapy is Effective and Well Tolerated: Results from the McGill 0913 Phase II Clinical Trial","internal_url":"https://www.academia.edu/115450591/11_Prostate_Bed_Treatment_Intensification_with_Long_Term_Androgen_Deprivation_and_Pelvic_Nodal_Radiotherapy_is_Effective_and_Well_Tolerated_Results_from_the_McGill_0913_Phase_II_Clinical_Trial","owner_id":42486127,"coauthors_can_edit":true,"owner":{"id":42486127,"first_name":"Luis","middle_initials":null,"last_name":"Souhami","page_name":"LSouhami","domain_name":"independent","created_at":"2016-02-01T10:54:47.452-08:00","display_name":"Luis Souhami","url":"https://independent.academia.edu/LSouhami"},"attachments":[{"id":111854036,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/111854036/thumbnails/1.jpg","file_name":"s0167-814028192933160-320240226-1-hh8j13.pdf","download_url":"https://www.academia.edu/attachments/111854036/download_file","bulk_download_file_name":"11_Prostate_Bed_Treatment_Intensificatio.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/111854036/s0167-814028192933160-320240226-1-hh8j13-libre.pdf?1708960037=\u0026response-content-disposition=attachment%3B+filename%3D11_Prostate_Bed_Treatment_Intensificatio.pdf\u0026Expires=1740369698\u0026Signature=hAya9Yw67VI-G-bZ1zHqSWLOWzUQpPWxejpGq4xK1slmlQ0M7KQ2I-KNHfIpADyX-boaMQzmoKp-HGmApfClwXoEwL~IGbw4IQEqegWpHR5psQT7MjeMUPx4DRX-YC3mpJV-0YIZ095aq3Fo-ac~0oQ8f-HIG94TqfW1e6owPyue9FFpaS~UjQdK~5uis0hm8irSFAmyJWi0NU0euw-Hb7f0rJoW74SDvOJxrK3Yr5x13AuuERfknbhGm2NsfoTsdFZLHtiQ9gWWvvQPgVVPLu93kUMTkBQVGNW0f-Vjd-2UdFrpgIPO3kBnt0QlaHMXPbdxzKm7udha0Tl7mi0IgQ__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="115450590"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/115450590/171_High_Dose_Rate_Brachytherapy_as_Monotherapy_for_the_Treatment_of_Intermediate_Risk_Prostate_Cancer_Toxicity_Results"><img alt="Research paper thumbnail of 171 High-Dose-Rate Brachytherapy as Monotherapy for the Treatment of Intermediate Risk Prostate Cancer: Toxicity Results" class="work-thumbnail" src="https://attachments.academia-assets.com/111854035/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/115450590/171_High_Dose_Rate_Brachytherapy_as_Monotherapy_for_the_Treatment_of_Intermediate_Risk_Prostate_Cancer_Toxicity_Results">171 High-Dose-Rate Brachytherapy as Monotherapy for the Treatment of Intermediate Risk Prostate Cancer: Toxicity Results</a></div><div class="wp-workCard_item"><span>Radiotherapy and Oncology</span><span>, 2019</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">High conformality of delivered dose and the high susceptibility of prostate cancer (PrCa) to high...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">High conformality of delivered dose and the high susceptibility of prostate cancer (PrCa) to high dose radiation therapy has warranted a closer look at high dose-rate (HDR) brachytherapy as monotherapy in recent years. Objectives: We present the acute and late genitourinary (GU) and gastrointestinal (GI) toxicities among a cohort of medium risk PrCa patients who received HDR monotherapy. Materials and Methods: Between January 1, 2016 and November 30, 2017, 42 patients were treated using CT-planned HDR brachytherapy as a single, 21Gy fraction. Dose was prescribed as per GEC-ESTRO guidelines, except for the urethra D0.1cc = ⩽110Gy EQD2. The Common Toxicity Criteria for Adverse Event, Version 4.0 (CTAE v4.03) was used to report toxicity. In addition to the one-week post-treatment interval, toxicity assessments were grouped at the 1, 3, 6, 12, and 24 months non-overlapping intervals. Results: With a median follow-up of 13.5 months, (range 1-28.5), and median age of 69 years, 59% of our patients developed acute GU toxicity (Grade 1), 7% of our patients developed late GU toxicity (Grade 2). Most frequent GU toxicity was hematuria (52%) within the first week, followed by dysuria (17%) in the first 3 months. GI toxicity was observed in 9% (all Grade 1). There was one patient developed Grade 3 urethral stricture at 18 months. Pre-treatment PSA was 7.5 ug/L (range 2.1-18.0). Patients reached an average nadir of 1.7ug/L (range 0.1-9.0) at 10.6 months. Conclusions: HDR monotherapy resulted in very low late GU toxicity (7%, G2; 2.3% G3) and no G2 or above late GI toxicity. These results are favorable compare to published data. In light of the advantages associated with this treatment modality, HDR brachytherapy is the ultimate extreme hypofractionation we can offer our patients.</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="6d1d09c5ac6c6cabe47a0e1b7839e404" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":111854035,"asset_id":115450590,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/111854035/download_file?s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="115450590"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="115450590"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 115450590; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=115450590]").text(description); $(".js-view-count[data-work-id=115450590]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 115450590; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='115450590']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "6d1d09c5ac6c6cabe47a0e1b7839e404" } } $('.js-work-strip[data-work-id=115450590]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":115450590,"title":"171 High-Dose-Rate Brachytherapy as Monotherapy for the Treatment of Intermediate Risk Prostate Cancer: Toxicity Results","internal_url":"https://www.academia.edu/115450590/171_High_Dose_Rate_Brachytherapy_as_Monotherapy_for_the_Treatment_of_Intermediate_Risk_Prostate_Cancer_Toxicity_Results","owner_id":42486127,"coauthors_can_edit":true,"owner":{"id":42486127,"first_name":"Luis","middle_initials":null,"last_name":"Souhami","page_name":"LSouhami","domain_name":"independent","created_at":"2016-02-01T10:54:47.452-08:00","display_name":"Luis Souhami","url":"https://independent.academia.edu/LSouhami"},"attachments":[{"id":111854035,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/111854035/thumbnails/1.jpg","file_name":"s0167-814028192933228-120240226-1-ooyoob.pdf","download_url":"https://www.academia.edu/attachments/111854035/download_file","bulk_download_file_name":"171_High_Dose_Rate_Brachytherapy_as_Mono.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/111854035/s0167-814028192933228-120240226-1-ooyoob-libre.pdf?1708960034=\u0026response-content-disposition=attachment%3B+filename%3D171_High_Dose_Rate_Brachytherapy_as_Mono.pdf\u0026Expires=1740369698\u0026Signature=Cq6msRC8y8VL3crq4j4RsDjxpDsUBKImJyYx3upRtqlYnzwciwm88kQfm~a8Y0KD44oQ1iT8SGxpbrIDnQWtEDRrvvwgJn3Zr9cyau3jhmPecAewwCPysQhettHnK1zx4hpET3xoTHnvR3hUDvCAYWdsR3ltU12jZNXGopiTg9i2Bh3jq5-Iu83xl9ueCbdiDiHekG62YVQmnUfN7pY7wzvWSjBFy41yxblyQm8kP8AHNp0irkXIzqeuWKl92xxIa6WqSKPM44m-wQpMIUW4GcPU-UFEwP4AM7qu9Fav6YE8a30wqWLD-kWtfyHOmbn3zu0ezjk9bA3pMQM09pvKmw__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="115450589"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" rel="nofollow" href="https://www.academia.edu/115450589/NRG_Oncology_RTOG_9601_a_phase_III_trial_in_prostate_cancer_patients_Anti_androgen_therapy_AAT_with_bicalutamide_during_and_after_salvage_radiation_therapy_RT_following_radical_prostatectomy_RP_and_an_elevated_PSA"><img alt="Research paper thumbnail of NRG Oncology/RTOG 9601, a phase III trial in prostate cancer patients: Anti-androgen therapy (AAT) with bicalutamide during and after salvage radiation therapy (RT) following radical prostatectomy (RP) and an elevated PSA" class="work-thumbnail" src="https://a.academia-assets.com/images/blank-paper.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" rel="nofollow" href="https://www.academia.edu/115450589/NRG_Oncology_RTOG_9601_a_phase_III_trial_in_prostate_cancer_patients_Anti_androgen_therapy_AAT_with_bicalutamide_during_and_after_salvage_radiation_therapy_RT_following_radical_prostatectomy_RP_and_an_elevated_PSA">NRG Oncology/RTOG 9601, a phase III trial in prostate cancer patients: Anti-androgen therapy (AAT) with bicalutamide during and after salvage radiation therapy (RT) following radical prostatectomy (RP) and an elevated PSA</a></div><div class="wp-workCard_item"><span>Journal of Clinical Oncology</span><span>, 2016</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">3 Background: Previous reports suggested that AAT when combined with salvage RT following RP in p...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">3 Background: Previous reports suggested that AAT when combined with salvage RT following RP in patients may improve prostate cancer control outcomes. Methods: Post-RP patients with pT3pN0 or with pT2pN0 and positive margins who had or developed elevated PSA levels from 0.2 to 4.0 ng/ml were randomized on a phase III, double-blind, trial of RT + placebo (64.8 Gy in 36 fractions of 1.8 Gy) vs. RT + AAT (24 months bicalutamide, 150 mg daily) during and after RT. The primary end-point was overall survival. Trial design required 725 patients and provided 80% power to detect a reduction in death rate by at least 28.5% and a 1-sided significance level of 0.046. Results: From 3/98 to 3/03, 761 eligible patients (median age 65) were randomized to RT + AAT (384) or RT + placebo (377). 248 patients (33%) were pT2pN0 and 513 (67%) were pT3pN0. 671 (88%) had a PSA nadir after RP of &lt; 0.5 ng/ml. 649 (85%) had an entry PSA value of &lt;1.6, 112 patients (15%) had an entry PSA of 1.6-4. Median ...</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="115450589"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="115450589"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 115450589; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=115450589]").text(description); $(".js-view-count[data-work-id=115450589]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 115450589; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='115450589']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (false){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "-1" } } $('.js-work-strip[data-work-id=115450589]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":115450589,"title":"NRG Oncology/RTOG 9601, a phase III trial in prostate cancer patients: Anti-androgen therapy (AAT) with bicalutamide during and after salvage radiation therapy (RT) following radical prostatectomy (RP) and an elevated PSA","internal_url":"https://www.academia.edu/115450589/NRG_Oncology_RTOG_9601_a_phase_III_trial_in_prostate_cancer_patients_Anti_androgen_therapy_AAT_with_bicalutamide_during_and_after_salvage_radiation_therapy_RT_following_radical_prostatectomy_RP_and_an_elevated_PSA","owner_id":42486127,"coauthors_can_edit":true,"owner":{"id":42486127,"first_name":"Luis","middle_initials":null,"last_name":"Souhami","page_name":"LSouhami","domain_name":"independent","created_at":"2016-02-01T10:54:47.452-08:00","display_name":"Luis Souhami","url":"https://independent.academia.edu/LSouhami"},"attachments":[]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="115450588"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" rel="nofollow" href="https://www.academia.edu/115450588/Evaluation_and_Visualization_of_Radiogenomic_Modeling_Frameworks_for_the_Prediction_of_Normal_Tissue_Toxicities"><img alt="Research paper thumbnail of Evaluation and Visualization of Radiogenomic Modeling Frameworks for the Prediction of Normal Tissue Toxicities" class="work-thumbnail" src="https://a.academia-assets.com/images/blank-paper.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" rel="nofollow" href="https://www.academia.edu/115450588/Evaluation_and_Visualization_of_Radiogenomic_Modeling_Frameworks_for_the_Prediction_of_Normal_Tissue_Toxicities">Evaluation and Visualization of Radiogenomic Modeling Frameworks for the Prediction of Normal Tissue Toxicities</a></div><div class="wp-workCard_item"><span>IFMBE Proceedings</span><span>, 2015</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">We explore techniques for the evaluation and visualization of radiogenomic data-driven models in ...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">We explore techniques for the evaluation and visualization of radiogenomic data-driven models in an effort to investigate the integration of genetic variations (single nucleotide polymorphisms [SNPs] and copy number variations [CNVs]) with dosimetric and clinical variables in modeling radiation-induced rectal bleeding (RB).</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="115450588"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="115450588"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 115450588; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=115450588]").text(description); $(".js-view-count[data-work-id=115450588]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 115450588; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='115450588']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (false){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "-1" } } $('.js-work-strip[data-work-id=115450588]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":115450588,"title":"Evaluation and Visualization of Radiogenomic Modeling Frameworks for the Prediction of Normal Tissue Toxicities","internal_url":"https://www.academia.edu/115450588/Evaluation_and_Visualization_of_Radiogenomic_Modeling_Frameworks_for_the_Prediction_of_Normal_Tissue_Toxicities","owner_id":42486127,"coauthors_can_edit":true,"owner":{"id":42486127,"first_name":"Luis","middle_initials":null,"last_name":"Souhami","page_name":"LSouhami","domain_name":"independent","created_at":"2016-02-01T10:54:47.452-08:00","display_name":"Luis Souhami","url":"https://independent.academia.edu/LSouhami"},"attachments":[]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="115450587"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" rel="nofollow" href="https://www.academia.edu/115450587/4021_POSTER_Testosterone_recovery_following_prolonged_adjuvant_androgen_blockade_in_localized_prostate_cancer_is_there_an_effect_on_outcome"><img alt="Research paper thumbnail of 4021 POSTER Testosterone recovery following prolonged adjuvant androgen blockade in localized prostate cancer: is there an effect on outcome?" class="work-thumbnail" src="https://a.academia-assets.com/images/blank-paper.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" rel="nofollow" href="https://www.academia.edu/115450587/4021_POSTER_Testosterone_recovery_following_prolonged_adjuvant_androgen_blockade_in_localized_prostate_cancer_is_there_an_effect_on_outcome">4021 POSTER Testosterone recovery following prolonged adjuvant androgen blockade in localized prostate cancer: is there an effect on outcome?</a></div><div class="wp-workCard_item"><span>European Journal of Cancer Supplements</span><span>, 2007</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="115450587"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="115450587"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 115450587; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=115450587]").text(description); $(".js-view-count[data-work-id=115450587]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 115450587; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='115450587']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (false){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "-1" } } $('.js-work-strip[data-work-id=115450587]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":115450587,"title":"4021 POSTER Testosterone recovery following prolonged adjuvant androgen blockade in localized prostate cancer: is there an effect on outcome?","internal_url":"https://www.academia.edu/115450587/4021_POSTER_Testosterone_recovery_following_prolonged_adjuvant_androgen_blockade_in_localized_prostate_cancer_is_there_an_effect_on_outcome","owner_id":42486127,"coauthors_can_edit":true,"owner":{"id":42486127,"first_name":"Luis","middle_initials":null,"last_name":"Souhami","page_name":"LSouhami","domain_name":"independent","created_at":"2016-02-01T10:54:47.452-08:00","display_name":"Luis Souhami","url":"https://independent.academia.edu/LSouhami"},"attachments":[]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> </div><div class="profile--tab_content_container js-tab-pane tab-pane" data-section-id="6398969" id="papers"><div class="js-work-strip profile--work_container" data-work-id="115450617"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" rel="nofollow" href="https://www.academia.edu/115450617/WE_D_BRE_02_BEST_IN_PHYSICS_THERAPY_Radiogenomic_Modeling_of_Normal_Tissue_Toxicities_in_Prostate_Cancer_Patients_Receiving_Hypofractionated_Radiotherapy"><img alt="Research paper thumbnail of WE-D-BRE-02: BEST IN PHYSICS (THERAPY) - Radiogenomic Modeling of Normal Tissue Toxicities in Prostate Cancer Patients Receiving Hypofractionated Radiotherapy" class="work-thumbnail" src="https://a.academia-assets.com/images/blank-paper.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" rel="nofollow" href="https://www.academia.edu/115450617/WE_D_BRE_02_BEST_IN_PHYSICS_THERAPY_Radiogenomic_Modeling_of_Normal_Tissue_Toxicities_in_Prostate_Cancer_Patients_Receiving_Hypofractionated_Radiotherapy">WE-D-BRE-02: BEST IN PHYSICS (THERAPY) - Radiogenomic Modeling of Normal Tissue Toxicities in Prostate Cancer Patients Receiving Hypofractionated Radiotherapy</a></div><div class="wp-workCard_item"><span>Medical Physics</span><span>, May 29, 2014</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">It has been realized that inter-patient radiation sensitivity variability is a multifactorial pro...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">It has been realized that inter-patient radiation sensitivity variability is a multifactorial process involving dosimetric, clinical, and genetic factors. Therefore, we explore a new framework to integrate physical, clinical, and biological data denoted as radiogenomic modeling. In demonstrating the feasibility of this work, we investigate the association of genetic variants (copy number variations [CNVs] and single nucleotide polymorphisms [SNPs]) with radiation induced rectal bleeding (RB) and erectile dysfunction (ED) while taking into account dosimetric and clinical variables in prostate cancer patients treated with curative irradiation. A cohort of 62 prostate cancer patients who underwent hypofractionated radiotherapy (66 Gy in 22 fractions) was retrospectively genotyped for CNV and SNP rs25489 in the xrcc1 DNA repair gene. Dosevolume metrics were extracted from treatment plans of 54 patients who had complete dosimetric profiles. Treatment outcomes were considered to be a RESULT OF FUNCTIONAL MAPPING OF RADIOGENOMIC INPUT VARIABLES ACCORDING TO A LOGIT TRANSFORMATION. MODEL ORDERS WERE ESTIMATED USING RESAMPLING BY LEAVE-ONE OUT CROSS-VALIDATION (LOO-CV). RADIOGENOMIC MODEL PERFORMANCE WAS EVALUATED USING AREA UNDER THE ROC CURVE (AUC) AND LOO-CV. FOR CONTINUOUS UNIVARIATE DOSIMETRIC AND CLINICAL VARIABLES, SPEARMANS RANK COEFFICIENTS WERE CALCULATED AND P-VALUES REPORTED ACCORDINGLY. IN THE CASE OF BINARY VARIABLES, CHI-SQUARED STATISTICS AND CONTINGENCY TABLE CALCULATIONS WERE USED. Ten patients were found to have three copies of xrcc1 CNV (RB: χ2=14.6 [p&amp;lt;0.001] and ED: χ2=4.88[p=0.0272]) and twelve had heterozygous rs25489 SNP (RB: χ2=0.278[p=0.599] and ED: χ2=0.112[p=0.732]). LOO-CV identified penile bulb D60 as the only significant QUANTEC predictor (rs=0.312 [p=0.0145]) for ED. Radiogenomic modeling yielded statistically significant, cross-validated NTCP models for RB (rs=0.243[p=0.0443], AUC=0.665) and ED (rs=0.276[p=0.0217], AUC=0.754). The radiogenomic modeling approach presented herein has been shown to identify NTCP models which have increased predictive power. Furthermore, CNVs appears to be useful genetic variants when added to dosimetric NTCP models. This work was partially supported by CIHR grant MOP-114910.</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="115450617"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="115450617"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 115450617; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=115450617]").text(description); $(".js-view-count[data-work-id=115450617]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 115450617; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='115450617']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (false){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "-1" } } $('.js-work-strip[data-work-id=115450617]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":115450617,"title":"WE-D-BRE-02: BEST IN PHYSICS (THERAPY) - Radiogenomic Modeling of Normal Tissue Toxicities in Prostate Cancer Patients Receiving Hypofractionated Radiotherapy","internal_url":"https://www.academia.edu/115450617/WE_D_BRE_02_BEST_IN_PHYSICS_THERAPY_Radiogenomic_Modeling_of_Normal_Tissue_Toxicities_in_Prostate_Cancer_Patients_Receiving_Hypofractionated_Radiotherapy","owner_id":42486127,"coauthors_can_edit":true,"owner":{"id":42486127,"first_name":"Luis","middle_initials":null,"last_name":"Souhami","page_name":"LSouhami","domain_name":"independent","created_at":"2016-02-01T10:54:47.452-08:00","display_name":"Luis Souhami","url":"https://independent.academia.edu/LSouhami"},"attachments":[]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="115450615"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/115450615/Endometrial_Carcinoma_in_Elderly_Women_Disease_Outcome_and_Treatment_Morbidity"><img alt="Research paper thumbnail of Endometrial Carcinoma in Elderly Women: Disease Outcome and Treatment Morbidity" class="work-thumbnail" src="https://attachments.academia-assets.com/111854040/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/115450615/Endometrial_Carcinoma_in_Elderly_Women_Disease_Outcome_and_Treatment_Morbidity">Endometrial Carcinoma in Elderly Women: Disease Outcome and Treatment Morbidity</a></div><div class="wp-workCard_item"><span>International Journal of Radiation Oncology Biology Physics</span><span>, Nov 1, 2007</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="1071b40cd9c1877f81571cb3bec00c6a" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":111854040,"asset_id":115450615,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/111854040/download_file?s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="115450615"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="115450615"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 115450615; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=115450615]").text(description); $(".js-view-count[data-work-id=115450615]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 115450615; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='115450615']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "1071b40cd9c1877f81571cb3bec00c6a" } } $('.js-work-strip[data-work-id=115450615]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":115450615,"title":"Endometrial Carcinoma in Elderly Women: Disease Outcome and Treatment Morbidity","internal_url":"https://www.academia.edu/115450615/Endometrial_Carcinoma_in_Elderly_Women_Disease_Outcome_and_Treatment_Morbidity","owner_id":42486127,"coauthors_can_edit":true,"owner":{"id":42486127,"first_name":"Luis","middle_initials":null,"last_name":"Souhami","page_name":"LSouhami","domain_name":"independent","created_at":"2016-02-01T10:54:47.452-08:00","display_name":"Luis Souhami","url":"https://independent.academia.edu/LSouhami"},"attachments":[{"id":111854040,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/111854040/thumbnails/1.jpg","file_name":"j.ijrobp.2007.07.152120240226-1-y1fijc.pdf","download_url":"https://www.academia.edu/attachments/111854040/download_file","bulk_download_file_name":"Endometrial_Carcinoma_in_Elderly_Women_D.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/111854040/j.ijrobp.2007.07.152120240226-1-y1fijc-libre.pdf?1708960034=\u0026response-content-disposition=attachment%3B+filename%3DEndometrial_Carcinoma_in_Elderly_Women_D.pdf\u0026Expires=1740369698\u0026Signature=cJVLagwFhmduzGRGfyaiLHlDrOctvql5zJojuA78wVJWPuFCjH2vY4J7xsLDjzH2kZg55G4~fs2Q9rPjYSv2McxXpzi7yebAJQBFnxfp2hv4lqXlzdaH8r-fDy9BKyTJ9QYsmQSVwNw0d-qKS1y8Lh4Msdk3utCIx5t4oR4H1p6r5Ut4UF4M1lcQrhIUjNlYhPrZk6JW92THsH1Zq--94EVHQg8q~XIsltMfNDK6jHCktrfTS4N4Du89Fr5JmLp74mVPjNbuNsU7gNi0sDLjIOlt9Jj5HYNBVV7smKUL1W1YFmqwOUHdsELeBNLgVN2McyvKyiuJDeSlIeu77zzppA__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="115450612"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/115450612/Met%C3%A1stase_cerebral_tratamento_paliativo_com_radiocirurgia"><img alt="Research paper thumbnail of Metástase cerebral: tratamento paliativo com radiocirurgia" class="work-thumbnail" src="https://attachments.academia-assets.com/111854362/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/115450612/Met%C3%A1stase_cerebral_tratamento_paliativo_com_radiocirurgia">Metástase cerebral: tratamento paliativo com radiocirurgia</a></div><div class="wp-workCard_item"><span>Arquivos De Neuro-psiquiatria</span><span>, Sep 1, 1995</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">RESUMO-O artigo faz avaliação de 52 pacientes com metástase cerebral tratados com radiocirurgia e...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">RESUMO-O artigo faz avaliação de 52 pacientes com metástase cerebral tratados com radiocirurgia estereotática na Universidade McGill, em Montreal. A radiocirurgia foi realizada com a técnica dinâmica em que, ao mesmo tempo, giram a mesa e a cabeça do acelerador linear de 10 MV. Todos os pacientes (56 tratamentos ao todo) foram tratados com um único isocentro e uma dose única mediana de 1800 cGy na periferia da metástase. Em 88% dos casos a radiocirurgia foi usada após falha de tratamento radioterápico fracionado em todo cérebro. Todos os 52 casos tiveram avaliação com CT pós radiocirurgia. O seguimento mediano foi de 6 meses (variou entre 1 e 37 meses) e a taxa de resposta, parcial ou completa, foi de 64%. Apenas 4 pacientes (7%) tiveram algum tipo de complicação tardia relacionada ao tratamento. Estes achados vão de encontro com dados da literatura. A radiocirurgia é tratamento pouco agressivo, bem tolerado e com alta taxa de resposta para lesões locais e pode ser útil para pacientes selecionados. O seu valor definitivo, como tratamento único ou combinado com radioterapia em todo cérebro, está sendo avaliado de forma prospectiva e randomizada. PALAVRAS-CHAVE : radiocirurgia estereotática, metástase cerebral, tratamento paliativo. Brain metastasis: palliative treatment with radiosurgery SUMMARY-This is a retrospective review of 52 patients with metastatic brain disease who underwent stereotactic radiosurgery at McGill University in Montreal. The radiosurgical treatment was performed with the dynamic rotation technique in which there is continuous and simultaneous movement of treatment couch and machine gantry of a 10 MV linac. All patients were treated with a single isocenter and a median dose of 1800 cGy was delivered. In 88% of the cases radiosurgery was given after failure from whole brain conventional irradiation. All 52 cases were assessed with brain CT post radiosurgery. The median follow up time was 6 months (range 1-37 months) and the response rate (partial or complete) was 64%. Only 4 patientes (7%) developed late complications related to the treatment. These findings are similar to the literature. Stereotactic radiosurgery is a well tolerated, effective and minimally invasive treatment technique which has a high response rate in selected patients with small, well delineated metastatic brain lesion. Its definitive value as a single therapy or combined with whole brain conventional radiotherapy is being studied in prospective and randomized trials.</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="689fd1e8c5ac9d477c4f8d02729af7d9" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":111854362,"asset_id":115450612,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/111854362/download_file?s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="115450612"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="115450612"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 115450612; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=115450612]").text(description); $(".js-view-count[data-work-id=115450612]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 115450612; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='115450612']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "689fd1e8c5ac9d477c4f8d02729af7d9" } } $('.js-work-strip[data-work-id=115450612]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":115450612,"title":"Metástase cerebral: tratamento paliativo com radiocirurgia","internal_url":"https://www.academia.edu/115450612/Met%C3%A1stase_cerebral_tratamento_paliativo_com_radiocirurgia","owner_id":42486127,"coauthors_can_edit":true,"owner":{"id":42486127,"first_name":"Luis","middle_initials":null,"last_name":"Souhami","page_name":"LSouhami","domain_name":"independent","created_at":"2016-02-01T10:54:47.452-08:00","display_name":"Luis Souhami","url":"https://independent.academia.edu/LSouhami"},"attachments":[{"id":111854362,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/111854362/thumbnails/1.jpg","file_name":"hrrHQBsjZzzQ6DTGy9cd4Pm.pdf","download_url":"https://www.academia.edu/attachments/111854362/download_file","bulk_download_file_name":"Metastase_cerebral_tratamento_paliativo.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/111854362/hrrHQBsjZzzQ6DTGy9cd4Pm-libre.pdf?1708960021=\u0026response-content-disposition=attachment%3B+filename%3DMetastase_cerebral_tratamento_paliativo.pdf\u0026Expires=1740208816\u0026Signature=MeP2UHCHfAx0D6dXzQ4qqGVT0JqjmAYQkuf1a4H8n5un39BVuJMrK9Knw~3xzA~GVjRREfY0l45ktADtig7ufaEmoKQIxguZqX1I4uNwJz1ThNY2g7LepaGXdDNBCTTOgv2eFKzZPR92a27KRnInQKFDEWD6cmGJYprL1Wt38oJXQA~scD53Tp4iEJIrSylGjwTvmQzqgpUVgqXWQjAEe5CH19VXNSr0e0MjdsPWEEZ9u8Oc8WVZwVLI5Ra36fHl~VLyZiJqEXBovrpB-9efaD1i0mUdUcARHwS8~CDbmogqolwPIFx31OZyk9C613iqaffJMrmfIC9YFFM5z2g1OQ__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="115450605"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/115450605/Bladder_Sparing_Hypofractionated_Intensity_Modulated_Radiation_Therapy_plus_Weekly_Gemcitabine_in_Patients_with_Invasive_Bladder_Cancer"><img alt="Research paper thumbnail of Bladder-Sparing Hypofractionated Intensity Modulated Radiation Therapy plus Weekly Gemcitabine in Patients with Invasive Bladder Cancer" class="work-thumbnail" src="https://attachments.academia-assets.com/111854039/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/115450605/Bladder_Sparing_Hypofractionated_Intensity_Modulated_Radiation_Therapy_plus_Weekly_Gemcitabine_in_Patients_with_Invasive_Bladder_Cancer">Bladder-Sparing Hypofractionated Intensity Modulated Radiation Therapy plus Weekly Gemcitabine in Patients with Invasive Bladder Cancer</a></div><div class="wp-workCard_item"><span>International Journal of Radiation Oncology Biology Physics</span><span>, Nov 1, 2018</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">Time to local failure was defined from the start of radiotherapy to pathological confirmation of ...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">Time to local failure was defined from the start of radiotherapy to pathological confirmation of relapse, and was estimated using Kaplan Meier method. Cystoscopy and imaging (CT/MRI) were used to reconstruct the bladder relapse volume (GTV relapse) on the initial planning CT. Dose to GTV relapse (D 98%) was determined from planning scan used for treatment. Results: Twenty-seven of 38 (71%) of all patients had disease recurrence. Eighteen of 38 (47%) patients experienced first relapse within the bladder following radiotherapy. Median time to local relapse was 9.0 months (95% CI, 6.3-11.7 months). Fifteen of 18 (83.3%) of these patients received neoadjuvant chemotherapy and 10/18 (56.6%) had received concurrent chemotherapy. Ten of 18 (55.6%) patients relapsed with T2 local disease, 5/18 (27.8%) with pTa/pT1 disease, and 3/18 (16.7%) with carcinoma in situ. Fifteen of 18 (83%) of these relapses occurred within 1cm of the original bladder tumor site. Overall median GTV relapse D 98% was 57.1Gy (range 49.9-63.3Gy), 89.1% (77.9-99.0) of the prescribed dose (64Gy). Median GTV relapse D 98% where all or partial of the relapse volume was within 1cm of the original bladder tumor edge was 54.5Gy (range 51.4-63.3Gy), 85.2% (range 80.3-99.0%) of the prescribed dose (64Gy). Conclusion: Relapse patterns suggest local failure occurs within close proximity of the original bladder boost volume but outside the high dose treatment field (64Gy). Work is ongoing to expand the patient numbers and to determine actual dose delivered to GTV relapse D 98% from on-line CBCT data. This will inform whether dose escalation, and or margin modification could improve reported outcomes.</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="6c2e9ceb7fd93361bba66f5f6245529b" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":111854039,"asset_id":115450605,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/111854039/download_file?s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="115450605"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="115450605"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 115450605; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=115450605]").text(description); $(".js-view-count[data-work-id=115450605]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 115450605; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='115450605']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "6c2e9ceb7fd93361bba66f5f6245529b" } } $('.js-work-strip[data-work-id=115450605]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":115450605,"title":"Bladder-Sparing Hypofractionated Intensity Modulated Radiation Therapy plus Weekly Gemcitabine in Patients with Invasive Bladder Cancer","internal_url":"https://www.academia.edu/115450605/Bladder_Sparing_Hypofractionated_Intensity_Modulated_Radiation_Therapy_plus_Weekly_Gemcitabine_in_Patients_with_Invasive_Bladder_Cancer","owner_id":42486127,"coauthors_can_edit":true,"owner":{"id":42486127,"first_name":"Luis","middle_initials":null,"last_name":"Souhami","page_name":"LSouhami","domain_name":"independent","created_at":"2016-02-01T10:54:47.452-08:00","display_name":"Luis Souhami","url":"https://independent.academia.edu/LSouhami"},"attachments":[{"id":111854039,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/111854039/thumbnails/1.jpg","file_name":"j.ijrobp.2018.07.44420240226-1-hxr3kf.pdf","download_url":"https://www.academia.edu/attachments/111854039/download_file","bulk_download_file_name":"Bladder_Sparing_Hypofractionated_Intensi.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/111854039/j.ijrobp.2018.07.44420240226-1-hxr3kf-libre.pdf?1708960035=\u0026response-content-disposition=attachment%3B+filename%3DBladder_Sparing_Hypofractionated_Intensi.pdf\u0026Expires=1740208816\u0026Signature=AQVksJTWlqERYiZlsz6UKuaVsfPazC9n4wLn-aVfZKKP2sd1C4yHF9hRH9O8m~B~Mah8aXusc4oKFCMUaviqVr5gK5mr6SsUpS1HsjMx6vTUfQMgSb3aFHizJOQK9JeVWk~t~gS8fldMetsb5PGmraUVIcFU4uNKEEXkzZLawTo1XmJtUinrEet8RyRBziqFCXzTLZMkFKScsyZWFDVxtcYL4TfKYVWyuolLiDyt-BiaQAEzJDrhoSOTzwRuy6WJKScM109Q3Vv~qnKxL5UW4HBMHsJB73mBWSRciIkamn2HiKoYp3VfPsPJq9iJWAJ7KHkKosVhMA~fjpJlhcitYQ__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="115450603"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/115450603/ACTR_13_Final_Results_with_Chemoradiotherapy_for_Anaplastic_Oligodendroglial_Tumors_from_NRG_Oncology_Rtog_9402"><img alt="Research paper thumbnail of ACTR-13. Final Results with Chemoradiotherapy for Anaplastic Oligodendroglial Tumors from NRG Oncology/Rtog 9402" class="work-thumbnail" src="https://attachments.academia-assets.com/111854038/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/115450603/ACTR_13_Final_Results_with_Chemoradiotherapy_for_Anaplastic_Oligodendroglial_Tumors_from_NRG_Oncology_Rtog_9402">ACTR-13. Final Results with Chemoradiotherapy for Anaplastic Oligodendroglial Tumors from NRG Oncology/Rtog 9402</a></div><div class="wp-workCard_item"><span>Neuro-oncology</span><span>, Nov 1, 2019</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">NEURO-ONCOLOGY • NOVEMBER 2019 tients experience recurrent/progressive disease, with a median sur...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">NEURO-ONCOLOGY • NOVEMBER 2019 tients experience recurrent/progressive disease, with a median survival after recurrence of 3-9 months. Second-line treatment for recurrent GBM with bevacizumab (BEV) has not improved survival, and effective therapies for GBM are lacking. Unmethylated promoter for O 6-methylguanine-DNAmethyltransferase (MGMT) is a validated biomarker for TMZ-resistance and is correlated with poor patient prognosis. VAL-083 is a bi-functional DNA-targeting agent which rapidly induces interstrand DNA cross-links at N 7-guanine, induces double-strand breaks and acts independent of MGMT DNA repair. The current ongoing trial is a biomarker-driven Phase 2 study in MGMT-unmethylated BEV-naïve adult GBM. The primary objective of this study is to determine the effect of VAL-083 on median overall survival (mOS) for MGMT-unmethylated GBM patients compared to historical control. Secondary efficacy endpoints include progression-free survival (PFS), overall response rate (ORR), duration of response (DOR), and quality-of-life. Thirtyfive (35) subjects with recurrent GBM have received 40 mg/m 2 /day VAL-083 on days 1, 2, 3 of a 21-day cycle as the starting dose. Myelosuppression is the most common adverse event and a higher potential for this toxicity correlated with those patients who received a higher number of cycles of prior TMZ maintenance therapy, (>5 cycles vs. ≤5 cycles, p< 0.05). To minimize the potential for hematological toxicity in rGBM, subsequent subjects initiated treatment at 30 mg/m 2 /d VAL-083 x 3 consecutive days every 21 days. In addition, since TMZ is of limited value in the MGMT-unmethylated setting, a second arm in newly diagnosed GBM has been included to explore whether substituting TMZ with VAL-083 offers clinical benefit and extends the time to recurrence. Enrollment, safety data and study updates will be presented at the meeting. Clinicaltrials.gov identifier: NCT02717962.</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="c1eebb099f9e2d4fa0e36fd783e82ca0" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":111854038,"asset_id":115450603,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/111854038/download_file?s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="115450603"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="115450603"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 115450603; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=115450603]").text(description); $(".js-view-count[data-work-id=115450603]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 115450603; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='115450603']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "c1eebb099f9e2d4fa0e36fd783e82ca0" } } $('.js-work-strip[data-work-id=115450603]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":115450603,"title":"ACTR-13. Final Results with Chemoradiotherapy for Anaplastic Oligodendroglial Tumors from NRG Oncology/Rtog 9402","internal_url":"https://www.academia.edu/115450603/ACTR_13_Final_Results_with_Chemoradiotherapy_for_Anaplastic_Oligodendroglial_Tumors_from_NRG_Oncology_Rtog_9402","owner_id":42486127,"coauthors_can_edit":true,"owner":{"id":42486127,"first_name":"Luis","middle_initials":null,"last_name":"Souhami","page_name":"LSouhami","domain_name":"independent","created_at":"2016-02-01T10:54:47.452-08:00","display_name":"Luis Souhami","url":"https://independent.academia.edu/LSouhami"},"attachments":[{"id":111854038,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/111854038/thumbnails/1.jpg","file_name":"noz175.056.pdf","download_url":"https://www.academia.edu/attachments/111854038/download_file","bulk_download_file_name":"ACTR_13_Final_Results_with_Chemoradiothe.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/111854038/noz175.056-libre.pdf?1708960035=\u0026response-content-disposition=attachment%3B+filename%3DACTR_13_Final_Results_with_Chemoradiothe.pdf\u0026Expires=1740369698\u0026Signature=abzIMTolImd3qGQdOXVqRjOg2FMiCBbmCQ4sw~kMI00AS2Z0B34tTZHY-MR1q4E2T0E-iDxjRglwBq4PfWHROOWFzsEl~MFkVpflzSv11d13ZlN1565-z0OQUeZJR9xbZsmNwb9OePS~WUvl6JXEVeuFKqt6E8paGwntO9Mgd7xt6CEXm00zYWSREMWCRG72DsHb27BLjIGpkCZFwhrazyMTFGsNamBX0A4dEeKPq6u2h~MOf4KzmLoLzUNzACCEY3BGgOvJXa5of-0vcuKpu9c2zpN9cwVO4ZnQiSZYlm4uybqFtPsb63l2C-1kw3HwzICsJDFf6IxV8~Ej3rxgbQ__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="115450601"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" rel="nofollow" href="https://www.academia.edu/115450601/Pelvic_lymph_node_displacement_in_high_risk_prostate_cancer_patients_treated_with_image_guided_intensity_modulated_radiation_therapy_with_2_independent_target_volumes"><img alt="Research paper thumbnail of Pelvic lymph node displacement in high-risk prostate cancer patients treated with image guided intensity modulated radiation therapy with 2 independent target volumes" class="work-thumbnail" src="https://a.academia-assets.com/images/blank-paper.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" rel="nofollow" href="https://www.academia.edu/115450601/Pelvic_lymph_node_displacement_in_high_risk_prostate_cancer_patients_treated_with_image_guided_intensity_modulated_radiation_therapy_with_2_independent_target_volumes">Pelvic lymph node displacement in high-risk prostate cancer patients treated with image guided intensity modulated radiation therapy with 2 independent target volumes</a></div><div class="wp-workCard_item"><span>Practical radiation oncology</span><span>, Nov 1, 2015</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">To evaluate the displacement of the pelvic lymph node (PLN) target when using cone beam computed ...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">To evaluate the displacement of the pelvic lymph node (PLN) target when using cone beam computed tomography (CBCT) for localization of the prostate in patients treated with simultaneous integrated boost. High-risk prostate cancer patients treated with image guided intensity modulated radiation therapy with simultaneous integrated boost receiving 60 Gy in 20 fractions to the prostate and proximal seminal vesicles (PTV60) and 44 Gy in the same 20 fractions to the PLN (PTV44) were studied. Two hundred weekly CBCTs of 50 patients were retrospectively reviewed to assess the displacement of the iliac vessels compared with the simulation computed tomography. For each CBCT, possible displacements were analyzed at 3 levels of PTV44: a superior, middle, and inferior slice, making a total of 600 slices reviewed. Geographical miss (GM) was defined when any part of the iliac vessels on the CBCT was outside of the PTV44 contour. GM was found in 7 of the 600 CBCT slices, all in different patients. All GMs were of ≤5 mm. Four GMs occurred on the middle slice and 3 on the superior slice. In 3 cases, the GM was related to shifts ≥7 mm applied to the prostate. Our review suggests that for high-risk prostate cancer, the chance of not appropriately covering the PLN target after adjusting the prostate is low. GM was uncommon and in the order of only a few millimeters when it occurred.</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="115450601"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="115450601"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 115450601; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=115450601]").text(description); $(".js-view-count[data-work-id=115450601]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 115450601; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='115450601']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (false){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "-1" } } $('.js-work-strip[data-work-id=115450601]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":115450601,"title":"Pelvic lymph node displacement in high-risk prostate cancer patients treated with image guided intensity modulated radiation therapy with 2 independent target volumes","internal_url":"https://www.academia.edu/115450601/Pelvic_lymph_node_displacement_in_high_risk_prostate_cancer_patients_treated_with_image_guided_intensity_modulated_radiation_therapy_with_2_independent_target_volumes","owner_id":42486127,"coauthors_can_edit":true,"owner":{"id":42486127,"first_name":"Luis","middle_initials":null,"last_name":"Souhami","page_name":"LSouhami","domain_name":"independent","created_at":"2016-02-01T10:54:47.452-08:00","display_name":"Luis Souhami","url":"https://independent.academia.edu/LSouhami"},"attachments":[]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="115450600"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" rel="nofollow" href="https://www.academia.edu/115450600/Report_of_NRG_Oncology_RTOG_9601_A_Phase_3_Trial_in_Prostate_Cancer_Anti_androgen_Therapy_AAT_With_Bicalutamide_During_and_After_Radiation_Therapy_RT_in_Patients_Following_Radical_Prostatectomy_RP_With_pT2_3pN0_Disease_and_an_Elevated_PSA"><img alt="Research paper thumbnail of Report of NRG Oncology/RTOG 9601, A Phase 3 Trial in Prostate Cancer: Anti-androgen Therapy (AAT) With Bicalutamide During and After Radiation Therapy (RT) in Patients Following Radical Prostatectomy (RP) With pT2-3pN0 Disease and an Elevated PSA" class="work-thumbnail" src="https://a.academia-assets.com/images/blank-paper.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" rel="nofollow" href="https://www.academia.edu/115450600/Report_of_NRG_Oncology_RTOG_9601_A_Phase_3_Trial_in_Prostate_Cancer_Anti_androgen_Therapy_AAT_With_Bicalutamide_During_and_After_Radiation_Therapy_RT_in_Patients_Following_Radical_Prostatectomy_RP_With_pT2_3pN0_Disease_and_an_Elevated_PSA">Report of NRG Oncology/RTOG 9601, A Phase 3 Trial in Prostate Cancer: Anti-androgen Therapy (AAT) With Bicalutamide During and After Radiation Therapy (RT) in Patients Following Radical Prostatectomy (RP) With pT2-3pN0 Disease and an Elevated PSA</a></div><div class="wp-workCard_item"><span>International Journal of Radiation Oncology Biology Physics</span><span>, 2016</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">Hospitalization final 90 days of life 48.3% 64.0% .0004 Hospitalization final 30 days of life 31....</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">Hospitalization final 90 days of life 48.3% 64.0% .0004 Hospitalization final 30 days of life 31.5% 61.5% &lt;.0001 Died in a hospital 8.4% 38.5% &lt;.0001 Hospice care provided 69.6% 47.0% &lt;.0001 Hospice median stay (days) 22 days 13 days .0004 Mean inpatient costs final 90 days of life $12,976 $20,398 .0065 Mean total costs final 90 days of life $20,771 $28,088 .0128 Volume 94 Number 1 2016 Selected for Clinical Trials and Plenary Sessions 3</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="115450600"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="115450600"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 115450600; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=115450600]").text(description); $(".js-view-count[data-work-id=115450600]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 115450600; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='115450600']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (false){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "-1" } } $('.js-work-strip[data-work-id=115450600]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":115450600,"title":"Report of NRG Oncology/RTOG 9601, A Phase 3 Trial in Prostate Cancer: Anti-androgen Therapy (AAT) With Bicalutamide During and After Radiation Therapy (RT) in Patients Following Radical Prostatectomy (RP) With pT2-3pN0 Disease and an Elevated PSA","internal_url":"https://www.academia.edu/115450600/Report_of_NRG_Oncology_RTOG_9601_A_Phase_3_Trial_in_Prostate_Cancer_Anti_androgen_Therapy_AAT_With_Bicalutamide_During_and_After_Radiation_Therapy_RT_in_Patients_Following_Radical_Prostatectomy_RP_With_pT2_3pN0_Disease_and_an_Elevated_PSA","owner_id":42486127,"coauthors_can_edit":true,"owner":{"id":42486127,"first_name":"Luis","middle_initials":null,"last_name":"Souhami","page_name":"LSouhami","domain_name":"independent","created_at":"2016-02-01T10:54:47.452-08:00","display_name":"Luis Souhami","url":"https://independent.academia.edu/LSouhami"},"attachments":[]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="115450599"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" rel="nofollow" href="https://www.academia.edu/115450599/Body_composition_and_mortality_in_men_receiving_prostate_radiotherapy_A_pooled_analysis_of_NRG_RTOG_9406_and_NRG_RTOG_0126"><img alt="Research paper thumbnail of Body composition and mortality in men receiving prostate radiotherapy: A pooled analysis of NRG/RTOG 9406 and NRG/RTOG 0126" class="work-thumbnail" src="https://a.academia-assets.com/images/blank-paper.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" rel="nofollow" href="https://www.academia.edu/115450599/Body_composition_and_mortality_in_men_receiving_prostate_radiotherapy_A_pooled_analysis_of_NRG_RTOG_9406_and_NRG_RTOG_0126">Body composition and mortality in men receiving prostate radiotherapy: A pooled analysis of NRG/RTOG 9406 and NRG/RTOG 0126</a></div><div class="wp-workCard_item"><span>Cancer</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">PurposeTo validate the association between body composition and mortality in men treated with rad...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">PurposeTo validate the association between body composition and mortality in men treated with radiation for localized prostate cancer (PCa). Secondarily, to integrate body composition as a factor to classify patients by risk of all‐cause mortality.Materials and MethodsParticipants of NRG/Radiation Therapy Oncology Group (RTOG) 9406 and NRG/RTOG 0126 with archived computed tomography were included. Muscle mass and muscle density were estimated by measuring the area and attenuation of the psoas muscles on a single slice at L4–L5. Bone density was estimated by measuring the attenuation of the vertebral body at mid‐L5. Survival analyses, including Cox proportional hazards models, assessed the relationship between body composition and mortality. Recursive partitioning analysis (RPA) was used to create a classification tree to classify participants by risk of death.ResultsData from 2066 men were included in this study. In the final multivariable model, psoas area, comorbidity score, basel...</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="115450599"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="115450599"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 115450599; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=115450599]").text(description); $(".js-view-count[data-work-id=115450599]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 115450599; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='115450599']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (false){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "-1" } } $('.js-work-strip[data-work-id=115450599]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":115450599,"title":"Body composition and mortality in men receiving prostate radiotherapy: A pooled analysis of NRG/RTOG 9406 and NRG/RTOG 0126","internal_url":"https://www.academia.edu/115450599/Body_composition_and_mortality_in_men_receiving_prostate_radiotherapy_A_pooled_analysis_of_NRG_RTOG_9406_and_NRG_RTOG_0126","owner_id":42486127,"coauthors_can_edit":true,"owner":{"id":42486127,"first_name":"Luis","middle_initials":null,"last_name":"Souhami","page_name":"LSouhami","domain_name":"independent","created_at":"2016-02-01T10:54:47.452-08:00","display_name":"Luis Souhami","url":"https://independent.academia.edu/LSouhami"},"attachments":[]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="115450598"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" rel="nofollow" href="https://www.academia.edu/115450598/Validation_of_the_performance_of_the_Decipher_biopsy_genomic_classifier_in_intermediate_risk_prostate_cancer_on_the_phase_III_randomized_trial_NRG_Oncology_RTOG_0126"><img alt="Research paper thumbnail of Validation of the performance of the Decipher biopsy genomic classifier in intermediate-risk prostate cancer on the phase III randomized trial NRG Oncology/RTOG 0126" class="work-thumbnail" src="https://a.academia-assets.com/images/blank-paper.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" rel="nofollow" href="https://www.academia.edu/115450598/Validation_of_the_performance_of_the_Decipher_biopsy_genomic_classifier_in_intermediate_risk_prostate_cancer_on_the_phase_III_randomized_trial_NRG_Oncology_RTOG_0126">Validation of the performance of the Decipher biopsy genomic classifier in intermediate-risk prostate cancer on the phase III randomized trial NRG Oncology/RTOG 0126</a></div><div class="wp-workCard_item"><span>Journal of Clinical Oncology</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">269 Background: The 22-gene Decipher genomic classifier (GC) is a prognostic biomarker that has b...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">269 Background: The 22-gene Decipher genomic classifier (GC) is a prognostic biomarker that has been validated in phase III trials in high-risk localized, post-prostatectomy, and metastatic and non-metastatic castration-resistant prostate cancer. Herein, we report the first validation of the biopsy GC in intermediate-risk prostate cancer from the phase III randomized trial NRG/RTOG 0126. Methods: After National Cancer Institute approval, biopsy slides were collected from the NRG biobank from RTOG 0126, a phase III randomized trial of men with intermediate-risk prostate cancer randomized to 70.2 Gy versus 79.2 Gy of radiotherapy without the use of concomitant hormone therapy. RNA was extracted from the highest grade tumor foci and processed through a quality control (QC) pipeline prior to generation of the previously locked 22-gene GC model. After GC data was generated it was linked with clinical outcomes to assess prognostic performance. The primary endpoint for this ancillary proje...</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="115450598"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="115450598"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 115450598; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=115450598]").text(description); $(".js-view-count[data-work-id=115450598]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 115450598; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='115450598']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (false){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "-1" } } $('.js-work-strip[data-work-id=115450598]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":115450598,"title":"Validation of the performance of the Decipher biopsy genomic classifier in intermediate-risk prostate cancer on the phase III randomized trial NRG Oncology/RTOG 0126","internal_url":"https://www.academia.edu/115450598/Validation_of_the_performance_of_the_Decipher_biopsy_genomic_classifier_in_intermediate_risk_prostate_cancer_on_the_phase_III_randomized_trial_NRG_Oncology_RTOG_0126","owner_id":42486127,"coauthors_can_edit":true,"owner":{"id":42486127,"first_name":"Luis","middle_initials":null,"last_name":"Souhami","page_name":"LSouhami","domain_name":"independent","created_at":"2016-02-01T10:54:47.452-08:00","display_name":"Luis Souhami","url":"https://independent.academia.edu/LSouhami"},"attachments":[]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="115450597"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" rel="nofollow" href="https://www.academia.edu/115450597/Analysis_of_10_327_pre_treatment_ultrasound_localizations_for_387_prostate_cancer_patients_treated_with_conformal_3D_external_beam_radiation_therapy"><img alt="Research paper thumbnail of Analysis of 10,327 pre-treatment ultrasound localizations for 387 prostate cancer patients treated with conformal 3D external beam radiation therapy" class="work-thumbnail" src="https://a.academia-assets.com/images/blank-paper.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" rel="nofollow" href="https://www.academia.edu/115450597/Analysis_of_10_327_pre_treatment_ultrasound_localizations_for_387_prostate_cancer_patients_treated_with_conformal_3D_external_beam_radiation_therapy">Analysis of 10,327 pre-treatment ultrasound localizations for 387 prostate cancer patients treated with conformal 3D external beam radiation therapy</a></div><div class="wp-workCard_item"><span>Apresentado no: 48th Annual Meeting American Association of Physics in Medicine, July 30 - August 3, Orlando, EUA</span><span>, Aug 6, 2014</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="115450597"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="115450597"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 115450597; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=115450597]").text(description); $(".js-view-count[data-work-id=115450597]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 115450597; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='115450597']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (false){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "-1" } } $('.js-work-strip[data-work-id=115450597]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":115450597,"title":"Analysis of 10,327 pre-treatment ultrasound localizations for 387 prostate cancer patients treated with conformal 3D external beam radiation therapy","internal_url":"https://www.academia.edu/115450597/Analysis_of_10_327_pre_treatment_ultrasound_localizations_for_387_prostate_cancer_patients_treated_with_conformal_3D_external_beam_radiation_therapy","owner_id":42486127,"coauthors_can_edit":true,"owner":{"id":42486127,"first_name":"Luis","middle_initials":null,"last_name":"Souhami","page_name":"LSouhami","domain_name":"independent","created_at":"2016-02-01T10:54:47.452-08:00","display_name":"Luis Souhami","url":"https://independent.academia.edu/LSouhami"},"attachments":[]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="115450596"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" rel="nofollow" href="https://www.academia.edu/115450596/PROGRAMME_SCIENTIFIQUE_Samedi_le_15_novembre_2008_Session_scientifique_VIII"><img alt="Research paper thumbnail of PROGRAMME SCIENTIFIQUE : Samedi, le 15 novembre 2008, Session scientifique VIII" class="work-thumbnail" src="https://a.academia-assets.com/images/blank-paper.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" rel="nofollow" href="https://www.academia.edu/115450596/PROGRAMME_SCIENTIFIQUE_Samedi_le_15_novembre_2008_Session_scientifique_VIII">PROGRAMME SCIENTIFIQUE : Samedi, le 15 novembre 2008, Session scientifique VIII</a></div><div class="wp-workCard_item"><span>Canadian Urological Association Journal = Journal de L'association des Urologues du Canada</span><span>, Oct 1, 2008</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="115450596"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="115450596"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 115450596; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=115450596]").text(description); $(".js-view-count[data-work-id=115450596]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 115450596; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='115450596']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (false){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "-1" } } $('.js-work-strip[data-work-id=115450596]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":115450596,"title":"PROGRAMME SCIENTIFIQUE : Samedi, le 15 novembre 2008, Session scientifique VIII","internal_url":"https://www.academia.edu/115450596/PROGRAMME_SCIENTIFIQUE_Samedi_le_15_novembre_2008_Session_scientifique_VIII","owner_id":42486127,"coauthors_can_edit":true,"owner":{"id":42486127,"first_name":"Luis","middle_initials":null,"last_name":"Souhami","page_name":"LSouhami","domain_name":"independent","created_at":"2016-02-01T10:54:47.452-08:00","display_name":"Luis Souhami","url":"https://independent.academia.edu/LSouhami"},"attachments":[]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="115450595"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" rel="nofollow" href="https://www.academia.edu/115450595/Quality_of_Life_Implications_of_Dose_Escalated_External_Beam_Radiation_for_Localized_Prostate_Cancer_Results_of_a_Prospective_Randomized_Phase_3_Clinical_Trial_NRG_RTOG_0126"><img alt="Research paper thumbnail of Quality of Life Implications of Dose-Escalated External Beam Radiation for Localized Prostate Cancer: Results of a Prospective Randomized Phase 3 Clinical Trial, NRG/RTOG 0126" class="work-thumbnail" src="https://a.academia-assets.com/images/blank-paper.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" rel="nofollow" href="https://www.academia.edu/115450595/Quality_of_Life_Implications_of_Dose_Escalated_External_Beam_Radiation_for_Localized_Prostate_Cancer_Results_of_a_Prospective_Randomized_Phase_3_Clinical_Trial_NRG_RTOG_0126">Quality of Life Implications of Dose-Escalated External Beam Radiation for Localized Prostate Cancer: Results of a Prospective Randomized Phase 3 Clinical Trial, NRG/RTOG 0126</a></div><div class="wp-workCard_item"><span>International Journal of Radiation Oncology*Biology*Physics</span><span>, 2022</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">External beam radiation therapy (EBRT) dose escalation has been tested in multiple prospective tr...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">External beam radiation therapy (EBRT) dose escalation has been tested in multiple prospective trials. However, the impact on patient reported outcomes (PROs) associated with higher doses of EBRT remain poorly understood. We sought to assess the differences in PROs between men treated with a dose of 70.2 Gy versus 79.2 Gy of EBRT for prostate cancer. The phase 3 clinical trial RTOG 0126 randomized 1532 patients with prostate cancer between March 2002 and August 2008 to 79.2 Gy over 44 fractions versus 70.2 Gy over 39 fractions. Eligible patients participated in the PRO data collection. PROs completed included the International Index of Erectile Function Questionnaire (IIEF), Functional Alterations due to Changes in Elimination (FACE), and the Spitzer Quality of Life Index (SQLI). The timepoints for the IIEF were collected pre-entry and at 6, 12, and 24 months. The FACE and SQLI were collected pre-entry and at 3, 6, 12, 18, and 24 months. The impact of EBRT dose to normal structures (penile bulb, rectum, and bladder) on PROs was also examined. Mixed effects models were used to analyze trends across time. In total, 1144 patients completed baseline IIEF forms and of these, 56%, 64%, and 61% completed the IIEF at 6, 12, and 24 months, respectively; 1123 patients completed the FACE score at baseline and 50%, 61%, 73%, 61%, and 65% completed all 15 items for the FACE metric at timepoints of 3, 6, 12, 18, and 24 months, respectively. Erectile dysfunction at 12 months based on the single question was not significantly different between arms (38.1% for the standard dose radiation therapy arm vs 49.7% for the dose escalated radiation therapy arm; P = .051). Treatment arm (70.2 vs 79.2) had no significant impact on any PRO metrics measured across all collected domains. Comprehensive dosimetric analyses are presented and reveal multiple significant differences to regional organs at risk. Compliance with PRO data collection was lower than anticipated in this phase 3 trial. Examining the available data, dose escalated EBRT did not appear to be associated with any detriment to PROs across numerous prospectively collected domains. These data, notwithstanding limitations, add to our understanding of the implications of EBRT dose escalation in prostate cancer. Furthermore, these results illustrate challenges associated with PRO data collection.</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="115450595"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="115450595"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 115450595; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=115450595]").text(description); $(".js-view-count[data-work-id=115450595]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 115450595; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='115450595']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (false){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "-1" } } $('.js-work-strip[data-work-id=115450595]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":115450595,"title":"Quality of Life Implications of Dose-Escalated External Beam Radiation for Localized Prostate Cancer: Results of a Prospective Randomized Phase 3 Clinical Trial, NRG/RTOG 0126","internal_url":"https://www.academia.edu/115450595/Quality_of_Life_Implications_of_Dose_Escalated_External_Beam_Radiation_for_Localized_Prostate_Cancer_Results_of_a_Prospective_Randomized_Phase_3_Clinical_Trial_NRG_RTOG_0126","owner_id":42486127,"coauthors_can_edit":true,"owner":{"id":42486127,"first_name":"Luis","middle_initials":null,"last_name":"Souhami","page_name":"LSouhami","domain_name":"independent","created_at":"2016-02-01T10:54:47.452-08:00","display_name":"Luis Souhami","url":"https://independent.academia.edu/LSouhami"},"attachments":[]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="115450594"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/115450594/NCOG_12_Cognitive_Function_CF_Quality_of_Life_Qol_in_Patients_Treated_with_Procarbazine_Ccnu_Vincristine_PCV_Radiotherapy_RT_vs_RT_for_Anaplastic_Oligodendroglioma_Ao_on_NRG_Rtog_Trial_9402"><img alt="Research paper thumbnail of NCOG-12. Cognitive Function (CF) Quality of Life (Qol) in Patients Treated with Procarbazine, Ccnu, Vincristine (PCV) + Radiotherapy (RT) vs. RT for Anaplastic Oligodendroglioma (Ao) on NRG Rtog Trial 9402" class="work-thumbnail" src="https://attachments.academia-assets.com/111854037/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/115450594/NCOG_12_Cognitive_Function_CF_Quality_of_Life_Qol_in_Patients_Treated_with_Procarbazine_Ccnu_Vincristine_PCV_Radiotherapy_RT_vs_RT_for_Anaplastic_Oligodendroglioma_Ao_on_NRG_Rtog_Trial_9402">NCOG-12. Cognitive Function (CF) Quality of Life (Qol) in Patients Treated with Procarbazine, Ccnu, Vincristine (PCV) + Radiotherapy (RT) vs. RT for Anaplastic Oligodendroglioma (Ao) on NRG Rtog Trial 9402</a></div><div class="wp-workCard_item"><span>Neuro-Oncology</span><span>, 2021</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">BACKGROUND PCV+RT substantially prolongs survival in AO patients, but long-term CF and QOL implic...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">BACKGROUND PCV+RT substantially prolongs survival in AO patients, but long-term CF and QOL implications are unclear. We compared CF and QOL by treatment arm in RTOG 9402 participants and evaluated the impact that baseline characteristics had on CF, QOL, and survival. METHODS CF and QOL were evaluated using the Mini Mental State Exam (MMSE) and Brain-Quality of Life (B-QOL) scale at baseline and annually. Scores were analyzed between treatment arms at each time point for patients with ≥ 10 years of follow-up data. Shared parameter models evaluated MMSE and B-QOL scores and survival for all patients. RESULTS 42/148 (28.4%) participants in PCV+RT and 20/143 (14%) in RT alone arms survived ≥ 10 years. 35/42 and 39/42 (PCV+RT) and 18/20 and 17/20 (RT) participants completed baseline B-QOL and MMSE assessments, respectively. B-QOL scores did not differ between treatment groups at any time-point. Among 16 patients (10 PCV+RT, 6 RT) who completed year 10 MMSE evaluations, mean MMSE score at...</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="73562f4897c5107fdcee54433b9bdcad" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":111854037,"asset_id":115450594,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/111854037/download_file?s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="115450594"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="115450594"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 115450594; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=115450594]").text(description); $(".js-view-count[data-work-id=115450594]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 115450594; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='115450594']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "73562f4897c5107fdcee54433b9bdcad" } } $('.js-work-strip[data-work-id=115450594]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":115450594,"title":"NCOG-12. Cognitive Function (CF) Quality of Life (Qol) in Patients Treated with Procarbazine, Ccnu, Vincristine (PCV) + Radiotherapy (RT) vs. RT for Anaplastic Oligodendroglioma (Ao) on NRG Rtog Trial 9402","internal_url":"https://www.academia.edu/115450594/NCOG_12_Cognitive_Function_CF_Quality_of_Life_Qol_in_Patients_Treated_with_Procarbazine_Ccnu_Vincristine_PCV_Radiotherapy_RT_vs_RT_for_Anaplastic_Oligodendroglioma_Ao_on_NRG_Rtog_Trial_9402","owner_id":42486127,"coauthors_can_edit":true,"owner":{"id":42486127,"first_name":"Luis","middle_initials":null,"last_name":"Souhami","page_name":"LSouhami","domain_name":"independent","created_at":"2016-02-01T10:54:47.452-08:00","display_name":"Luis Souhami","url":"https://independent.academia.edu/LSouhami"},"attachments":[{"id":111854037,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/111854037/thumbnails/1.jpg","file_name":"noab196.603.pdf","download_url":"https://www.academia.edu/attachments/111854037/download_file","bulk_download_file_name":"NCOG_12_Cognitive_Function_CF_Quality_of.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/111854037/noab196.603-libre.pdf?1708960036=\u0026response-content-disposition=attachment%3B+filename%3DNCOG_12_Cognitive_Function_CF_Quality_of.pdf\u0026Expires=1740369698\u0026Signature=SwJVgcZJK2kxFmdKen9LbHLKhL5VNlF6QJqAupsPMGD5reAyRIlKfytF869klY1m7pr4Q6D~nqnTY-rugPyJdnIZESdJaBAQZZiwEa2hJfdeLbDyuQ15ZkRBi4nwyJPIQ9Psm63gBuL3gtdNG4TjzKpVEnhhEaxkARcR5ggtGpHP~HKqlI1VI~hR4-g-qxW7hlLEy3gHPbTq1CgHsmvgnZiYKqOtER0MPCl9ihor6bCsKD3VHbJQkpigRbpdJ~VqMqlrwsBvWWgdASDEud4ND80VjSKlqApK-ZP3cp~BHeGXLt~~o2leKG0Xa54Uj6K-ETSEITfqL0yiSgNJcK0otg__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="115450593"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" rel="nofollow" href="https://www.academia.edu/115450593/Body_Composition_and_Risk_of_All_Cause_Mortality_in_Men_Treated_With_Radiation_Therapy_for_Prostate_Cancer_A_Pooled_Analysis_of_NRG_RTOG_9406_and_NRG_RTOG_0126"><img alt="Research paper thumbnail of Body Composition and Risk of All-Cause Mortality in Men Treated With Radiation Therapy for Prostate Cancer: A Pooled Analysis of NRG/RTOG 9406 and NRG/RTOG 0126" class="work-thumbnail" src="https://a.academia-assets.com/images/blank-paper.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" rel="nofollow" href="https://www.academia.edu/115450593/Body_Composition_and_Risk_of_All_Cause_Mortality_in_Men_Treated_With_Radiation_Therapy_for_Prostate_Cancer_A_Pooled_Analysis_of_NRG_RTOG_9406_and_NRG_RTOG_0126">Body Composition and Risk of All-Cause Mortality in Men Treated With Radiation Therapy for Prostate Cancer: A Pooled Analysis of NRG/RTOG 9406 and NRG/RTOG 0126</a></div><div class="wp-workCard_item"><span>International Journal of Radiation Oncology*Biology*Physics</span><span>, 2021</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">PURPOSE/OBJECTIVE(S) To validate the association between body composition and all-cause mortality...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">PURPOSE/OBJECTIVE(S) To validate the association between body composition and all-cause mortality in men treated with radiation therapy for localized prostate cancer (PCa). Secondarily, to integrate body composition as a factor to help classify patients by risk of all-cause mortality. MATERIALS/METHODS All participants of NRG/RTOG 9406 and NRG/RTOG 0126 with archived computed tomography that extended cranially to include the L4-L5 interface were included. Muscle mass and muscle density were estimated by measuring the cross-sectional area and average attenuation of the paired psoas muscles on a single slice at the level of L4-L5. Bone density was estimated by measuring the average attenuation of the vertebral body cancellous bone on a single slice at mid-L5. Adipose tissue density was estimated by measuring the average attenuation of the subcutaneous adipose tissue on a single slice at L4-L5. Survival analyses, including Cox proportional hazards models, were performed to assess the relationship between body composition variables and all-cause mortality. Recursive partitioning (RPA) was utilized to create a classification tree to classify NRG/RTOG 0126 participants by risk of death, and the discriminant ability of the classification model was validated using the NRG/RTOG 9406 data set. RESULTS Data from 2,066 men was included in this study (864 from NRG/RTOG 9406 and 1,202 from NRG/RTOG 0126). A total of 648 men died in the follow-up period and 51 (7.9%) were due to PCa. Psoas area, psoas density, and vertebral body density were individually associated with overall survival. In the final multivariable model, psoas area, comorbidity score, and age were associated with overall survival (Table). The RPA yielded a classification tree with 4 prognostic groups determined by age, comorbidity, and psoas cross-sectional area. When the RPA classification was applied to the NRG/RTOG 9406 validation set the discriminant ability was preserved (P &lt; 0.001 groupwise log-rank). CONCLUSION The results of this study strongly support that body composition is related to all-cause mortality in men with localized PCa, with most deaths due to causes other than PCa. The inclusion of psoas cross-sectional area in the RPA classification tree suggests that body composition provides additive information to age and comorbidity status for mortality prediction. This study also confirms the feasibility of performing body composition analysis using archived CT scans using NRG Oncology clinical trial data sets. These methods can be applied to other NRG Oncology data sets to further explore how body composition is related to patient outcomes.</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="115450593"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="115450593"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 115450593; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=115450593]").text(description); $(".js-view-count[data-work-id=115450593]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 115450593; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='115450593']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (false){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "-1" } } $('.js-work-strip[data-work-id=115450593]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":115450593,"title":"Body Composition and Risk of All-Cause Mortality in Men Treated With Radiation Therapy for Prostate Cancer: A Pooled Analysis of NRG/RTOG 9406 and NRG/RTOG 0126","internal_url":"https://www.academia.edu/115450593/Body_Composition_and_Risk_of_All_Cause_Mortality_in_Men_Treated_With_Radiation_Therapy_for_Prostate_Cancer_A_Pooled_Analysis_of_NRG_RTOG_9406_and_NRG_RTOG_0126","owner_id":42486127,"coauthors_can_edit":true,"owner":{"id":42486127,"first_name":"Luis","middle_initials":null,"last_name":"Souhami","page_name":"LSouhami","domain_name":"independent","created_at":"2016-02-01T10:54:47.452-08:00","display_name":"Luis Souhami","url":"https://independent.academia.edu/LSouhami"},"attachments":[]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="115450592"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/115450592/Combined_Long_Term_Androgen_Deprivation_and_Pelvic_Radiotherapy_in_the_Post_operative_Management_of_Pathologically_Defined_High_Risk_Prostate_Cancer_Patients_Results_of_the_Prospective_Phase_II_McGill_0913_Study"><img alt="Research paper thumbnail of Combined Long-Term Androgen Deprivation and Pelvic Radiotherapy in the Post-operative Management of Pathologically Defined High-Risk Prostate Cancer Patients: Results of the Prospective Phase II McGill 0913 Study" class="work-thumbnail" src="https://attachments.academia-assets.com/111854034/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/115450592/Combined_Long_Term_Androgen_Deprivation_and_Pelvic_Radiotherapy_in_the_Post_operative_Management_of_Pathologically_Defined_High_Risk_Prostate_Cancer_Patients_Results_of_the_Prospective_Phase_II_McGill_0913_Study">Combined Long-Term Androgen Deprivation and Pelvic Radiotherapy in the Post-operative Management of Pathologically Defined High-Risk Prostate Cancer Patients: Results of the Prospective Phase II McGill 0913 Study</a></div><div class="wp-workCard_item"><span>Frontiers in Oncology</span><span>, 2020</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">Following radical prostatectomy, prostate bed radiotherapy (PBRT) has been combined with either l...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">Following radical prostatectomy, prostate bed radiotherapy (PBRT) has been combined with either long-term androgen deprivation therapy (LT-ADT) or short-term ADT with pelvic lymph node radiotherapy (PLNRT) to provide an oncological benefit in randomized trials. McGill 0913 was designed to characterize the efficacy of combining PBRT, PLNRT, and LT-ADT. It is the first study to do so prospectively. Methods: In a single arm phase II trial conduced from 2010 to 2016, 46 post-prostatectomy prostate cancer patients at a high-risk for relapse (pathological Gleason 8+ or T3) were assessed for treatment with combined LT-ADT (24 months), PBRT, and PLNRT. Patients received PLNRT and PBRT (44 Gy in 22 fractions) followed by a PBRT boost (22 Gy in 11 fractions). The primary endpoint was progression-free survival (PFS). Toxicity and quality of life (QoL) were evaluated using CTCAE V3.0 and EQ-5D-3L questionnaires, respectively. Results: Among the 43 patients were treated as per protocol, median PSA was 0.30 µg/L. On surgical pathology, 51% had positive margins, 40% had Gleason 8+ disease, 42% had seminal vesicle involvement, and 19% had lymph node involvement. At a median follow-up of 5.2 years, there were no deaths or clinical progression. At 5 years, PFS was 78.0% (95% Confidence Interval 63.7-95.5%). Not including erectile dysfunction, patients experienced: 14% grade 2 endocrine toxicity while on ADT, one incident of long-term gynecomastia, 5% grade 2 acute urinary toxicity, 5% grade 2 late Kucharczyk et al. McGill 0913: Pelvic Radiotherapy and LT-ADT Urinary toxicity, and 24% long-term hypogonadism. No comparison between the average or minimum self-reported QoL at baseline, during ADT, nor after ADT demonstrated a statistically significant difference. Conclusions: Combining PBRT, PLNRT, and LT-ADT had an acceptable PFS in patients with significant post-operative risk factors for recurrence. While therapy was well-tolerated, long-term hypogonadism was a substantial risk. Further investigations are needed to determine if this combination is beneficial. Trial registration: NCT01255891.</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="bac08c8ed0ff8f5274c5762219e8e1fa" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":111854034,"asset_id":115450592,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/111854034/download_file?s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="115450592"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="115450592"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 115450592; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=115450592]").text(description); $(".js-view-count[data-work-id=115450592]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 115450592; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='115450592']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "bac08c8ed0ff8f5274c5762219e8e1fa" } } $('.js-work-strip[data-work-id=115450592]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":115450592,"title":"Combined Long-Term Androgen Deprivation and Pelvic Radiotherapy in the Post-operative Management of Pathologically Defined High-Risk Prostate Cancer Patients: Results of the Prospective Phase II McGill 0913 Study","internal_url":"https://www.academia.edu/115450592/Combined_Long_Term_Androgen_Deprivation_and_Pelvic_Radiotherapy_in_the_Post_operative_Management_of_Pathologically_Defined_High_Risk_Prostate_Cancer_Patients_Results_of_the_Prospective_Phase_II_McGill_0913_Study","owner_id":42486127,"coauthors_can_edit":true,"owner":{"id":42486127,"first_name":"Luis","middle_initials":null,"last_name":"Souhami","page_name":"LSouhami","domain_name":"independent","created_at":"2016-02-01T10:54:47.452-08:00","display_name":"Luis Souhami","url":"https://independent.academia.edu/LSouhami"},"attachments":[{"id":111854034,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/111854034/thumbnails/1.jpg","file_name":"pdf.pdf","download_url":"https://www.academia.edu/attachments/111854034/download_file","bulk_download_file_name":"Combined_Long_Term_Androgen_Deprivation.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/111854034/pdf-libre.pdf?1708960040=\u0026response-content-disposition=attachment%3B+filename%3DCombined_Long_Term_Androgen_Deprivation.pdf\u0026Expires=1740369698\u0026Signature=bzCWWJE-3oJoE5HhA9GpHaM2i72klwggx0hmo0eHogNK00wsfTL9OJH9ZFElmBvEC1uN-iG52XlBgHmVJtv7UKlRlm20P5EMGXxsLhIlAj7lyza5P4squAPvJRYEerD8b5b2alHhVUVhvBzfN2YZldQGbElNZEQCCFM3uftTo3hJLHD3JDn9BYdwzUk2BBI~RniTBQJ84dtBCLlHumzxsR5xs3mHrOqyB~UshnQbK4-MmUvztEio~pd-9T-SkX2I6iTl3IQN588jwthluPL8ozOYuVB~Rb4QlbcaEFeJ4S25jY4fp9TnpfdNS7pc-7XEX~8vkSlApGcc92tu4NJa1g__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="115450591"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/115450591/11_Prostate_Bed_Treatment_Intensification_with_Long_Term_Androgen_Deprivation_and_Pelvic_Nodal_Radiotherapy_is_Effective_and_Well_Tolerated_Results_from_the_McGill_0913_Phase_II_Clinical_Trial"><img alt="Research paper thumbnail of 11 Prostate Bed Treatment Intensification with Long Term Androgen Deprivation and Pelvic Nodal Radiotherapy is Effective and Well Tolerated: Results from the McGill 0913 Phase II Clinical Trial" class="work-thumbnail" src="https://attachments.academia-assets.com/111854036/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/115450591/11_Prostate_Bed_Treatment_Intensification_with_Long_Term_Androgen_Deprivation_and_Pelvic_Nodal_Radiotherapy_is_Effective_and_Well_Tolerated_Results_from_the_McGill_0913_Phase_II_Clinical_Trial">11 Prostate Bed Treatment Intensification with Long Term Androgen Deprivation and Pelvic Nodal Radiotherapy is Effective and Well Tolerated: Results from the McGill 0913 Phase II Clinical Trial</a></div><div class="wp-workCard_item"><span>Radiotherapy and Oncology</span><span>, 2019</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">The dose to the bladder neck was only reported and no constraint was applied. The International P...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">The dose to the bladder neck was only reported and no constraint was applied. The International Prostate Symptom Score (IPSS) at six weeks and six months and urinary obstruction rate were used to report acute and late urinary toxicity, respectively. Clinical and dosimetric factors associated with urinary toxicity were analyzed using multivariate generalized linear model including pretreatment IPSS, bladder neck D2cc and prostate volume as covariates. Results: Mean age and median follow-up were 69.9 years and 25 months, respectively. The mean pretreatment PSA was 9.30 ng/ml. According to D'Amico definition 70% were intermediate risk and 30% high-risk. The mean prostate volume was 57.5 cc. The mean pretreatment, six weeks and six months IPSS were 8.35, 12.24 and 9.97 respectively. We observed 17 cases (5.34%) of GU obstruction in our cohort of patients. Pretreatment IPSS was significantly associated with acute and late urinary toxicity (p<0.001). Prostate volume was also associated with acute (p=0.013) and late urinary toxicity (p=0.024). The dose for the most exposed 2cc (D2cc) of bladder neck was not correlated with acute mean IPSS 12.24 (p=0.737) or late mean IPSS 9.97 (p=0.785). There was also no correlation between D2cc and urinary obstruction 8.5 Gy versus 7.5 Gy (p = 0.191). Even if the mean D2cc was higher in the US group 10.1 Gy versus 7.6 Gy CT p < 0.00001 it was also not correlated with GU acute/late toxicity and urinary obstruction.</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="d0aa02263a04ee15a000be432e465fce" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":111854036,"asset_id":115450591,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/111854036/download_file?s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="115450591"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="115450591"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 115450591; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=115450591]").text(description); $(".js-view-count[data-work-id=115450591]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 115450591; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='115450591']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "d0aa02263a04ee15a000be432e465fce" } } $('.js-work-strip[data-work-id=115450591]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":115450591,"title":"11 Prostate Bed Treatment Intensification with Long Term Androgen Deprivation and Pelvic Nodal Radiotherapy is Effective and Well Tolerated: Results from the McGill 0913 Phase II Clinical Trial","internal_url":"https://www.academia.edu/115450591/11_Prostate_Bed_Treatment_Intensification_with_Long_Term_Androgen_Deprivation_and_Pelvic_Nodal_Radiotherapy_is_Effective_and_Well_Tolerated_Results_from_the_McGill_0913_Phase_II_Clinical_Trial","owner_id":42486127,"coauthors_can_edit":true,"owner":{"id":42486127,"first_name":"Luis","middle_initials":null,"last_name":"Souhami","page_name":"LSouhami","domain_name":"independent","created_at":"2016-02-01T10:54:47.452-08:00","display_name":"Luis Souhami","url":"https://independent.academia.edu/LSouhami"},"attachments":[{"id":111854036,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/111854036/thumbnails/1.jpg","file_name":"s0167-814028192933160-320240226-1-hh8j13.pdf","download_url":"https://www.academia.edu/attachments/111854036/download_file","bulk_download_file_name":"11_Prostate_Bed_Treatment_Intensificatio.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/111854036/s0167-814028192933160-320240226-1-hh8j13-libre.pdf?1708960037=\u0026response-content-disposition=attachment%3B+filename%3D11_Prostate_Bed_Treatment_Intensificatio.pdf\u0026Expires=1740369698\u0026Signature=hAya9Yw67VI-G-bZ1zHqSWLOWzUQpPWxejpGq4xK1slmlQ0M7KQ2I-KNHfIpADyX-boaMQzmoKp-HGmApfClwXoEwL~IGbw4IQEqegWpHR5psQT7MjeMUPx4DRX-YC3mpJV-0YIZ095aq3Fo-ac~0oQ8f-HIG94TqfW1e6owPyue9FFpaS~UjQdK~5uis0hm8irSFAmyJWi0NU0euw-Hb7f0rJoW74SDvOJxrK3Yr5x13AuuERfknbhGm2NsfoTsdFZLHtiQ9gWWvvQPgVVPLu93kUMTkBQVGNW0f-Vjd-2UdFrpgIPO3kBnt0QlaHMXPbdxzKm7udha0Tl7mi0IgQ__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="115450590"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/115450590/171_High_Dose_Rate_Brachytherapy_as_Monotherapy_for_the_Treatment_of_Intermediate_Risk_Prostate_Cancer_Toxicity_Results"><img alt="Research paper thumbnail of 171 High-Dose-Rate Brachytherapy as Monotherapy for the Treatment of Intermediate Risk Prostate Cancer: Toxicity Results" class="work-thumbnail" src="https://attachments.academia-assets.com/111854035/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/115450590/171_High_Dose_Rate_Brachytherapy_as_Monotherapy_for_the_Treatment_of_Intermediate_Risk_Prostate_Cancer_Toxicity_Results">171 High-Dose-Rate Brachytherapy as Monotherapy for the Treatment of Intermediate Risk Prostate Cancer: Toxicity Results</a></div><div class="wp-workCard_item"><span>Radiotherapy and Oncology</span><span>, 2019</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">High conformality of delivered dose and the high susceptibility of prostate cancer (PrCa) to high...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">High conformality of delivered dose and the high susceptibility of prostate cancer (PrCa) to high dose radiation therapy has warranted a closer look at high dose-rate (HDR) brachytherapy as monotherapy in recent years. Objectives: We present the acute and late genitourinary (GU) and gastrointestinal (GI) toxicities among a cohort of medium risk PrCa patients who received HDR monotherapy. Materials and Methods: Between January 1, 2016 and November 30, 2017, 42 patients were treated using CT-planned HDR brachytherapy as a single, 21Gy fraction. Dose was prescribed as per GEC-ESTRO guidelines, except for the urethra D0.1cc = ⩽110Gy EQD2. The Common Toxicity Criteria for Adverse Event, Version 4.0 (CTAE v4.03) was used to report toxicity. In addition to the one-week post-treatment interval, toxicity assessments were grouped at the 1, 3, 6, 12, and 24 months non-overlapping intervals. Results: With a median follow-up of 13.5 months, (range 1-28.5), and median age of 69 years, 59% of our patients developed acute GU toxicity (Grade 1), 7% of our patients developed late GU toxicity (Grade 2). Most frequent GU toxicity was hematuria (52%) within the first week, followed by dysuria (17%) in the first 3 months. GI toxicity was observed in 9% (all Grade 1). There was one patient developed Grade 3 urethral stricture at 18 months. Pre-treatment PSA was 7.5 ug/L (range 2.1-18.0). Patients reached an average nadir of 1.7ug/L (range 0.1-9.0) at 10.6 months. Conclusions: HDR monotherapy resulted in very low late GU toxicity (7%, G2; 2.3% G3) and no G2 or above late GI toxicity. These results are favorable compare to published data. In light of the advantages associated with this treatment modality, HDR brachytherapy is the ultimate extreme hypofractionation we can offer our patients.</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="6d1d09c5ac6c6cabe47a0e1b7839e404" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":111854035,"asset_id":115450590,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/111854035/download_file?s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="115450590"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="115450590"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 115450590; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=115450590]").text(description); $(".js-view-count[data-work-id=115450590]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 115450590; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='115450590']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "6d1d09c5ac6c6cabe47a0e1b7839e404" } } $('.js-work-strip[data-work-id=115450590]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":115450590,"title":"171 High-Dose-Rate Brachytherapy as Monotherapy for the Treatment of Intermediate Risk Prostate Cancer: Toxicity Results","internal_url":"https://www.academia.edu/115450590/171_High_Dose_Rate_Brachytherapy_as_Monotherapy_for_the_Treatment_of_Intermediate_Risk_Prostate_Cancer_Toxicity_Results","owner_id":42486127,"coauthors_can_edit":true,"owner":{"id":42486127,"first_name":"Luis","middle_initials":null,"last_name":"Souhami","page_name":"LSouhami","domain_name":"independent","created_at":"2016-02-01T10:54:47.452-08:00","display_name":"Luis Souhami","url":"https://independent.academia.edu/LSouhami"},"attachments":[{"id":111854035,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/111854035/thumbnails/1.jpg","file_name":"s0167-814028192933228-120240226-1-ooyoob.pdf","download_url":"https://www.academia.edu/attachments/111854035/download_file","bulk_download_file_name":"171_High_Dose_Rate_Brachytherapy_as_Mono.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/111854035/s0167-814028192933228-120240226-1-ooyoob-libre.pdf?1708960034=\u0026response-content-disposition=attachment%3B+filename%3D171_High_Dose_Rate_Brachytherapy_as_Mono.pdf\u0026Expires=1740369698\u0026Signature=Cq6msRC8y8VL3crq4j4RsDjxpDsUBKImJyYx3upRtqlYnzwciwm88kQfm~a8Y0KD44oQ1iT8SGxpbrIDnQWtEDRrvvwgJn3Zr9cyau3jhmPecAewwCPysQhettHnK1zx4hpET3xoTHnvR3hUDvCAYWdsR3ltU12jZNXGopiTg9i2Bh3jq5-Iu83xl9ueCbdiDiHekG62YVQmnUfN7pY7wzvWSjBFy41yxblyQm8kP8AHNp0irkXIzqeuWKl92xxIa6WqSKPM44m-wQpMIUW4GcPU-UFEwP4AM7qu9Fav6YE8a30wqWLD-kWtfyHOmbn3zu0ezjk9bA3pMQM09pvKmw__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="115450589"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" rel="nofollow" href="https://www.academia.edu/115450589/NRG_Oncology_RTOG_9601_a_phase_III_trial_in_prostate_cancer_patients_Anti_androgen_therapy_AAT_with_bicalutamide_during_and_after_salvage_radiation_therapy_RT_following_radical_prostatectomy_RP_and_an_elevated_PSA"><img alt="Research paper thumbnail of NRG Oncology/RTOG 9601, a phase III trial in prostate cancer patients: Anti-androgen therapy (AAT) with bicalutamide during and after salvage radiation therapy (RT) following radical prostatectomy (RP) and an elevated PSA" class="work-thumbnail" src="https://a.academia-assets.com/images/blank-paper.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" rel="nofollow" href="https://www.academia.edu/115450589/NRG_Oncology_RTOG_9601_a_phase_III_trial_in_prostate_cancer_patients_Anti_androgen_therapy_AAT_with_bicalutamide_during_and_after_salvage_radiation_therapy_RT_following_radical_prostatectomy_RP_and_an_elevated_PSA">NRG Oncology/RTOG 9601, a phase III trial in prostate cancer patients: Anti-androgen therapy (AAT) with bicalutamide during and after salvage radiation therapy (RT) following radical prostatectomy (RP) and an elevated PSA</a></div><div class="wp-workCard_item"><span>Journal of Clinical Oncology</span><span>, 2016</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">3 Background: Previous reports suggested that AAT when combined with salvage RT following RP in p...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">3 Background: Previous reports suggested that AAT when combined with salvage RT following RP in patients may improve prostate cancer control outcomes. Methods: Post-RP patients with pT3pN0 or with pT2pN0 and positive margins who had or developed elevated PSA levels from 0.2 to 4.0 ng/ml were randomized on a phase III, double-blind, trial of RT + placebo (64.8 Gy in 36 fractions of 1.8 Gy) vs. RT + AAT (24 months bicalutamide, 150 mg daily) during and after RT. The primary end-point was overall survival. Trial design required 725 patients and provided 80% power to detect a reduction in death rate by at least 28.5% and a 1-sided significance level of 0.046. Results: From 3/98 to 3/03, 761 eligible patients (median age 65) were randomized to RT + AAT (384) or RT + placebo (377). 248 patients (33%) were pT2pN0 and 513 (67%) were pT3pN0. 671 (88%) had a PSA nadir after RP of &lt; 0.5 ng/ml. 649 (85%) had an entry PSA value of &lt;1.6, 112 patients (15%) had an entry PSA of 1.6-4. Median ...</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="115450589"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="115450589"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 115450589; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=115450589]").text(description); $(".js-view-count[data-work-id=115450589]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 115450589; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='115450589']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (false){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "-1" } } $('.js-work-strip[data-work-id=115450589]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":115450589,"title":"NRG Oncology/RTOG 9601, a phase III trial in prostate cancer patients: Anti-androgen therapy (AAT) with bicalutamide during and after salvage radiation therapy (RT) following radical prostatectomy (RP) and an elevated PSA","internal_url":"https://www.academia.edu/115450589/NRG_Oncology_RTOG_9601_a_phase_III_trial_in_prostate_cancer_patients_Anti_androgen_therapy_AAT_with_bicalutamide_during_and_after_salvage_radiation_therapy_RT_following_radical_prostatectomy_RP_and_an_elevated_PSA","owner_id":42486127,"coauthors_can_edit":true,"owner":{"id":42486127,"first_name":"Luis","middle_initials":null,"last_name":"Souhami","page_name":"LSouhami","domain_name":"independent","created_at":"2016-02-01T10:54:47.452-08:00","display_name":"Luis Souhami","url":"https://independent.academia.edu/LSouhami"},"attachments":[]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="115450588"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" rel="nofollow" href="https://www.academia.edu/115450588/Evaluation_and_Visualization_of_Radiogenomic_Modeling_Frameworks_for_the_Prediction_of_Normal_Tissue_Toxicities"><img alt="Research paper thumbnail of Evaluation and Visualization of Radiogenomic Modeling Frameworks for the Prediction of Normal Tissue Toxicities" class="work-thumbnail" src="https://a.academia-assets.com/images/blank-paper.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" rel="nofollow" href="https://www.academia.edu/115450588/Evaluation_and_Visualization_of_Radiogenomic_Modeling_Frameworks_for_the_Prediction_of_Normal_Tissue_Toxicities">Evaluation and Visualization of Radiogenomic Modeling Frameworks for the Prediction of Normal Tissue Toxicities</a></div><div class="wp-workCard_item"><span>IFMBE Proceedings</span><span>, 2015</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">We explore techniques for the evaluation and visualization of radiogenomic data-driven models in ...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">We explore techniques for the evaluation and visualization of radiogenomic data-driven models in an effort to investigate the integration of genetic variations (single nucleotide polymorphisms [SNPs] and copy number variations [CNVs]) with dosimetric and clinical variables in modeling radiation-induced rectal bleeding (RB).</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="115450588"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="115450588"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 115450588; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=115450588]").text(description); $(".js-view-count[data-work-id=115450588]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 115450588; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='115450588']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (false){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "-1" } } $('.js-work-strip[data-work-id=115450588]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":115450588,"title":"Evaluation and Visualization of Radiogenomic Modeling Frameworks for the Prediction of Normal Tissue Toxicities","internal_url":"https://www.academia.edu/115450588/Evaluation_and_Visualization_of_Radiogenomic_Modeling_Frameworks_for_the_Prediction_of_Normal_Tissue_Toxicities","owner_id":42486127,"coauthors_can_edit":true,"owner":{"id":42486127,"first_name":"Luis","middle_initials":null,"last_name":"Souhami","page_name":"LSouhami","domain_name":"independent","created_at":"2016-02-01T10:54:47.452-08:00","display_name":"Luis Souhami","url":"https://independent.academia.edu/LSouhami"},"attachments":[]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="115450587"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" rel="nofollow" href="https://www.academia.edu/115450587/4021_POSTER_Testosterone_recovery_following_prolonged_adjuvant_androgen_blockade_in_localized_prostate_cancer_is_there_an_effect_on_outcome"><img alt="Research paper thumbnail of 4021 POSTER Testosterone recovery following prolonged adjuvant androgen blockade in localized prostate cancer: is there an effect on outcome?" class="work-thumbnail" src="https://a.academia-assets.com/images/blank-paper.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" rel="nofollow" href="https://www.academia.edu/115450587/4021_POSTER_Testosterone_recovery_following_prolonged_adjuvant_androgen_blockade_in_localized_prostate_cancer_is_there_an_effect_on_outcome">4021 POSTER Testosterone recovery following prolonged adjuvant androgen blockade in localized prostate cancer: is there an effect on outcome?</a></div><div class="wp-workCard_item"><span>European Journal of Cancer Supplements</span><span>, 2007</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="115450587"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="115450587"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 115450587; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=115450587]").text(description); $(".js-view-count[data-work-id=115450587]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 115450587; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='115450587']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (false){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "-1" } } $('.js-work-strip[data-work-id=115450587]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":115450587,"title":"4021 POSTER Testosterone recovery following prolonged adjuvant androgen blockade in localized prostate cancer: is there an effect on outcome?","internal_url":"https://www.academia.edu/115450587/4021_POSTER_Testosterone_recovery_following_prolonged_adjuvant_androgen_blockade_in_localized_prostate_cancer_is_there_an_effect_on_outcome","owner_id":42486127,"coauthors_can_edit":true,"owner":{"id":42486127,"first_name":"Luis","middle_initials":null,"last_name":"Souhami","page_name":"LSouhami","domain_name":"independent","created_at":"2016-02-01T10:54:47.452-08:00","display_name":"Luis Souhami","url":"https://independent.academia.edu/LSouhami"},"attachments":[]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> </div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/google_contacts-0dfb882d836b94dbcb4a2d123d6933fc9533eda5be911641f20b4eb428429600.js"], function() { // from javascript_helper.rb $('.js-google-connect-button').click(function(e) { e.preventDefault(); GoogleContacts.authorize_and_show_contacts(); Aedu.Dismissibles.recordClickthrough("WowProfileImportContactsPrompt"); }); $('.js-update-biography-button').click(function(e) { e.preventDefault(); Aedu.Dismissibles.recordClickthrough("UpdateUserBiographyPrompt"); $.ajax({ url: $r.api_v0_profiles_update_about_path({ subdomain_param: 'api', about: "", }), type: 'PUT', success: function(response) { location.reload(); } }); }); $('.js-work-creator-button').click(function (e) { e.preventDefault(); window.location = $r.upload_funnel_document_path({ source: encodeURIComponent(""), }); }); $('.js-video-upload-button').click(function (e) { e.preventDefault(); window.location = $r.upload_funnel_video_path({ source: encodeURIComponent(""), }); }); $('.js-do-this-later-button').click(function() { $(this).closest('.js-profile-nag-panel').remove(); Aedu.Dismissibles.recordDismissal("WowProfileImportContactsPrompt"); }); $('.js-update-biography-do-this-later-button').click(function(){ $(this).closest('.js-profile-nag-panel').remove(); Aedu.Dismissibles.recordDismissal("UpdateUserBiographyPrompt"); }); $('.wow-profile-mentions-upsell--close').click(function(){ $('.wow-profile-mentions-upsell--panel').hide(); Aedu.Dismissibles.recordDismissal("WowProfileMentionsUpsell"); }); $('.wow-profile-mentions-upsell--button').click(function(){ Aedu.Dismissibles.recordClickthrough("WowProfileMentionsUpsell"); }); new WowProfile.SocialRedesignUserWorks({ initialWorksOffset: 20, allWorksOffset: 20, maxSections: 1 }) }); </script> </div></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile_edit-5ea339ee107c863779f560dd7275595239fed73f1a13d279d2b599a28c0ecd33.js","https://a.academia-assets.com/assets/add_coauthor-22174b608f9cb871d03443cafa7feac496fb50d7df2d66a53f5ee3c04ba67f53.js","https://a.academia-assets.com/assets/tab-dcac0130902f0cc2d8cb403714dd47454f11fc6fb0e99ae6a0827b06613abc20.js","https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js"], function() { // from javascript_helper.rb window.ae = window.ae || {}; window.ae.WowProfile = window.ae.WowProfile || {}; if(Aedu.User.current && Aedu.User.current.id === $viewedUser.id) { window.ae.WowProfile.current_user_edit = {}; new WowProfileEdit.EditUploadView({ el: '.js-edit-upload-button-wrapper', model: window.$current_user, }); new AddCoauthor.AddCoauthorsController(); } var userInfoView = new WowProfile.SocialRedesignUserInfo({ recaptcha_key: "6LdxlRMTAAAAADnu_zyLhLg0YF9uACwz78shpjJB" }); WowProfile.router = new WowProfile.Router({ userInfoView: userInfoView }); Backbone.history.start({ pushState: true, root: "/" + $viewedUser.page_name }); new WowProfile.UserWorksNav() }); </script> </div> <div class="bootstrap login"><div class="modal fade login-modal" id="login-modal"><div class="login-modal-dialog modal-dialog"><div class="modal-content"><div class="modal-header"><button class="close close" data-dismiss="modal" type="button"><span aria-hidden="true">×</span><span class="sr-only">Close</span></button><h4 class="modal-title text-center"><strong>Log In</strong></h4></div><div class="modal-body"><div class="row"><div class="col-xs-10 col-xs-offset-1"><button class="btn btn-fb btn-lg btn-block btn-v-center-content" id="login-facebook-oauth-button"><svg style="float: left; width: 19px; line-height: 1em; margin-right: .3em;" aria-hidden="true" focusable="false" data-prefix="fab" data-icon="facebook-square" class="svg-inline--fa fa-facebook-square fa-w-14" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 448 512"><path fill="currentColor" d="M400 32H48A48 48 0 0 0 0 80v352a48 48 0 0 0 48 48h137.25V327.69h-63V256h63v-54.64c0-62.15 37-96.48 93.67-96.48 27.14 0 55.52 4.84 55.52 4.84v61h-31.27c-30.81 0-40.42 19.12-40.42 38.73V256h68.78l-11 71.69h-57.78V480H400a48 48 0 0 0 48-48V80a48 48 0 0 0-48-48z"></path></svg><small><strong>Log in</strong> with <strong>Facebook</strong></small></button><br /><button class="btn btn-google btn-lg btn-block btn-v-center-content" id="login-google-oauth-button"><svg style="float: left; width: 22px; line-height: 1em; margin-right: .3em;" aria-hidden="true" focusable="false" data-prefix="fab" data-icon="google-plus" class="svg-inline--fa fa-google-plus fa-w-16" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512"><path fill="currentColor" d="M256,8C119.1,8,8,119.1,8,256S119.1,504,256,504,504,392.9,504,256,392.9,8,256,8ZM185.3,380a124,124,0,0,1,0-248c31.3,0,60.1,11,83,32.3l-33.6,32.6c-13.2-12.9-31.3-19.1-49.4-19.1-42.9,0-77.2,35.5-77.2,78.1S142.3,334,185.3,334c32.6,0,64.9-19.1,70.1-53.3H185.3V238.1H302.2a109.2,109.2,0,0,1,1.9,20.7c0,70.8-47.5,121.2-118.8,121.2ZM415.5,273.8v35.5H380V273.8H344.5V238.3H380V202.8h35.5v35.5h35.2v35.5Z"></path></svg><small><strong>Log in</strong> with <strong>Google</strong></small></button><br /><style type="text/css">.sign-in-with-apple-button { width: 100%; height: 52px; border-radius: 3px; border: 1px solid black; cursor: pointer; } .sign-in-with-apple-button > div { margin: 0 auto; / This centers the Apple-rendered button horizontally }</style><script src="https://appleid.cdn-apple.com/appleauth/static/jsapi/appleid/1/en_US/appleid.auth.js" type="text/javascript"></script><div class="sign-in-with-apple-button" data-border="false" data-color="white" id="appleid-signin"><span   ="Sign Up with Apple" class="u-fs11"></span></div><script>AppleID.auth.init({ clientId: 'edu.academia.applesignon', scope: 'name email', redirectURI: 'https://www.academia.edu/sessions', state: "08874579848fdd1abaf6c890474529c7e778ffd2a5f301973efaf74bc4a13480", });</script><script>// Hacky way of checking if on fast loswp if (window.loswp == null) { (function() { const Google = window?.Aedu?.Auth?.OauthButton?.Login?.Google; const Facebook = window?.Aedu?.Auth?.OauthButton?.Login?.Facebook; if (Google) { new Google({ el: '#login-google-oauth-button', rememberMeCheckboxId: 'remember_me', track: null }); } if (Facebook) { new Facebook({ el: '#login-facebook-oauth-button', rememberMeCheckboxId: 'remember_me', track: null }); } })(); }</script></div></div></div><div class="modal-body"><div class="row"><div class="col-xs-10 col-xs-offset-1"><div class="hr-heading login-hr-heading"><span class="hr-heading-text">or</span></div></div></div></div><div class="modal-body"><div class="row"><div class="col-xs-10 col-xs-offset-1"><form class="js-login-form" action="https://www.academia.edu/sessions" accept-charset="UTF-8" method="post"><input type="hidden" name="authenticity_token" value="hFMM_BUoYWwK-G8zsu46HGXM2CnMK5Xd5AcnSDq4wKl3nMxcTEA3V6t4ZkPjkGsnoCUD27lBOMX86lwLzg5jSQ" autocomplete="off" /><div class="form-group"><label class="control-label" for="login-modal-email-input" style="font-size: 14px;">Email</label><input class="form-control" id="login-modal-email-input" name="login" type="email" /></div><div class="form-group"><label class="control-label" for="login-modal-password-input" style="font-size: 14px;">Password</label><input class="form-control" id="login-modal-password-input" name="password" type="password" /></div><input type="hidden" name="post_login_redirect_url" id="post_login_redirect_url" value="https://independent.academia.edu/LSouhami" autocomplete="off" /><div class="checkbox"><label><input type="checkbox" name="remember_me" id="remember_me" value="1" checked="checked" /><small style="font-size: 12px; margin-top: 2px; display: inline-block;">Remember me on this computer</small></label></div><br><input type="submit" name="commit" value="Log In" class="btn btn-primary btn-block btn-lg js-login-submit" data-disable-with="Log In" /></br></form><script>typeof window?.Aedu?.recaptchaManagedForm === 'function' && window.Aedu.recaptchaManagedForm( document.querySelector('.js-login-form'), document.querySelector('.js-login-submit') );</script><small style="font-size: 12px;"><br />or <a data-target="#login-modal-reset-password-container" data-toggle="collapse" href="javascript:void(0)">reset password</a></small><div class="collapse" id="login-modal-reset-password-container"><br /><div class="well margin-0x"><form class="js-password-reset-form" action="https://www.academia.edu/reset_password" accept-charset="UTF-8" method="post"><input type="hidden" name="authenticity_token" value="A-nmYSlFoRYMlvM_u-uRuCFmMG_KZi7Dji5yDqXVRQ3wJibBcC33La0W-k_qlcCD5I_rnb8Mg9uWwwlNUWPm7Q" autocomplete="off" /><p>Enter the email address you signed up with and we'll email you a reset link.</p><div class="form-group"><input class="form-control" name="email" type="email" /></div><script src="https://recaptcha.net/recaptcha/api.js" async defer></script> <script> var invisibleRecaptchaSubmit = function () { var closestForm = function (ele) { var curEle = ele.parentNode; while (curEle.nodeName !== 'FORM' && curEle.nodeName !== 'BODY'){ curEle = curEle.parentNode; } return curEle.nodeName === 'FORM' ? curEle : null }; var eles = document.getElementsByClassName('g-recaptcha'); if (eles.length > 0) { var form = closestForm(eles[0]); if (form) { form.submit(); } } }; </script> <input type="submit" data-sitekey="6Lf3KHUUAAAAACggoMpmGJdQDtiyrjVlvGJ6BbAj" data-callback="invisibleRecaptchaSubmit" class="g-recaptcha btn btn-primary btn-block" value="Email me a link" value=""/> </form></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/collapse-45805421cf446ca5adf7aaa1935b08a3a8d1d9a6cc5d91a62a2a3a00b20b3e6a.js"], function() { // from javascript_helper.rb $("#login-modal-reset-password-container").on("shown.bs.collapse", function() { $(this).find("input[type=email]").focus(); }); }); </script> </div></div></div><div class="modal-footer"><div class="text-center"><small style="font-size: 12px;">Need an account? <a rel="nofollow" href="https://www.academia.edu/signup">Click here to sign up</a></small></div></div></div></div></div></div><script>// If we are on subdomain or non-bootstrapped page, redirect to login page instead of showing modal (function(){ if (typeof $ === 'undefined') return; var host = window.location.hostname; if ((host === $domain || host === "www."+$domain) && (typeof $().modal === 'function')) { $("#nav_log_in").click(function(e) { // Don't follow the link and open the modal e.preventDefault(); $("#login-modal").on('shown.bs.modal', function() { $(this).find("#login-modal-email-input").focus() }).modal('show'); }); } })()</script> <div class="bootstrap" id="footer"><div class="footer-content clearfix text-center padding-top-7x" style="width:100%;"><ul class="footer-links-secondary footer-links-wide list-inline margin-bottom-1x"><li><a href="https://www.academia.edu/about">About</a></li><li><a href="https://www.academia.edu/press">Press</a></li><li><a href="https://www.academia.edu/documents">Papers</a></li><li><a href="https://www.academia.edu/topics">Topics</a></li><li><a href="https://www.academia.edu/journals">Academia.edu Journals</a></li><li><a rel="nofollow" href="https://www.academia.edu/hiring"><svg style="width: 13px; height: 13px;" aria-hidden="true" focusable="false" data-prefix="fas" data-icon="briefcase" class="svg-inline--fa fa-briefcase fa-w-16" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512"><path fill="currentColor" d="M320 336c0 8.84-7.16 16-16 16h-96c-8.84 0-16-7.16-16-16v-48H0v144c0 25.6 22.4 48 48 48h416c25.6 0 48-22.4 48-48V288H320v48zm144-208h-80V80c0-25.6-22.4-48-48-48H176c-25.6 0-48 22.4-48 48v48H48c-25.6 0-48 22.4-48 48v80h512v-80c0-25.6-22.4-48-48-48zm-144 0H192V96h128v32z"></path></svg> <strong>We're Hiring!</strong></a></li><li><a rel="nofollow" href="https://support.academia.edu/hc/en-us"><svg style="width: 12px; height: 12px;" aria-hidden="true" focusable="false" data-prefix="fas" data-icon="question-circle" class="svg-inline--fa fa-question-circle fa-w-16" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512"><path fill="currentColor" d="M504 256c0 136.997-111.043 248-248 248S8 392.997 8 256C8 119.083 119.043 8 256 8s248 111.083 248 248zM262.655 90c-54.497 0-89.255 22.957-116.549 63.758-3.536 5.286-2.353 12.415 2.715 16.258l34.699 26.31c5.205 3.947 12.621 3.008 16.665-2.122 17.864-22.658 30.113-35.797 57.303-35.797 20.429 0 45.698 13.148 45.698 32.958 0 14.976-12.363 22.667-32.534 33.976C247.128 238.528 216 254.941 216 296v4c0 6.627 5.373 12 12 12h56c6.627 0 12-5.373 12-12v-1.333c0-28.462 83.186-29.647 83.186-106.667 0-58.002-60.165-102-116.531-102zM256 338c-25.365 0-46 20.635-46 46 0 25.364 20.635 46 46 46s46-20.636 46-46c0-25.365-20.635-46-46-46z"></path></svg> <strong>Help Center</strong></a></li></ul><ul class="footer-links-tertiary list-inline margin-bottom-1x"><li class="small">Find new research papers in:</li><li class="small"><a href="https://www.academia.edu/Documents/in/Physics">Physics</a></li><li class="small"><a href="https://www.academia.edu/Documents/in/Chemistry">Chemistry</a></li><li class="small"><a href="https://www.academia.edu/Documents/in/Biology">Biology</a></li><li class="small"><a href="https://www.academia.edu/Documents/in/Health_Sciences">Health Sciences</a></li><li class="small"><a href="https://www.academia.edu/Documents/in/Ecology">Ecology</a></li><li class="small"><a href="https://www.academia.edu/Documents/in/Earth_Sciences">Earth Sciences</a></li><li class="small"><a href="https://www.academia.edu/Documents/in/Cognitive_Science">Cognitive Science</a></li><li class="small"><a href="https://www.academia.edu/Documents/in/Mathematics">Mathematics</a></li><li class="small"><a href="https://www.academia.edu/Documents/in/Computer_Science">Computer Science</a></li></ul></div></div><div class="DesignSystem" id="credit" style="width:100%;"><ul class="u-pl0x footer-links-legal list-inline"><li><a rel="nofollow" href="https://www.academia.edu/terms">Terms</a></li><li><a rel="nofollow" href="https://www.academia.edu/privacy">Privacy</a></li><li><a rel="nofollow" href="https://www.academia.edu/copyright">Copyright</a></li><li>Academia ©2025</li></ul></div><script> //<![CDATA[ window.detect_gmtoffset = true; window.Academia && window.Academia.set_gmtoffset && Academia.set_gmtoffset('/gmtoffset'); //]]> </script> <div id='overlay_background'></div> <div id='bootstrap-modal-container' class='bootstrap'></div> <div id='ds-modal-container' class='bootstrap DesignSystem'></div> <div id='full-screen-modal'></div> </div> </body> </html>